

US010335614B2

(12) United States Patent

Messerly et al.

(54) DEVICES AND TECHNIQUES FOR CUTTING AND COAGULATING TISSUE

(71) Applicant: Ethicon LLC, Guaynabo, PR (US)

(72) Inventors: Jeffrey D. Messerly, Cincinnati, OH
(US); Eitan T. Wiener, Cincinnati, OH
(US); Brian T. Noyes, Montclair, NJ
(US); Jeffrey L. Aldridge, Lebanon,
OH (US); James R. Giordano,
Milford, OH (US); Robert J. Beetel,
III, Sunnyvale, CA (US); Daniel J.
Abbott, Maple Valley, WA (US);
Matthew C. Miller, Cincinnati, OH
(US); Jeffrey P. Wiley, Milford, OH
(US); Nathan J. Price, Albuquerque,
NM (US); Daniel W. Price, Loveland,
OH (US); Robert L. Koch, Jr.,
Cincinnati, OH (US)

(73) Assignee: Ethicon LLC, Guaynabo, PR (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 2 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 15/290,570

(22) Filed: Oct. 11, 2016

(65) Prior Publication Data

US 2017/0095267 A1 Apr. 6, 2017

Related U.S. Application Data

- (60) Continuation of application No. 14/664,233, filed on Mar. 20, 2015, now Pat. No. 9,504,855, which is a (Continued)
- (51) **Int. Cl. H01L 41/09** (2006.01) **A61N 7/00** (2006.01)

 (Continued)

(10) Patent No.: US 10,335,614 B2

(45) **Date of Patent:** *Jul. 2, 2019

(52) U.S. Cl.

CPC A61N 7/00 (2013.01); A61B 17/320092 (2013.01); A61B 18/14 (2013.01);

(Continued)

(58) Field of Classification Search

CPC A61N 7/02; A61B 17/320092; A61B 18/14

(Continued)

(56) References Cited

U.S. PATENT DOCUMENTS

969,528 A 9/1910 Disbrow 1,570,025 A 1/1926 Young (Continued)

FOREIGN PATENT DOCUMENTS

AU 2003241752 A1 9/2003 CA 2535467 A1 4/1993 (Continued)

OTHER PUBLICATIONS

http://www.dotmed.com/listing/electrosurical-unit/ethicon/ultracision-g110-/1466724.


(Continued)

Primary Examiner — Thomas M Dougherty

(57) ABSTRACT

Various embodiments are directed to a method of driving an end effector coupled to an ultrasonic drive system of a surgical instrument. The method comprises generating at least one electrical signal. The at least one electrical signal is monitored against a first set of logic conditions. A first response is triggered when the first set of logic conditions is met. A parameter is determined from the at least one electrical signal.

18 Claims, 41 Drawing Sheets



3,513,848 A 3,514,856 A Related U.S. Application Data 5/1970 Winston et al. 6/1970 Camp et al division of application No. 12/896,351, filed on Oct. 8/1970 3,525,912 A Wallin 1, 2010, now Pat. No. 9,089,360, which is a contin-3,526,219 A 9/1970 Balamuth 3,554,198 A 1/1971 Tatoian et al. uation-in-part of application No. 12/503,775, filed on 3,580,841 A 5/1971 Cadotte et al. Jul. 15, 2009, now Pat. No. 8,058,771. 3,606,682 A 9/1971 Camp et al. 3,614,484 A 10/1971 Shoh 3,616,375 A 10/1971 Inoue (60) Provisional application No. 61/250,217, filed on Oct. 3.629.726 A 12/1971 Popescu 9, 2009, provisional application No. 61/188,790, filed 1/1972 3.636,943 A Balamuth on Aug. 13, 2008, provisional application No. 6/1972 3,668,486 A Silver 61/086,619, filed on Aug. 6, 2008. 3,702,948 A 11/1972 Balamuth 3,703,651 11/1972 Blowers 3,776,238 A 12/1973 Peyman et al. (51) Int. Cl. 3,777,760 A 12/1973 Essner A61B 17/32 (2006.01)3,805,787 4/1974 Banko B06B 1/02 (2006.01)3,809,977 5/1974 Balamuth et al. G05B 15/02 (2006.01)3,830,098 A 8/1974 Antonevich A61B 18/14 (2006.01)3,854,737 12/1974 Gilliam, Sr. 3,862,630 A 3,875,945 A 1/1975 A61N 7/02 (2006.01)Balamuth 4/1975 Friedman A61B 5/053 (2006.01)3,885,438 A 5/1975 Harris, Sr. et al. A61B 5/00 (2006.01)3,900,823 A 8/1975 Sokal et al. A61B 17/00 (2006.01)3,918,442 A 11/1975 Nikolaev et al A61B 18/00 (2006.01)3,924,335 A 12/1975 Balamuth et al. 3,946,738 A 3/1976 Newton et al. (52) U.S. Cl. 3,955,859 A 5/1976 Stella et al. CPC A61N 7/02 (2013.01); B06B 1/0284 3,956,826 A 5/1976 Perdreaux, Jr. (2013.01); G05B 15/02 (2013.01); A61B 5/053 4,005,714 A 2/1977 Hiltebrandt 3/1977 (2013.01); A61B 5/4836 (2013.01); A61B 4,012,647 A Balamuth et al. 4,034,762 A 7/1977 Cosens et al. 2017/00026 (2013.01); A61B 2017/00084 4,058,126 A 11/1977 Leveen (2013.01); A61B 2017/00176 (2013.01); A61B 4,074,719 A 2/1978 Semm 2017/00203 (2013.01); A61B 2017/00973 4,156,187 A 5/1979 Murry et al. (2013.01); A61B 2018/00005 (2013.01); A61B 4,167,944 A 9/1979 Banko 2018/0063 (2013.01); A61B 2018/00303 4,188,927 A 2/1980 Harris 4,200,106 A 4/1980 Douvas et al. (2013.01); A61B 2018/00589 (2013.01); A61B 4,203,430 A 5/1980 Takahashi 2018/00601 (2013.01); A61B 2018/00666 5/1980 4,203,444 A Bonnell et al. (2013.01); A61B 2018/00791 (2013.01); A61B 4,220,154 A 9/1980 Semm 2018/00845 (2013.01); A61B 2018/00875 4,237,441 A 12/1980 van Konynenburg et al. 4,281,785 A (2013.01); A61B 2018/00994 (2013.01); B06B 8/1981 **Brooks** 4,300,083 A 11/1981 Heiges 2201/76 (2013.01) 4,302,728 A 11/1981 Nakamura (58) Field of Classification Search 4.304.987 A 12/1981 van Konynenburg USPC 310/316.01, 317-319 4,306,570 A 12/1981 Matthews 4,314,559 2/1982 See application file for complete search history. Allen 4/1984 4,445,063 A Smith 4,463,759 A 8/1984 Garito et al. (56)References Cited 4,491,132 A 1/1985 Aikins 4,492,231 A 1/1985 Auth U.S. PATENT DOCUMENTS 4,494,759 1/1985 Kieffer 4,504,264 A 3/1985 Kelman 1,813,902 A 7/1931 Bovie 4.512.344 A 4/1985 Barber 1/1940 Calva 2,188,497 A 4.526.571 A 7/1985 Wuchinich 2,366,274 A 1/1945 Luth et al. 4,535,773 A 8/1985 Yoon 2,425,245 A 2,442,966 A 8/1947 Johnson 4,541,638 A 9/1985 Ogawa et al. 6/1948 Wallace 4,545,374 10/1985 Jacobson 2,458,152 A 1/1949 Eakins 4,545,926 A 10/1985 Fouts, Jr. et al. 2,510,693 A 6/1950 Green 4,549,147 10/1985 Kondo 2,597,564 A 5/1952 Bugg 4,550,870 A 11/1985 Krumme et al. 2,704,333 A 3/1955 Calosi et al. 4,553,544 A 11/1985 Nomoto et al. 2,736,960 A 3/1956 Armstrong 4,562,838 A 1/1986 Walker 2,748,967 A 6/1956 Roach 4,574,615 A 3/1986 Bower et al 2,845,072 A 7/1958 Shafer 4.582,236 A 4/1986 Hirose 2,849,788 A 9/1958 Creek 4,617,927 10/1986 Manes 2,867,039 A 1/1959 Zach 4,633,119 A 12/1986 Thompson 2.874.470 A 2/1959 Richards 4,634,420 A 1/1987 Spinosa et al. 7/1961 2,990,616 A Balamuth et al. 4,640,279 A 2/1987 Beard RE25,033 E 8/1961 Balamuth et al. 4,641,053 A 2/1987 Takeda 3,015,961 A 1/1962 Roney 4,646,738 A 3/1987 Trott 3,033,407 A 5/1962 Alfons 4,646,756 A 3/1987 Watmough et al. 3,053,124 A 9/1962 Balamuth et al. 4,649,919 A 3/1987 Thimsen et al. 3,082,805 A 3/1963 Royce

3,166,971 A

3,322,403 A

3,432,691 A

3,433,226 A

3,489,930 A

1/1965

5/1967

3/1969

3/1969

1/1970 Shoh

Stoecker

Murphy

Shoh

Boyd

4,662,068 A

4,674,502 A

4,694,835 A

4.708.127 A

4,712,722 A

5/1987

6/1987

9/1987

11/1987

Polonsky

Abdelghani

Imonti

Strand

12/1987 Hood et al.

(56)		Referen	ces Cited	5,214,			5/1993	
	TTC	DATENIT	DOCLIMENTS	5,217, 5,218.				Knoepfler Meyer et al.
	0.5.	PATENT	DOCUMENTS	5,221.				Wuchinich
4,735,60)3 A	4/1988	Goodson et al.	5,222				Kagawa
4,761,87			O'Connor et al.	5,226,				Evans et al.
4,808,15	54 A		Freeman	5,226,				Kajiyama et al.
4,819,63			Shapiro	5,231, 5,234,			8/1993 8/1993	Middleman et al. Kaufman
4,827,91			Broadwin et al.	5,241.			8/1993	Sasaki et al.
4,830,46 4,832,68			Karny et al. Idemoto et al.	5,241.			9/1993	Slater
4,836,18		6/1989		5,242,			9/1993	Thornton
4,838,85		6/1989		5,242,			9/1993	Klein et al.
4,844,06			Thimsen et al.	5,246, 5,254,				DeLonzor Alexander
4,849,13 4,850,35			Yoshida et al. McGurk-Burleson et al.	5,257,				L'Esperance, Jr.
4,852,57			Companion et al.	5,258,				Rydell et al.
4,860,74	15 A		Farin et al.	5,261,			11/1993	
4,862,89			Stasz et al.	5,263, 5,264,			11/1993	Davison Shipp et al.
4,865,15			Jamison McGurk-Burleson et al.	5,275.				Vaitekunas et al.
4,867,15 4,878,49			Pasternak et al.	5,275,				Lo et al.
4,880,01			Nierman	5,275,				Pingleton et al.
4,881,55	50 A	11/1989		5,282,				Foshee et al.
4,896,00			Pawlowski	5,282, 5,285,				Hoogeboom et al. Ryan et al.
4,903,69 4,910,38			Stasz et al. Sherman et al.	5,285,				Brinkerhoff et al.
4,915,64			Samejima et al.	5,290.			3/1994	
4,920,97		5/1990		5,300,				Rosar et al.
4,922,90			Wuchinich et al.	5,304,				Pflueger et al.
4,936,84			D'Amelio et al.	D347. 5,307.	976	A A	5/1994 5/1994	Olson et al.
4,954,96 4,965,53		10/1990	Lo et al.	5,309.			5/1994	
4,979,95			Kubota et al.	5,312,	,023	A	5/1994	Green et al.
4,981,75			Rhandhawa	5,312,				Evans et al.
5,001,64			Lo et al.	5,318, 5,318,			6/1994 6/1994	Malis et al.
5,013,95			Kurozumi et al.	5,318.				Lichtman
5,015,22 5,020,51			Broadwin et al. Heckele	5,322				Davison et al.
5,026,37			Lottick	5,324,				Davison et al.
5,026,38			Thomas	5,326,				Green et al.
5,035,69			Weber, Jr. et al.	5,326, 5,330,			7/1994 7/1994	Pflueger et al.
5,042,70 5,061,26		8/1991 10/1991		5,330.				Hassler et al.
5,084,05		1/1992		5,339,	723	A		Huitema
5,099,84		3/1992	Goble et al.	5,342,				Ellman et al.
5,104,02			Main et al.	5,342, 5,344.			8/1994	Rydell Hilal et al.
5,105,11 5,106,53			Yamaguchi Barma et al.	5,345.				Middleman et al.
5,100,33		4/1992		5,346.	,502	A		Estabrook et al.
5,109,81			Custer et al.	5,353.				Good et al.
5,112,30	00 A		Ureche	5,357, 5,357.				Imabayashi et al.
5,113,13			Furukawa	5,357, 5,359.				Weaver et al. Krauter et al.
5,123,90 5,126,61			Quaid et al. Takahashi et al.	5,361.				Huitema
D327,87			McMills et al.	5,366,			11/1994	Christian et al.
5,152,76	52 A	10/1992	McElhenney	5,368,				Nita et al.
5,156,63		10/1992		5,370, 5,371.			12/1994 12/1994	Klicek et al.
5,160,33 5,162,04			Billings et al. Gahn et al.	5,374,			12/1994	
5,163,42			Bernstein et al.	D354.				Medema
5,163,53		11/1992		5,381,				Greenstein et al.
5,163,94			Ortiz et al.	5,383, 5,387.				Jackson et al. Dyer et al.
5,167,61			Wuchinich	5,387,			2/1995	
5,167,72 5,172,34		12/1992	Clark et al.	5,389,			2/1995	Tsuruta et al.
5,174,27			Crockard	5,394.			2/1995	Shipp
D332,66			Rawson et al.	5,395,			3/1995	
5,176,67			Wuchinich	5,395, 5,395.			3/1995 3/1995	Billings et al. Anderhub et al.
5,176,69 5,184,60			Dulebohn Grzeszykowski	5,395, 5,396.			3/1995	Brimhall
5,188,10			Idemoto et al.	5,396				
D334,17			Liu et al.	5,400.				Denen et al.
5,190,51			Zieve et al.	5,403.				Yates et al.
5,190,54			Abele et al.	5,403,				Evans et al.
5,196,00			Ellman et al.	5,408,			4/1995	
5,205,45 5,209,71			Brinkerhoff et al. Baruch et al.	D358, 5,411,				Feinberg Allen et al.
5,209,71		5/1993		5,417.			5/1995	
3,213,30		0, 1000		5,117,	,		2. 1330	

(56)		Referen	ces Cited	5,628,760			Knoepfler
	U.S.	PATENT	DOCUMENTS	5,630,420 5,632,432	A		Vaitekunas Schulze et al.
				5,632,717		5/1997	
5,419,76			Narayanan et al.	5,640,741 D381,077		6/1997 7/1997	
5,421,82 5,423,84		6/1995	Olichney et al. Miller	5,647,871			Levine et al.
5,428,50		6/1995		5,649,937			Bito et al.
5,429,13			Scheinman et al.	5,651,780 5,653,713			Jackson et al. Michelson
5,438,99 5,441,49			Sieben et al. Fritzsch	5,655,100			Ebrahim et al.
5,443,46			Stern et al.	5,658,281		8/1997	
5,445,63			Rydell et al.	5,662,662 5,662,667			Bishop et al. Knodel
5,445,63 5,449,37			Kuslich et al. Vaitekunas	5,665,085			Nardella
5,451,05			Garrido	5,665,100		9/1997	
5,451,22		9/1995		5,669,922 5,674,219		9/1997	Monson et al.
5,451,22 5,456,68			Michaelson Schmidt et al.	5,674,220			Fox et al.
5,458,59			Feinberg et al.	5,674,235		10/1997	
5,465,89			Knodel et al.	5,678,568 5,688,270			Uchikubo et al. Yates et al.
5,471,98 5,472,44			Fujio et al. Cordis et al.	5,690,269			Bolanos et al.
5,476,47			Green et al.	5,693,051			Schulze et al.
5,478,00	3 A		Green et al.	5,694,936 5,695,510		12/1997 12/1997	Fujimoto et al.
5,480,40 5,483,50		1/1996	Riza Park et al.	5,700,261			Brinkerhoff
5,484,43			Eggers et al.	5,704,534	A	1/1998	Huitema et al.
5,486,16			Brumbach	5,707,369	A *	1/1998	Vaitekunas A61B 18/1442 606/27
5,486,18 5,490,86			Mudry et al. Middle et al.	5,709,680	A	1/1998	Yates et al.
5,496,31			Goble et al.	5,711,472	A	1/1998	
5,500,21			Julian et al.	5,713,896 5,715,817			Nardella Stevens-Wright et al.
5,501,65 5,504,65			Failla et al. Katsui et al.	5,716,366		2/1998	
5,505,69			Mackool	5,717,306	A	2/1998	Shipp
5,507,29			Slater et al.	5,720,742 5,720,744			Zacharias Eggleston et al.
5,507,73 5,509,92		4/1996 4/1996	Aranyi et al.	5,723,970		3/1998	
5,511,55			DeSantis	5,728,130			Ishikawa et al.
5,520,70			Castro et al.	5,730,752 5,733,074			Alden et al. Stock et al.
5,522,83 5,527,33		6/1996 6/1996	Kresch et al.	5,735,848			Yates et al.
5,531,74		7/1996	Nardella et al.	5,741,226			Strukel et al.
5,540,68		7/1996 7/1996	Strul et al.	5,743,906 5,752,973			Parins et al. Kieturakis
5,540,69 5,542,91			Hirsch et al.	5,755,717			Yates et al.
5,548,28	6 A	8/1996	Craven	5,762,255			Chrisman et al.
5,549,63 5,553,63			Crainich Pitzen et al.	5,766,164 5,772,659			Mueller et al. Becker et al.
5,553,67 5,558,67	1 A *		Yates A61B 17/07207	5,776,155	A	7/1998	Beaupre et al.
			606/34	5,779,701			McBrayer et al. Lucey et al.
5,562,60 5,562,61			Brumbach Brumbach	5,782,834 5,792,135			Madhani et al.
5,562,65		10/1996		5,792,138	A	8/1998	Shipp
5,563,17	9 A		Stone et al.	5,792,165 5,796,188		8/1998 8/1998	Klieman et al.
5,569,16 5,571,12		10/1996 11/1996		5,797,941			Schulze et al.
5,573,42		11/1996		5,797,958	A	8/1998	Yoon
5,573,53		11/1996		5,797,959 5,800,432			Castro et al. Swanson
5,577,65 5,584,83		11/1996	Bishop Ladd et al.	5,800,449		9/1998	
5,591,18		1/1997		5,805,140	A		Rosenberg et al.
5,593,41			Shipp et al.	5,807,393 5,808,396			Williamson, IV et al. Boukhny
5,599,35 5,600,52			Schulze et al. Russell et al.	5,810,811		9/1998	Yates et al.
5,601,60			Tal et al.	5,810,859			DiMatteo et al.
5,603,77			Campbell	5,817,033 5,817,084		10/1998	DeSantis et al.
5,607,43 5,607,45	0 A 0 A		Pratt et al. Zvenyatsky et al.	5,817,093			Williamson, IV et al.
5,609,57	3 A	3/1997	Sandock	5,817,119	A	10/1998	Klieman et al.
5,611,81			Lichtman	5,823,197			Edwards Buyese et al
5,618,30 5,618,30			Hart et al. Donlon et al.	5,827,271 5,827,323			Buysse et al. Klieman et al.
5,618,49	2 A		Auten et al.	5,828,160	A	10/1998	Sugishita
5,620,44			Smith et al.	5,833,696	A	11/1998	Whitfield et al.
5,624,45 5,626,58		4/1997 5/1997	Yates Bishop et al.	5,836,897 5,836,909			Sakurai et al. Cosmescu
5,626,59			Sklar et al.	5,836,943			Miller, III
				, , ,			*

(56)	Referen	ces Cited	6,074,389			Levine et al.
J	J.S. PATENT	DOCUMENTS	6,077,285 6,080,149	A A	6/2000	Boukhny Huang et al.
			6,083,191		7/2000	
5,836,957	A 11/1998	Schulz et al.	6,086,584		7/2000	
5,836,990			6,090,120			Wright et al.
5,843,109		Mehta et al.	6,091,995			Ingle et al.
5,851,212		Zirps et al.	6,096,033			Tu et al. Palmer et al.
5,853,412		Mayenberger	6,099,483 6,099,542			Cohn et al.
5,858,018 . 5,865,361 .		Shipp et al. Milliman et al.	6,099,550		8/2000	
5,873,873		Smith et al.	6,109,500		8/2000	Alli et al.
5,873,882		Straub et al.	6,110,127		8/2000	
5,876,401	A 3/1999	Schulze et al.	6,113,594			Savage
5,878,193		Wang et al.	6,117,152 H001904			Huitema Yates et al.
5,879,364		Bromfield et al.	6,126,629			Perkins
5,880,668 . 5,883,615 .		Fago et al.	6,126,658		0/2000	
5,891,142		Eggers et al.	6,129,735			Okada et al.
5,893,835		Witt et al.	6,129,740			Michelson
5,897,523	A 4/1999	Wright et al.	6,132,368			Cooper
5,897,569		Kellogg et al.	6,132,427			Jones et al.
5,903,607		Tailliet	6,132,429 6,132,448		0/2000	Perez et al.
5,904,681 . 5,906,625 .		West, Jr. Bito et al.	6,139,320		0/2000	
5,906,627		Spaulding	6,139,561			Shibata et al.
5,906,628		Miyawaki et al.	6,142,615	A 1	1/2000	Qiu et al.
5,910,129		Koblish et al.	6,142,994			Swanson et al.
5,911,699		Anis et al.	6,144,402			Norsworthy et al.
5,913,823		Hedberg et al.	6,147,560 6,152,902			Erhage et al. Christian et al.
5,916,229			6,152,902		1/2000	
5,921,956 . 5,929,846 .		Grinberg et al. Rosenberg et al.	6,154,198			Rosenberg
5,935,143			6,159,160			Hsei et al.
5,935,144		Estabrook	6,159,175		2/2000	
5,938,633		Beaupre	6,162,194		2/2000	
5,944,718		Austin et al.	6,162,208		2/2000 2/2000	
5,944,737		Tsonton et al.	6,165,150 6,174,309			Wrublewski et al.
5,947,984 . 5,954,717 .		Whipple Behl et al.	6,174,310			Kirwan, Jr.
5,954,736		Bishop et al.	6,176,857			Ashley
5,954,746		Holthaus et al.	6,179,853		1/2001	
5,957,882		Nita et al.	6,183,426	B1	2/2001	Akisada et al.
5,957,943		Vaitekunas	6,187,003 6,190,386		2/2001 2/2001	Buysse et al.
5,968,007		Simon et al.	6,193,709			Miyawaki et al.
5,968,060 . 5,974,342 .		Petrofsky	6,204,592		3/2001	
D416,089		Barton et al.	6,205,855			Pfeiffer
5,980,510		Tsonton et al.	6,206,844			Reichel et al.
5,980,546	A 11/1999	Hood	6,206,876			Levine et al.
5,984,938			6,210,337 6,210,402			Dunham et al. Olsen et al.
5,989,274		Davison et al.	6,210,403		4/2001	
5,989,275 5,993,465		Estabrook et al. Shipp et al.	6,214,023			Whipple et al.
5,993,972		Reich et al.	6,228,080		5/2001	Gines
5,994,855		Lundell et al.	6,231,565		5/2001	Tovey et al.
6,003,517		Sheffield et al.	6,233,476		5/2001	Strommer et al.
6,013,052		Durman et al.	6,238,366 6,245,065		5/2001 6/2001	Savage et al. Panescu et al.
6,024,741		Williamson, IV et al.	6,251,110			Wampler
6,024,744 <i>.</i> 6,024,750 <i>.</i>		Kese et al. Mastri et al.	6,252,110			Uemura et al.
6,027,515		Cimino	D444,365			Bass et al.
6,031,526			D445,092		7/2001	
6,033,375		Brumbach	D445,764		7/2001	
6,033,399			6,254,623 6,257,241			Haibel, Jr. et al. Wampler
6,036,667		Manna et al.	6,258,034			Hanafy
6,036,707 <i>.</i> 6,039,734 <i>.</i>		Spaulding Goble	6,259,230		7/2001	•
6,048,224			6,267,761	B1	7/2001	Ryan
6,050,943		Slayton et al.	6,270,831			Kumar et al.
6,050,996	A 4/2000	Schmaltz et al.	6,273,852			Lehe et al.
6,051,010		DiMatteo et al.	6,274,963			Estabrook et al.
6,056,735		Okada et al.	6,277,115		8/2001	
6,063,098 . 6,066,132 .		Houser et al. Chen et al.	6,277,117 6,278,218		8/2001 8/2001	Tetzlaff et al. Madan et al.
6,066,151		Miyawaki et al.	6,280,407		8/2001	
6,068,627		Orszulak et al.	6,283,981		9/2001	
6,068,629		Haissaguerre et al.	6,287,344		9/2001	Wampler et al.
6,068,647		Witt et al.	6,290,575		9/2001	
, -,						• •

(56)		Referen	ces Cited	6,514,267		2/2003	
	U.S.	PATENT	DOCUMENTS	6,517,565 6,524,251	B2	2/2003	Whitman et al. Rabiner et al.
,	200 500 D1	0/2001	36 1 1	6,524,316 6,527,736			Nicholson et al. Attinger et al.
	5,292,700 B1 5,299,591 B1	9/2001 10/2001	Morrison et al.	6,531,846		3/2003	
	5,306,131 B1		Hareyama et al.	6,533,784			Truckai et al.
	,306,157 B1		Shchervinsky	6,537,272 6,537,291			Christopherson et al. Friedman et al.
	5,309,400 B2 5,311,783 B1	10/2001 11/2001		6,543,452			Lavigne
	5,319,221 B1	11/2001	Savage et al.	6,543,456	B1	4/2003	Freeman
6	5,325,795 B1	12/2001	Lindemann et al.	6,544,260			Markel et al. LePivert
	5,325,799 B1 5,325,811 B1	12/2001	Goble Messerly	6,551,309 6,554,829			Schulze et al.
	5,328,751 B1	12/2001		6,558,376	B2	5/2003	Bishop
6	5,332,891 B1	12/2001	Himes	6,561,983		5/2003 5/2003	Cronin et al.
	5,338,657 B1 5,340,352 B1		Harper et al. Okada et al.	6,562,035 6,562,037			Paton et al.
	5,340,878 B1		Oglesbee	6,565,558	B1	5/2003	Lindenmeier et al.
6	5,350,269 B1	2/2002	Shipp et al.	6,572,563		6/2003	
	5,352,532 B1		Kramer et al. Wohlfarth	6,572,632 6,572,639			Zisterer et al. Ingle et al.
	5,356,224 B1 5,358,246 B1		Behl et al.	6,575,969	Bi	6/2003	Rittman, III et al.
6	5,358,264 B2	3/2002	Banko	6,582,427			Goble et al.
	5,364,888 B1		Niemeyer et al.	6,582,451 6,584,360			Marucci et al. Francischelli et al.
	5,379,320 B1 0457,958 S		Lafon et al. Dycus et al.	D477,408	S	7/2003	Bromley
6	5,383,194 B1		Pothula	6,585,735			Frazier et al.
	5,384,690 B1		Wilhelmsson et al.	6,588,277 6,589,200			Giordano et al. Schwemberger et al.
	5,387,109 B1 5,388,657 B1	5/2002	Davison et al. Natoli	6,589,239	B2		Khandkar et al.
	5,390,973 B1	5/2002		6,590,733			Wilson et al.
	5,391,026 B1		Hung et al.	6,599,288 6,602,252			Maguire et al. Mollenauer
	5,391,042 B1 5,398,779 B1		Cimino Buysse et al.	6,607,540		8/2003	
	5,402,743 B1		Orszulak et al.	6,610,059			West, Jr.
	,402,748 B1		Schoenman et al.	6,610,060 6,611,793			Mulier et al. Burnside et al.
	5,405,733 B1 5,409,722 B1		Fogarty et al. Hoey et al.	6,616,450			Mossle et al.
	H002037 H	7/2002	Yates et al.	6,619,529	B2		Green et al.
	,416,486 B1		Wampler	6,620,161			Schulze et al. Daniel et al.
	5,419,675 B1 5,423,073 B2		Gallo, Sr. Bowman	6,622,731 6,623,482			Pendekanti et al.
	5,423,082 B1		Houser et al.	6,623,500	B1		Cook et al.
	,425,906 B1		Young et al.	6,623,501 6,626,848			Heller et al. Neuenfeldt
	5,428,538 B1 5,428,539 B1		Blewett et al. Baxter et al.	6,626,926			Friedman et al.
	5,430,446 B1		Knowlton	6,629,974	B2		Penny et al.
	5,432,118 B1		Messerly	6,633,234 6,635,057	B2		Wiener et al. Harano et al.
	5,436,114 B1 5,436,115 B1		Novak et al. Beaupre				Green et al.
	5,440,062 B1	8/2002		6,651,669	B1	11/2003	Burnside
	5,443,968 B1		Holthaus et al.	6,652,513 6,652,539			Panescu et al. Shipp et al.
	5,443,969 B1 5,449.006 B1	9/2002 9/2002	Novak et al.	6,652,545			Shipp et al.
	5,454,781 B1	9/2002	Witt et al.	6,656,132		12/2003	
	5,454,782 B1		Schwemberger	6,656,177 6,656,198			Truckai et al. Tsonton et al.
	5,458,128 B1 5,458,142 B1	10/2002	Schulze Faller et al.	6,660,017			Beaupre
	5,464,689 B1		Qin et al.	6,662,127			Wiener et al.
	5,464,702 B2		Schulze et al.	6,663,941 6,666,860			Brown et al. Takahashi
	5,468,270 B1 5,475,215 B1		Hovda et al. Tanrisever	6,666,875			Sakurai et al.
	5,480,796 B2	11/2002		6,669,690			Okada et al.
	5,485,490 B2		Wampler et al.	6,669,710 6,673,248			Moutafis et al. Chowdhury
	5,491,690 B1 5,491,701 B2		Goble et al. Tierney et al.	6,676,660			Wampler et al.
	5,491,708 B2		Madan et al.	6,678,621		1/2004	Wiener et al.
	,497,715 B2	12/2002		6,679,875			Honda et al.
	5,500,112 B1 5,500,176 B1	12/2002	Khouri Truckai et al.	6,679,882 6,679,899			Kornerup Wiener et al.
	5,500,176 B1 5,500,188 B2		Harper et al.	6,682,501			Nelson et al.
6	5,500,312 B2	12/2002	Wedekamp	6,682,544			Mastri et al.
	5,503,248 B1	1/2003	Levine Hunt et al.	6,685,700 6,685,701			Behl et al. Orszulak et al.
	5,506,208 B2 5,511,478 B1		Burnside et al.	6,685,703			Pearson et al.
6	5,511,480 B1	1/2003	Tetzlaff et al.	6,689,145	B2	2/2004	Lee et al.
	5,511,493 B1		Moutafis et al.	6,689,146		2/2004	
6	5,514,252 B2	2/2003	Nezhat et al.	6,690,960	В2	2/2004	Chen et al.

(56)	Referen	nces Cited	6,923,806 E 6,926,712 E		Hooven et al.
U.S	. PATENT	DOCUMENTS	6,926,716 E	8/2005	Baker et al.
C CO5 940 D2	2/2004	C-11-	6,926,717 E 6,929,602 E		Garito et al. Hirakui et al.
6,695,840 B2 6,702,821 B2		Schulze Bonutti	6,929,622 E	8/2005	Chian
6,716,215 B1	4/2004	David et al.	6,929,632 E		Nita et al.
6,719,692 B2 6,719,765 B2		Kleffner et al. Bonutti	6,929,644 E 6,933,656 E		Truckai et al. Matsushita et al.
6,719,776 B2		Baxter et al.	D509,589 S	9/2005	Wells
6,722,552 B2		Fenton, Jr.	6,942,660 E 6,942,677 E		Pantera et al. Nita et al.
6,723,091 B2 D490,059 S		Goble et al. Conway et al.	6,945,981 E	9/2005	Donofrio et al.
6,731,047 B2	5/2004	Kauf et al.	6,946,779 E		
6,733,498 B2		Paton et al. McDevitt et al.	6,948,503 E 6,953,461 E		Refior et al. McClurken et al.
6,733,506 B1 6,736,813 B2		Yamauchi et al.	D511,145 S	11/2005	Donofrio et al.
6,739,872 B1		Turri	6,974,450 E 6,976,844 E		Weber et al. Hickok et al.
6,740,079 B1 D491,666 S		Eggers et al. Kimmell et al.	6,976,969 E		Messerly
6,743,245 B2	6/2004	Lobdell	6,977,495 E		Donofrio
6,746,284 B1		Spink, Jr.	6,979,332 E 6,981,628 E		
6,746,443 B1 6,752,815 B2		Morley et al. Beaupre	6,984,220 E	1/2006	Wuchinich
6,755,825 B2	6/2004	Shoenman et al.	6,988,295 E 6,994,708 E		Tillim Manzo
6,761,698 B2 6,762,535 B2		Shibata et al. Take et al.	6,994,709 E		
6,766,202 B2		Underwood et al.	7,000,818 E	2/2006	Shelton, IV et al.
6,770,072 B1	8/2004	Truckai et al.	7,001,335 E 7,001,379 E		Adachi et al. Behl et al.
6,773,409 B2 6,773,435 B2	8/2004 8/2004	Truckai et al. Schulze et al.	7,001,382 E	2/2006	Gallo, Sr.
6,773,443 B2	8/2004	Truwit et al.	7,011,657 E		Truckai et al.
6,773,444 B2 6,775,575 B2		Messerly Bommannan et al.	7,014,638 E 7,025,732 E		Michelson Thompson et al.
6,778,023 B2		Christensen	7,033,357 E	4/2006	Baxter et al.
6,783,524 B2		Anderson et al.	7,037,306 E 7,041,083 E		Podany et al. Chu et al.
6,786,382 B1 6,786,383 B2		Hoffman Stegelmann	7,041,088 E		Nawrocki et al.
6,789,939 B2	9/2004	Schrodinger et al.	7,041,102 E		Truckai et al.
6,790,173 B2 6,790,216 B1		Saadat et al. Ishikawa	7,044,949 E 7,052,496 E		Orszulak et al. Yamauchi
6,794,027 B1		Araki et al.	7,055,731 E	6/2006	Shelton, IV et al.
6,796,981 B2		Wham et al.	7,063,699 E 7,066,893 E		Hess et al. Hibner et al.
D496,997 S 6,800,085 B2		Dycus et al. Selmon et al.	7,066,895 E		Podany
6,802,843 B2	10/2004	Truckai et al.	7,066,936 E		,
6,808,525 B2 6,809,508 B2		Latterell et al. Donofrio	7,070,597 E 7,074,218 E		Truckai et al. Washington et al.
6,810,281 B2		Brock et al.	7,074,219 E	7/2006	Levine et al.
6,811,842 B1		Ehrnsperger et al.	7,077,039 E 7,077,845 E		Gass et al. Hacker et al.
6,814,731 B2 6,819,027 B2	11/2004	Swanson Saraf	7,077,853 E	7/2006	Kramer et al.
6,821,273 B2	11/2004	Mollenauer	7,083,618 E	8/2006	Couture et al. Truckai et al.
6,827,712 B2 6,828,712 B2		Tovey et al. Battaglin et al.	7,083,619 E 7,087,054 E		Truckai et al.
6,835,082 B2		Gonnering	7,090,672 E		Underwood et al.
6,835,199 B2		McGuckin, Jr. et al. Morley et al.	7,094,235 E 7,101,371 E		Francischelli Dycus et al.
6,840,938 B1 6,843,789 B2		Goble	7,101,372 E	9/2006	Dycus et al.
6,849,073 B2	2/2005	Hoey et al.	7,101,373 E 7,101,378 E		Dycus et al. Salameh et al.
6,860,878 B2 6,860,880 B2		Brock Treat et al.	7,101,378 E		Robinson et al.
6,863,676 B2		Lee et al.	7,108,695 E		Witt et al.
6,866,671 B2		Tierney et al. White et al.	7,111,769 E 7,112,201 E		Wales et al. Truckai et al.
6,869,439 B2 6,875,220 B2		Du et al.	D531,311 S	10/2006	Guerra et al.
6,877,647 B2	4/2005	Green et al.	7,117,034 E 7,118,564 E		Kronberg Ritchie et al.
6,882,439 B2 6,887,209 B2		Ishijima Kadziauskas et al.	7,118,570 E		Tetzlaff et al.
6,887,252 B1		Okada et al.	7,124,932 E		Isaacson et al.
6,893,435 B2		Goble Wiener et al	7,125,409 E 7,128,720 E		Truckai et al.
6,898,536 B2 6,899,685 B2		Wiener et al. Kermode et al.	7,128,720 E		Sartor et al.
6,905,497 B2	6/2005	Truckai et al.	7,131,970 E	11/2006	Moses et al.
6,908,463 B2		Treat et al.	7,135,018 E		Ryan et al. Schwemberger et al.
6,908,472 B2 6,913,579 B2		Wiener et al. Truckai et al.	7,135,030 E 7,137,980 E		Buysse et al.
6,915,623 B2	7/2005	Dey et al.	7,143,925 E	12/2006	Shelton, IV et al.
6,923,804 B2	8/2005	Eggers et al.	7,144,403 E	12/2006	Booth

(56)	Referen	ces Cited	7,361,172			Cimino
U.S	S. PATENT	DOCUMENTS	7,364,577 7,367,976	B2	5/2008	Wham et al. Lawes et al.
5 1 45 120 D2	10/2006	CI I TY	7,371,227 RE40,388		5/2008 6/2008	
7,147,138 B2 7,153,315 B2	12/2006	Shelton, IV	7,380,695			Doll et al.
D536,093 S		Nakajima et al.	7,380,696	B2		Shelton, IV et al.
7,156,189 B1		Bar-Cohen et al.	7,381,209			Truckai et al.
7,156,846 B2		Dycus et al.	7,384,420			Dycus et al. Taylor et al.
7,156,853 B2		Muratsu Marhasin et al.	7,390,317 7,396,356			Mollenauer
7,157,058 B2 7,159,750 B2		Racenet et al.	7,403,224			Fuller et al.
7,160,296 B2		Pearson et al.	7,404,508			Smith et al.
7,160,298 B2		Lawes et al.	7,407,077 7,408,288		8/2008 8/2008	Ortiz et al.
7,160,299 B2 7,163,548 B2		Baily Stulen et al.	7,412,008		8/2008	
7,169,144 B2		Hoey et al.	7,416,101		8/2008	Shelton, IV et al.
7,169,146 B2	1/2007	Truckai et al.	7,416,437		8/2008	
7,169,156 B2			D576,725 7,419,490		9/2008	Shumer et al. Falkenstein et al.
7,179,254 B2 7,179,271 B2		Pendekanti et al. Friedman et al.	7,422,139			Shelton, IV et al.
7,186,253 B2		Truckai et al.	7,422,463	B2	9/2008	Kuo
7,189,233 B2	3/2007	Truckai et al.	7,422,582			Malackowski et al.
7,195,631 B2		Dumbauld	D578,643 D578,644			Shumer et al. Shumer et al.
D541,418 S 7,198,635 B2		Schechter et al. Danek et al.	D578,645		10/2008	Shumer et al.
7,204,820 B2		Akahoshi	7,431,704		10/2008	
7,207,471 B2		Heinrich et al.	7,431,720			Pendekanti et al. Zimmermann et al.
7,207,997 B2		Shipp et al.	7,435,582 7,441,684			Shelton, IV et al.
7,210,881 B2 7,211,079 B2		Greenberg Treat	7,442,193			Shields et al.
7,217,128 B2		Atkin et al.	7,445,621			Dumbauld et al.
7,217,269 B2		El-Galley et al.	7,455,208 7,462,181			Wales et al. Kraft et al.
7,220,951 B2 7,223,229 B2		Truckai et al. Inman et al.	7,464,846			Shelton, IV et al.
7,225,964 B2		Mastri et al.	7,472,815	B2	1/2009	Shelton, IV et al.
7,226,448 B2	6/2007	Bertolero et al.	7,473,145			Ehr et al.
7,229,455 B2		Sakurai et al.	7,473,253 7,473,263			Dycus et al. Johnston et al.
7,232,440 B2 7,235,071 B2		Dumbauld et al. Gonnering	7,479,148			Beaupre
7,235,071 B2		Levine et al.	7,479,160			Branch et al.
7,241,294 B2		Reschke	7,481,775 7,488,285			Weikel, Jr. et al. Honda et al.
7,244,262 B2 7,251,531 B2		Wiener et al. Mosher et al.	7,488,319		2/2009	
7,252,641 B2		Thompson et al.	7,491,201		2/2009	Shields et al.
7,252,667 B2	8/2007	Moses et al.	7,494,468			Rabiner et al.
7,258,688 B1			7,494,501 7,498,080		3/2009	Ahlberg et al. Tung et al.
7,267,677 B2 7,267,685 B2		Johnson et al. Butaric et al.	7,502,234		3/2009	Goliszek et al.
7,269,873 B2		Brewer et al.	7,503,893			Kucklick
7,273,483 B2	9/2007	Wiener et al.	7,503,895 7,506,790			Rabiner et al. Shelton, IV
D552,241 S 7,282,048 B2		Bromley et al. Goble et al.	7,506,790			Omaits et al.
7,282,048 B2 7,285,895 B2		Beaupre	7,510,107		3/2009	Timm et al.
7,287,682 B1	10/2007	Ezzat et al.	7,513,025			Fischer
7,297,149 B2		Vitali et al.	7,517,349 7,524,320			Truckai et al. Tierney et al.
7,300,431 B2 7,300,435 B2		Dubrovsky Wham et al.	7,530,986			Beaupre et al.
7,300,446 B2		Beaupre	7,534,243		5/2009	Chin et al.
7,300,450 B2		Vleugels et al.	7,535,233 D594,983			Kojovic et al. Price et al.
7,303,531 B2 7,303,557 B2		Lee et al. Wham et al.	7.540,871		6/2009	
7,306,597 B2			7,540,872	B2	6/2009	Schechter et al.
7,307,313 B2	12/2007	Ohyanagi et al.	7,543,730			Marczyk
7,309,849 B2		Truckai et al.	7,544,200 7,549,564			Houser Boudreaux
7,311,706 B2 7,311,709 B2		Schoenman et al. Truckai et al.	7,550,216			Ofer et al.
7,317,955 B2		McGreevy	7,553,309			Buysse et al.
7,318,831 B2	1/2008	Alvarez et al.	7,559,450		7/2009	
7,326,236 B2 7,329,257 B2		Andreas et al. Kanehira et al.	7,559,452 7,566,318			Wales et al. Haefner
7,329,237 B2 7,331,410 B2	2/2008	Yong et al.	7,567,012			Namikawa
7,335,165 B2	2/2008	Truwit et al.	7,568,603	B2	8/2009	Shelton, IV et al.
7,335,997 B2		Wiener	7,569,057			Liu et al.
7,337,010 B2		Howard et al.	7,572,266			Young et al.
7,353,068 B2 7,354,440 B2		Tanaka et al. Truckal et al.	7,572,268 7,578,820			Babaev Moore et al.
7,357,287 B2		Shelton, IV et al.	7,582,084		9/2009	Swanson et al.
7,357,802 B2		Palanker et al.	7,582,086	B2	9/2009	Privitera et al.

(56)	Referen	ices Cited	7,776,036 7,776,037		8/2010 8/2010	Schechter et al.
U.	S. PATENT	DOCUMENTS	7,778,733	B2	8/2010	Nowlin et al.
7.582.087 B2	9/2009	Tetzlaff et al.	7,780,054 7,780,593		8/2010 8/2010	Ueno et al.
7,582,095 B2	9/2009	Shipp et al.	7,780,651			Madhani et al.
7,585,181 B2 7,586,289 B2		Olsen Andruk et al.	7,780,659 7,780,663			Okada et al. Yates et al.
7,580,289 B2		McLeod	7,784,662	B2	8/2010	Wales et al.
7,588,176 B2		Timm et al. Danek et al.	7,784,663 7,789,883			Shelton, IV Takashino et al.
7,594,925 B2 7,597,693 B2		Garrison	7,793,814	B2	9/2010	Racenet et al.
7,601,119 B2		Shahinian	7,796,969 7,798,386		9/2010	Kelly et al. Schall et al.
7,601,136 B2 7,604,150 B2		Akahoshi Boudreaux	7,799,020	B2	9/2010	Shores et al.
7,607,557 B2		Shelton, IV et al.	7,799,045 7,803,152			Masuda Honda et al.
7,621,930 B2 7,628,791 B2	2 12/2009	Garrison et al.	7,803,156	B2	9/2010	Eder et al.
7,628,792 B2	2 12/2009		7,806,891 7,810,693			Nowlin et al. Broehl et al.
7,632,267 B2 7,632,269 B2	2 12/2009 2 12/2009	Dania Truckai et al.	7,811,283	B2	10/2010	Moses et al.
7,641,653 B2	2 1/2010	Dalla Betta et al.	7,815,641 7,819,298			Dodde et al. Hall et al.
7,641,671 B2 7,644,848 B2		Crainich Swayze et al.	7,819,299	B2	10/2010	Shelton, IV et al.
7,645,240 B2	2 1/2010	Thompson et al.	7,819,819 7,819,872			Quick et al. Johnson et al.
7,645,277 B2 7,645,278 B2		McClurken et al. Ichihashi et al.	7,821,143		10/2010	Wiener
7,648,499 B2	2 1/2010	Orszulak et al.	D627,066 7,824,401		11/2010	Romero Manzo et al.
7,654,431 B2 7,655,003 B2		Hueil et al. Lorang et al.	7,832,408	B2	11/2010	Shelton, IV et al.
7,658,311 B2	2/2010	Boudreaux	7,832,611 7,832,612			Boyden et al. Baxter, III et al.
7,659,833 B2 7,662,151 B2		Warner et al. Crompton, Jr. et al.	7,834,484		11/2010	
7,665,647 B2	2/2010	Shelton, IV et al.	7,837,699			Yamada et al. Shelton, IV et al.
7,666,206 B2 7,667,592 B2		Taniguchi et al. Ohyama et al.	7,845,537 7,846,155			Houser et al.
7,670,334 B2	2 3/2010	Hueil et al.	7,846,159			Morrison et al.
7,670,338 B2 7,674,263 B2		Albrecht et al.	7,846,160 7,846,161			Payne et al. Dumbauld et al.
7,678,069 B	3/2010	Baker et al.	7,854,735			Houser et al.
7,678,125 B2 7,682,366 B2	2 3/2010	Shipp Sakurai et al.	D631,155 7,861,906			Peine et al. Doll et al.
7,686,770 B2	2 3/2010	Cohen	7,862,560		1/2011	
7,686,826 B2 7,688,028 B2		Lee et al. Phillips et al.	7,871,392 7,876,030		1/2011 1/2011	Taki et al.
7,691,095 B2	2 4/2010	Bednarek et al.	D631,965		2/2011 2/2011	Price et al.
7,691,098 B2 7,699,846 B2		Wallace et al.	7,878,991 7,879,033		2/2011	Sartor et al.
7,703,459 B	2 4/2010	Saadat et al.	7,879,035	B2		Garrison et al.
7,703,653 B2 7,708,735 B2		Shah et al. Chapman et al.	7,879,070 7,892,606			Ortiz et al. Thies et al.
7,708,751 B2	2 5/2010	Hughes et al.	7,896,875	B2	3/2011	Heim et al.
7,708,768 B2 7,713,202 B2		Danek et al. Boukhny et al.	7,897,792 7,901,400			Iikura et al. Wham et al.
7,714,481 B	2 5/2010	Sakai	7,901,423		3/2011	Stulen et al.
7,717,312 B2 7,717,915 B2		Beetel Miyazawa	7,905,881 7,909,220		3/2011	Masuda et al. Viola
7,721,935 B2	5/2010	Racenet et al.	7,909,820			Lipson et al.
7,722,527 B2 7,722,607 B2		Bouchier et al. Dumbauld et al.	7,909,824 7,918,848			Masuda et al. Lau et al.
D618,797 S	6/2010	Price et al.	7,919,184	B2		Mohapatra et al.
7,726,537 B2 7,727,177 B2		Olson et al.	7,922,061 7,922,651			Shelton, IV et al. Yamada et al.
7,738,969 B2	6/2010	Bleich	7,931,649			Couture et al.
7,740,594 B2 7,751,115 B2		Hibner Song	D637,288 D638,540			Houghton Ijiri et al.
7,753,904 B2	7/2010	Shelton, IV et al.	7,935,114		5/2011	Takashino et al.
7,753,908 B2 7,762,445 B2		Swanson Heinrich et al.	7,936,203 7,951,095			Zimlich Makin et al.
D621,503 S	8/2010	Otten et al.	7,951,165	B2	5/2011	Golden et al.
7,766,210 B2 7,766,693 B2		Shelton, IV et al. Sartor et al.	7,955,331 7,956,620		6/2011 6/2011	Truckai et al. Gilbert
7,766,910 B	8/2010	Hixson et al.	7,959,050	B2	6/2011	Smith et al.
7,768,510 B2 7,770,774 B2		Tsai et al. Mastri et al.	7,959,626 7,963,963			Hong et al. Francischelli et al.
7,770,774 B2		Shelton, IV et al.	7,963,963			Lindquist
7,771,425 B	8/2010	Dycus et al.	7,972,329	B2	7/2011	Refior et al.
7,771,444 B2 7,775,972 B2		Patel et al. Brock et al.	7,976,544 7,980,443			McClurken et al. Scheib et al.
.,,	5,2010		,,			

(56)	J	Referen	ces Cited	8,246,618 B2		Bucciaglia et al.
	U.S. P.	ATENT	DOCUMENTS	8,251,994 B2 8,252,012 B2	8/2012	
				8,253,303 B2 8,257,377 B2		Giordano et al. Wiener et al.
7,981,050			Ritchart et al.	8,257,387 B2		Cunningham
7,981,113 7,997,278			Truckai et al. Utley et al.	8,262,563 B2		Bakos et al.
7,998,157			Culp et al.	8,267,300 B2		Boudreaux
8,020,743			Shelton, IV	8,273,087 B2		Kimura et al.
8,028,885			Smith et al.	D669,992 S		Schafer et al.
8,033,173			Ehlert et al.	D669,993 S 8,277,446 B2		Merchant et al.
8,038,693		10/2011	Allen O'Brien et al.	8,277,440 B2		Garrison et al.
8,048,070 8,052,672			Laufer et al.	8,277,471 B2		Wiener et al.
8,056,720			Hawkes	8,282,669 B2		Gerber et al.
8,056,787			Boudreaux et al.	8,286,846 B2		Smith et al.
8,057,468			Konesky	8,287,485 B2 8,287,528 B2		Kimura et al. Wham et al.
8,057,498			Robertson	8,287,532 B2		Carroll et al.
8,058,771 8,061,014			Giordano et al. Smith et al.	8,292,886 B2		Kerr et al.
8,066,167			Measamer et al.	8,292,888 B2	2 10/2012	Whitman
8,070,036		12/2011		8,292,905 B2		Taylor et al.
8,070,711			Bassinger et al.	8,298,223 B2		Wham et al.
8,070,762			Escudero et al.	8,298,225 B2 8,298,232 B2		
8,075,555 8,075,558			Truckai et al. Truckai et al.	8,298,233 B2		Mueller
8,089,197			Rinner et al.	8,303,576 B2		
8,092,475	5 B2		Cotter et al.	8,303,579 B2		Shibata
8,096,459			Ortiz et al.	8,303,580 B2		Wham et al.
8,097,012			Kagarise	8,303,583 B2 8,303,613 B2		Hosier et al. Crandall et al.
8,100,894 8,105,323			Mucko et al. Buysse et al.	8,306,629 B2		Mioduski et al.
8,114,104		2/2012	Young et al.	8,308,040 B2	11/2012	Huang et al.
8,118,276			Sanders et al.	8,319,400 B2		Houser et al.
8,128,624			Couture et al.	8,323,302 B2 8,323,310 B2		Robertson et al. Kingsley
8,133,218			Daw et al.	8,328,761 B2		Widenhouse et al.
8,136,712 8,141,762			Zingman Bedi et al.	8,328,802 B2		Deville et al.
8,142,421			Cooper et al.	8,328,833 B2		
8,142,461		3/2012	Houser et al.	8,328,834 B2		Isaacs et al.
8,147,508			Madan et al.	8,333,778 B2 8,333,779 B2		Smith et al. Smith et al.
8,152,801 8,152,825			Goldberg et al. Madan et al.	8,334,468 B2		Palmer et al.
8,157,145			Shelton, IV et al.	8,334,635 B2	2 12/2012	Voegele et al.
8,161,977			Shelton, IV et al.	8,337,407 B2		Quistgaard et al.
8,162,966			Connor et al.	8,338,726 B2 8,344,596 B2	1/2012	Palmer et al. Nield et al.
8,172,846 8,172,870		5/2012	Brunnett et al.	8,348,880 B2		Messerly et al.
8,177,800			Spitz et al.	8,348,947 B2	2 1/2013	
8,182,502			Stulen et al.	8,348,967 B2		Stulen
8,186,560			Hess et al.	8,357,103 B2 8,357,149 B2		Mark et al.
8,186,877			Klimovitch et al.	8,357,158 B2		Govari et al. McKenna et al.
8,187,267 D661,80			Pappone et al. Price et al.	8,361,066 B2		Long et al.
D661,802			Price et al.	8,361,072 B2		Dumbauld et al.
D661,803			Price et al.	8,361,569 B2 8,366,727 B2	2/2013	Saito et al.
D661,804			Price et al.	8,372,064 B2		Witt et al. Douglass et al.
8,197,472 8,197,479			Lau et al. Olson et al.	8,372,099 B2		Deville et al.
8,197,502			Smith et al.	8,372,101 B2		Smith et al.
8,207,651	1 B2		Gilbert	8,372,102 B2		Stulen et al.
8,210,411			Yates et al.	8,374,670 B2 8,377,044 B2		Selkee Coe et al.
8,221,415 8,226,580			Francischelli Govari et al.	8,377,059 B2		Deville et al.
8,226,675			Houser et al.	8,377,085 B2	2/2013	Smith et al.
8,231,607			Takuma	8,382,748 B2		
8,235,917			Joseph et al.	8,382,775 B1 8,382,782 B2		Bender et al. Robertson et al.
8,236,018			Yoshimine et al.	8,382,792 B2		Chojin
8,236,019 8,236,020			Houser Smith et al.	8,397,971 B2		Yates et al.
8,241,235			Kahler et al.	8,403,945 B2	2 3/2013	Whitfield et al.
8,241,271			Millman et al.	8,403,948 B2		Deville et al.
8,241,282			Unger et al.	8,403,949 B2		Palmer et al.
8,241,283 8,241,284			Guerra et al. Dycus et al.	8,403,950 B2 8,409,234 B2		Palmer et al. Stahler et al.
8,241,312			Messerly	8,414,577 B2		Boudreaux et al.
8,246,575		8/2012		8,418,073 B2		Mohr et al.
8,246,61	5 B2	8/2012	Behnke	8,418,349 B2		Smith et al.
8,246,616	5 B2	8/2012	Amoah et al.	8,419,757 B2	4/2013	Smith et al.

(56)	Referen	ces Cited	D695,407			Price et al.
US	PATENT	DOCUMENTS	D696,631 8,597,193			Price et al. Grunwald et al.
0.5			8,602,031	B2	12/2013	Reis et al.
8,419,758 B2 8,419,759 B2	4/2013 4/2013	Smith et al.	8,602,288 8,603,089		12/2013 12/2013	Shelton, IV et al. Viola
8,423,182 B2		Robinson et al.	8,608,044	B2	12/2013	Hueil et al.
8,425,410 B2		Murray et al.	8,608,745 8,613,383			Guzman et al. Beckman et al.
8,425,545 B2 8,430,811 B2		Smith et al. Hess et al.	8,616,431	B2	12/2013	Timm et al.
8,430,876 B2		Kappus et al.	8,622,274 8,623,011		1/2014 1/2014	Yates et al. Spivey
8,430,897 B2 8,430,898 B2		Novak et al. Wiener et al.	8,623,016	B2	1/2014	Fischer
8,435,257 B2	5/2013	Smith et al.	8,623,027 8,623,044			Price et al. Timm et al.
8,439,912 B2 8,439,939 B2		Cunningham et al. Deville et al.	8,628,529		1/2014	Aldridge et al.
8,444,637 B2	5/2013	Podmore et al.	8,632,461			Glossop
8,444,662 B2 8,444,664 B2		Palmer et al. Balanev et al.	8,638,428 8,640,788		1/2014 2/2014	Dachs, II et al.
8,453,906 B2		Huang et al.	8,647,350	B2	2/2014	Mohan et al.
8,454,639 B2		Du et al.	8,650,728 8,652,120			Wan et al. Giordano et al.
8,459,525 B2 8,460,288 B2		Yates et al. Tamai et al.	8,652,132	B2	2/2014	Tsuchiya et al.
8,460,292 B2		Truckai et al.	8,652,155 8,657,489			Houser et al. Ladurner et al.
8,461,744 B2 8,469,981 B2		Wiener et al. Robertson et al.	8,659,208	B1		Rose et al.
8,479,969 B2	7/2013	Shelton, IV	8,663,220	B2		Wiener et al.
8,480,703 B2 8,484,833 B2		Nicholas et al. Cunningham et al.	8,663,222 8,663,223			Anderson et al. Masuda et al.
8,485,413 B2		Scheib et al.	8,663,262	B2		Smith et al.
8,485,970 B2		Widenhouse et al.	8,668,691 8,668,710		3/2014 3/2014	Slipszenko et al.
8,486,057 B2 8,486,096 B2		Behnke, II Robertson et al.	8,684,253	B2	4/2014	Giordano et al.
8,491,578 B2		Manwaring et al.	8,685,016 8,685,020			Wham et al. Weizman et al.
8,491,625 B2 8,496,682 B2		Horner Guerra et al.	8,690,582			Rohrbach et al.
D687,549 S	8/2013	Johnson et al.	8,696,366 8,696,665			Chen et al. Hunt et al.
8,506,555 B2 8,509,318 B2		Ruiz Morales Tailliet	8,696,666			Sanai et al.
8,512,336 B2		Couture	8,702,609			Hadjicostis
8,512,359 B2 8,512,364 B2		Whitman et al. Kowalski et al.	8,702,704 8,704,425			Shelton, IV et al. Giordano et al.
8,512,365 B2		Wiener et al.	8,708,213	B2	4/2014	Shelton, IV et al.
8,518,067 B2		Masuda et al.	8,709,031 8,709,035		4/2014 4/2014	Stulen Johnson et al.
8,521,331 B2 8,523,882 B2		Itkowitz Huitema et al.	8,715,270	B2		Weitzner et al.
8,523,889 B2	9/2013	Stulen et al.	8,715,277 8,721,640		5/2014 5/2014	Weizman Taylor et al.
8,528,563 B2 8,529,437 B2		Gruber Taylor et al.	8,721,657			Kondoh et al.
8,529,565 B2	9/2013	Masuda et al.	8,734,443			Hixson et al.
8,531,064 B2 8,535,311 B2	9/2013 9/2013	Robertson et al.	8,747,238 8,747,351			Shelton, IV et al. Schultz
8,535,340 B2	9/2013		8,747,404	B2	6/2014	Boudreaux et al.
8,535,341 B2	9/2013		8,749,116 8,752,264			Messerly et al. Ackley et al.
8,540,128 B2 8,546,996 B2		Shelton, IV et al. Messerly et al.	8,752,749	B2	6/2014	Moore et al.
8,546,999 B2	10/2013	Houser et al.	8,753,338 8,754,570			Widenhouse et al. Voegele et al.
8,551,077 B2 8,551,086 B2		Main et al. Kimura et al.	8,758,342	B2		Bales et al.
8,562,592 B2	10/2013	Conlon et al.	8,758,352			Cooper et al.
8,562,598 B2 8,562,600 B2		Falkenstein et al. Kirkpatrick et al.	8,764,735 8,764,747			Coe et al. Cummings et al.
8,562,604 B2	10/2013	Nishimura	8,767,970		7/2014	Eppolito
8,568,390 B2 8,568,400 B2	10/2013 10/2013	Mueller	8,770,459 8,771,269		7/2014	Racenet et al. Sherman et al.
8,568,412 B2		Brandt et al.	8,771,270	B2	7/2014	Burbank
8,569,997 B2	10/2013		8,771,293 8,773,001			Surti et al. Wiener et al.
8,573,461 B2 8,573,465 B2		Shelton, IV et al. Shelton, IV	8,777,944		7/2014	Frankhouser et al.
8,574,231 B2	11/2013	Boudreaux et al.	8,779,648			Giordano et al.
8,574,253 B2 8,579,176 B2		Gruber et al. Smith et al.	8,783,541 8,784,415			Shelton, IV et al. Malackowski et al.
8,579,897 B2	11/2013	Vakharia et al.	8,784,418	B2	7/2014	Romero
8,579,928 B2		Robertson et al.	8,790,342			Stulen et al.
8,585,727 B2 8,588,371 B2	11/2013 11/2013	Polo Ogawa et al.	8,795,276 8,795,327			Dietz et al. Dietz et al.
8,591,459 B2	11/2013	Clymer et al.	8,800,838	B2	8/2014	Shelton, IV
8,591,506 B2		Wham et al.	8,801,710			Ullrich et al.
8,591,536 B2	11/2013	Robertson	8,808,319	В2	8/2014	Houser et al.

(56)	Referen	ces Cited	9,031,667			Williams
	C DATENIT	DOCUMENTS	9,033,973 9,035,741			Krapohl et al. Hamel et al.
0.	S. FAIENI	DOCUMENTS	9,039,690			Kersten et al.
8,814,856 B	2 8/2014	Elmouelhi et al.	9,039,695		5/2015	Giordano et al.
8,814,870 B		Paraschiv et al.	9,039,731		5/2015	
8,820,605 B		Shelton, IV	9,043,018		5/2015	Mohr Shelton, IV et al.
8,821,388 B		Naito et al.	9,044,227 9,044,238			Orszulak
8,827,992 B: 8,834,466 B:		Koss et al. Cummings et al.	9,044,243			Johnson et al.
8,834,518 B		Faller et al.	9,044,245			Condie et al.
8,844,789 B		Shelton, IV et al.	9,044,256		6/2015 6/2015	Cadeddu et al.
8,845,537 B		Tanaka et al.	9,044,261 9,050,093			Aldridge et al.
8,845,630 B: 8,848,808 B:		Mehta et al.	9,050,098			Deville et al.
8,851,354 B		Swensgard et al.	9,050,123			Krause et al.
8,852,184 B	2 10/2014	Kucklick	9,050,124		6/2015	
8,858,547 B			9,055,961 9,059,547			Manzo et al. McLawhorn
8,862,955 B: 8,864,749 B:			9,060,770			Shelton, IV et al.
8,864,757 B		Klimovitch et al.	9,060,775			Wiener et al.
8,864,761 B	2 10/2014	Johnson et al.	9,060,776			Yates et al.
8,870,865 B		Frankhouser et al.	9,066,723 9,066,747			Beller et al. Robertson
8,876,726 B: 8,876,858 B:		Amit et al.	9,072,523			Houser et al.
8,882,766 B		Couture et al.	9,072,535	B2	7/2015	Shelton, IV et al.
8,882,791 B			9,072,536			Shelton, IV et al.
8,888,776 B		Dietz et al.	9,072,539 9,084,624			Messerly et al. Larkin et al.
8,888,783 B: 8,888,809 B:		Young Davison et al.	9,089,327			Worrell et al.
8,899,462 B		Kostrzewski et al.	9,089,360			Messerly et al.
8,900,259 B		Houser et al.	9,095,362			Dachs, II et al.
8,906,016 B		Boudreaux et al.	9,095,367 9,101,385			Olson et al. Shelton, IV et al.
8,906,017 B: 8,911,438 B:		Rioux et al. Swoyer et al.	9,101,383			Robertson et al.
8,911,460 B		Neurohr et al.	9,107,690		8/2015	Bales, Jr. et al.
8,920,412 B		Fritz et al.	9,113,900			Buysse et al.
8,920,421 B			9,113,907 9,113,940			Allen, IV et al. Twomey
8,926,607 B		Norvell et al. Bacher et al.	9,119,657			Shelton, IV et al.
8,926,608 B 8,926,620 B		Chasmawala et al.	9,119,957		9/2015	Gantz et al.
8,931,682 B		Timm et al.	9,125,662			Shelton, IV
8,932,282 B		Gilbert	9,125,667 9,144,453		9/2015	Stone et al. Rencher et al.
8,932,299 B		Bono et al. Allen, IV	9,144,455		9/2015	
8,936,614 B: 8,939,974 B:		Boudreaux et al.	9,149,324		10/2015	Huang et al.
8,951,248 B	2 2/2015	Messerly et al.	9,149,325			Worrell et al.
8,951,272 B		Robertson et al.	9,161,803 9,165,114			Yates et al. Jain et al.
8,956,349 B: 8,960,520 B:		Aldridge et al. McCuen	9,168,054			Turner et al.
8,961,515 B		Twomey et al.	9,168,085	B2		Juzkiw et al.
8,961,547 B	2 2/2015	Dietz et al.	9,168,089			Buysse et al.
8,967,443 B		McCuen	9,179,912 9,186,204			Yates et al. Nishimura et al.
8,968,283 B: 8,968,294 B:		Kharin Maass et al.	9,186,796		11/2015	
8,968,355 B		Malkowski et al.	9,192,380		11/2015	Racenet et al.
8,974,447 B		Kimball et al.	9,192,421			Garrison
8,974,477 B		Yamada	9,192,428 9,192,431			Houser et al. Woodruff et al.
8,974,479 B: 8,979,843 B:		Ross et al. Timm et al.	9,198,714			Worrell et al.
8,979,844 B		White et al.	9,198,776		12/2015	
8,979,890 B	2 3/2015	Boudreaux	9,204,879			Shelton, IV
8,986,287 B		Park et al.	9,204,891 9,204,918			Weitzman Germain et al.
8,986,297 B: 8,986,302 B:		Daniel et al. Aldridge et al.	9,204,923			Manzo et al.
8,989,903 B		Weir et al.	9,216,050			Condie et al.
8,991,678 B		Wellman et al.	9,216,051			Fischer et al.
8,992,422 B		Spivey et al.	9,216,062 9,220,483			Duque et al. Frankhouser et al.
9,005,199 B: 9,011,437 B:		Beckman et al. Woodruff et al.	9,220,527			Houser et al.
9,011,437 B		Timm et al.	9,220,559	B2	12/2015	Worrell et al.
9,017,326 B	2 4/2015	DiNardo et al.	9,226,750			Weir et al.
9,017,355 B		Smith et al.	9,226,751			Shelton, IV et al.
9,023,071 B: 9,028,397 B:		Miller et al.	9,226,766 9,226,767			Aldridge et al. Stulen et al.
9,028,397 B			9,220,767			Parihar et al.
9,028,478 B		Mueller	9,237,891			Shelton, IV
9,028,494 B		Shelton, IV et al.	9,237,921			Messerly et al.
9,028,519 B	2 5/2015	Yates et al.	9,241,060	В1	1/2016	Fujisaki

U.S. PATENT DOCUMENTS 9.364.578 B2 12066 Messerby 661B 17/320002 9.244.09 B2 12066 Ganday et al. 9.244.09 B2 12066 Ganday et al. 9.244.09 B2 12066 Ganday et al. 9.244.730 B2 12066 Banday et al. 9.244.730 B2 12066 Sandharet al. 9.245.530 B2 12066 Sandharet al. 9.250.640 B2 12066 Sandharet al. 9.250.650 B2 12066 Sandharet al. 9.250.750 B2 12066 Sandharet al. 9.250.750 B2 12067 Sandharet al. 9.250.	(56)	References Cited	9,504,520 B2		Worrell et al.
9.241,692 B2 12016 Gonday et al. 9.241,739 B2 12016 Fire et al. 9.241,739 B2 12016 Bahace 9.241,731 B2 12016 Bahace 9.241,731 B2 12016 Bahace 9.241,731 B2 12016 Bahace 9.241,738 B2 12016 Sondward et al. 9.241,739 B2 12016 Sond	U.S.	. PATENT DOCUMENTS		11/2016	Messerly A61B 17/320092
9,241,738 B2 1,2016 Price of al. 9,522,029 B2 1,22016 Vates et al. 9,241,738 B2 1,2016 Behave 9,522,025 B2 1,2016 Pehave et al. 9,534,636 B2 1,2017 World et al. 9,534,636 B2 1,2017 World et al. 9,534,636 B2 1,2017 Boutlet at al. 9,534,636 B2 1,2017 World et al. 9,534,637 B2 1,2016 World et al. 9,534,637 B2 1,2017 World et al. 9,534,634 B2 1,2017 World et al. 9,534,637 B2 1,2017 World et al. 9,534,637 B2 1,2017 World et al. 9,534,637 B2 1,2017 World et al. 9,534,638 B2 1,2017 World et al. 9,534,538 B2 1,2017 World et al. 9,534,538 B2 1,2017 World et al. 9,734,538 B2 1,2017 World et al. 9,734,538 B2 1,2017 World	0.241.602 B2	1/2016 Gunday at al			
9.241,738 B2 12016 Bondreamy et al. 9,526,565 B2 122016 Rosin 9,247,938 B2 12016 Sambin et al. 9,545,238 B2 12017 Bondreamy et al. 9,545,238 B2 12016 Store et al. 9,545,238 B2 12017 Bondreamy et al. 9,545,248 B2 12017 Bondreamy et al. 9,545,248 B2 12016 Store et al. 9,545,248 B2 12017 Bondreamy et al. 9,545,248 B2 12016 Store et al. 9,545,248 B2 12017 Bondreamy et al. 9,545,248 B2 12016 Store et al. 9,545,248 B2 12016 Bondreamy et al. 9,545,148 B2 12017 Information et al. 9,545,248 B2 12016 Bondreamy et al. 9,545,148 B2 12017 Information et al. 9,545,148 B2 12016 Bondreamy et al. 9,545,148 B2 12017 Bondreamy	9,241,728 B2		9,522,029 B2	12/2016	Yates et al.
9,241,758 B2 122016 Annohu et al. 9,556,565 B2 122016 Stobb 9,241,678 B2 122016 Annohu et al. 9,554,521 B2 12017 Worrell et al. 9,545,521 B2 12017 Worrell et al. 9,545,521 B2 12017 Worrell et al. 9,545,541 B2 12017 Yes et al. 9,554,541 B2 12016 Yes et al. 9,654,577 B2 12017 Yes et al. 9,654,578 B2 12017 Yes et al. 9,654,577 B2 12017	9,241,730 B2				
9.254.165 B2 2.2016 Kontson et al. 9.554,346 B2 12.017 Boudreaux (9.259.265 B2 2.2016 Kontson et al. 9.554,346 B2 12.017 Visics et al. 9.259,365 B2 2.2016 Kontson et al. 9.551,348 B2 2.2017 Shelton, I'v et al. 9.255,926 B2 2.2016 Kontson et al. 9.579,464 B2 2.2017 Shelton, I'v et al. 9.255,926 B2 2.2016 Kontson et al. 9.579,468 B2 2.2017 Madan et al. 9.255,926 B2 2.2016 Kontson et al. 9.251,478 B2 2.2017 Madan et al. 9.255,926 B2 2.2016 Kontson et al. 9.251,927 B2 2.2016 Kontson et al. 9.252,927 B2 2.2016 Kontson et al. 9.252,927 B2 2.2016 Kontson et al. 9.253,927 B2 2.2017 Kontson et al. 9.252,925,925,925 B2 3.2016 Kontson et al. 9.253,927 B2 2.2017 Kontson et al. 9.252,925,925,925,925,925,925,925,925,925,			9,526,565 B2	12/2016	Strobl
9.259.254 B2 2.2016 Robertson et al. 9.554,384 B2 12.017 Yates et al. 9.256,367 B2 2.2016 Crhan, Ill et al. 9.561,088 B2 2.2017 Parithar et al. 9.256,567 B2 2.2016 Crhan, Ill et al. 9.574,644 B2 2.2017 Parithar et al. 9.256,567 B2 2.2016 Crhan, Ill et al. 9.574,644 B2 2.2017 Parithar et al. 9.256,567 B2 2.2016 Croble et al. 9.507,161 B2 2.2017 Parithar et al. 9.257,644 B2 2.2017 Parithar et al. 9.256,567 B2 2.2016 Croble et al. 9.651,577 B2 2.2017 Exorter, Ill et al. 9.256,161 B2 2.2016 Monson et al. 9.615,877 B2 2.2017 Exorter, Ill et al. 9.253,045 B2 2.2016 Monson et al. 9.636,158 B2 2.2017 Ill et al. 9.636,158 B2 2.2017 Ill et al. 9.636,158 B2 2.2017 Ill et al. 9.636,165 B2 2.2016 Sproye et al. 9.636,166 B2 2.2017 Ill except et al. 9.636,166 B2 2.2016 Ill except et al. 9.636,166 B2 2.2017 Ill except et al. 9.636,166 B2 2.2016 Ill except et al. 9.736,166 B2 2.2016 Ill except et al. 9.736,166					
9,265,507 B2 2,2016 Orban, III et al. 9,574,644 B2 2,2017 Parihar 9,269,205 B2 22016 Kors et al. 9,610,091 B2 3,2017 Madan et al. 9,279,062 B2 32016 Kors et al. 9,610,091 B2 4,2017 Johnson et al. 9,283,027 B2 32016 Monson et al. 9,615,377 B2 4,2017 Tyrrell et al. 9,283,027 B2 3,2016 Monson et al. 9,615,377 B2 4,2017 Tyrrell et al. 9,283,027 B2 3,2016 Shelton, IV et al. 9,632,373 B2 4,2017 Tyrrell et al. 9,283,027 B2 3,2016 Shelton, IV et al. 9,632,673 B2 4,2017 Tyrrell et al. 9,283,027 B2 3,2016 Shelton, IV et al. 9,632,673 B2 4,2017 Sturrer et al. 9,283,047 B2 3,2016 Shelton, IV et al. 9,638,778 B2 5,2017 Houser et al. 9,301,739 B2 4,2016 Stock et al. 9,642,678 B2 5,2017 Houser et al. 9,242,678 B2 4,2016 Stock et al. 9,642,678 B2 5,2017 Houser et al. 9,242,678 B2 5,2016 Houser et al. 9,242,678 B2 5,2017 Houser et al. 9,242,678 B2 5,2016 Houser et al. 9,242,743 B2 5,2016 Houser et al. 9,243,743 B2 5,2016 Houser	9,259,234 B2	2/2016 Robertson et al.	9,554,854 B2		
9,265,926 B2 2,2016 Strobl et al. 9,571,139 B2 4,2017 (Johnson et al. 9,273,027) B2 3,2016 (Soss et al. 9,510,109) B2 4,2017 (Johnson et al. 9,283,027) B2 3,2016 (Soss et al. 9,510,114 B2 4,2017 (Johnson et al. 9,283,027) B2 2,2016 (Sosten, IV 9,101,114 B2 4,2017 (Johnson et al. 9,283,027) B2 3,2016 (Solton, IV et al. 9,633,027) B2 4,2016 (Solton, IV et al. 9,635,161 B2 5,2017 (Johnson et al. 9,633,027) B2 4,2016 (Solton, IV et al. 9,636,165 B2 5,2017 (Johnson et al. 9,630,179) B2 4,2016 (Solton, IV et al. 9,636,165 B2 5,2017 (Johnson et al. 9,301,799) B2 4,2016 (Solton, IV et al. 9,636,165 B2 5,2017 (Johnson et al. 9,301,799) B2 4,2016 (Solton, IV et al. 9,636,165 B2 5,2017 (Johnson et al. 9,301,799) B2 4,2016 (Solton, IV et al. 9,634,666) B2 5,2017 (Johnson et al. 9,301,799) B2 4,2016 (Solton, IV et al. 9,643,667) B2 5,2017 (Johnson et al. 9,301,799) B2 4,2016 (Hall et al. 9,643,607) B2 5,2017 (Johnson et al. 9,643,667) B2 5,2016 (Johnson et al. 9,643,667) B2 5,2017 (Johnson et al. 9,643,667) B2 5,2016 (Johnson et al. 9,643,667) B2 6,2017 (Johnson et al. 9,643,667) B2 6,2016 (Johnson et al. 9,643,667) B2 6,2017 (Johnson et al. 9,643,667) B2 7,2017 (Johnson et al. 9,643,667)					
9.28.0.76 R2 3.0216 Shelron, IV 9.010.114 B2 4.2017 Baxter, III et al. 9.283.045 B2 32.016 Monson et al. 9.615.877 B2 4.2017 Turner et al. 9.283.045 B2 32.016 Shelron, IV et al. 9.636.135 B2 5.2017 Studen et al. 9.293.514 B2 32.016 Shelron, IV et al. 9.636.165 B2 5.2017 Studen et al. 9.305.918 B2 4.2016 Shelron, IV et al. 9.636.165 B2 5.2017 Larson et al. 9.305.918 B2 4.2016 Shelron, IV et al. 9.636.165 B2 5.2017 Larson et al. 9.305.918 B2 4.2016 Shelron, IV et al. 9.642.644 B2 5.2017 Houser et al. 9.307.986 B2 4.2016 Mastan et al. 9.642.644 B2 5.2017 Houser et al. 9.307.986 B2 4.2016 Mastan et al. 9.642.644 B2 5.2017 Houser et al. 9.307.986 B2 4.2016 Mastan et al. 9.642.644 B2 5.2017 Houser et al. 9.308.014 B2 4.2016 Et al. 9.642.644 B2 5.2017 Larson et al. 9.308.014 B2 4.2016 Et al. 9.642.644 B2 5.2017 Larson et al. 9.308.014 B2 4.2016 Elare et al. 9.649.05 B2 5.2017 Larson et al. 9.308.014 B2 4.2016 Darket al. 9.649.05 B2 5.2017 Larson et al. 9.308.014 B2 4.2016 Darket al. 9.650.13 B2 5.2017 Larson et al. 9.314.90 B2 4.2016 Bart-faint et al. 9.651.31 B2 5.2017 Larson et al. 9.3314.90 B2 4.2016 Bart-faint et al. 9.651.31 B2 5.2017 Larson et al. 9.336.787 B2 5.2016 Polster et al. 9.655.670 B2 5.2017 Sudien et al. 9.336.787 B2 5.2016 Sudien et al. 9.651.31 B2 5.2017 Larson et al. 9.336.787 B2 5.2016 Monson et al. 9.6575.378 B2 6.2017 Houser et al. 9.337.078 B2 5.2016 Monson et al. 9.675.378 B2 6.2017 Houser et al. 9.333.028 B2 5.2016 Monson et al. 9.675.378 B2 6.2017 Houser et al. 9.333.028 B2 5.2016 Monson et al. 9.675.378 B2 6.2017 Houser et al. 9.333.028 B2 5.2016 Monson et al. 9.707.030 B2 7.2017 Jaworek et al. 9.335.178 B2 5.2016 Monson et al. 9.707.030 B2 7.2017 Jaworek et al. 9.335.178 B2 5.2016 Monson et al. 9.707.478 B2 7.2017 Moseryly et al. 9.335.178 B2 5.2016 Monson et al. 9.707.478 B2 7.2017 Moseryly et al. 9.335.178 B2 5.2016 Monson et al. 9.707.378 B2 7.2017 Moseryly et al. 9.335.178 B2 5.2016 Monson et al. 9.707.378 B2 8.2017 Follor et al. 9.735.258 B2 7.2017 Moseryly et al. 9.735.258 B2 7.2017	9,265,926 B2	2/2016 Strobl et al.			
9,283,027 B2 3,2016 Monson et al. 9,615,877 B2 4,2017 Tjurrell et al. 9,283,027 B2 3,2016 Shelton, IV et al. 9,636,138 B2 5,2016 Shelton, IV et al. 9,636,138 B2 5,2017 Studen 9,205,514 B2 3,2016 Shelton, IV et al. 9,636,138 B2 5,2017 Tiurner et al. 9,301,759 B2 4,2016 Shelton, IV et al. 9,636,138 B2 5,2017 Dietz et al. 9,303,439 B2 4,2016 Shelton, IV et al. 9,636,138 B2 5,2017 Tiurner et al. 9,303,439 B2 4,2016 Shelton, IV et al. 9,642,468 B2 5,2017 Houser et al. 1,203,203,203,203,203,203,203,203,203,203					
9.289.256 B2 3.2016 Shelton, IV et al. 9.636.135 B2 5/2017 Studen 9.205.148 B2 32016 Shelton, IV et al. 9.636.166 B2 5/2017 Larson et al. 9.301.759 B2 4.2016 Spivey et al. 9.638.778 B2 5/2017 Dietz et al. 1. 9.301.759 B2 4.2016 Spivey et al. 9.638.767 B2 5/2017 Taksahino et al. 9.301.759 B2 4.2016 Liang et al. 9.642.660 B2 5/2017 Taksahino et al. 9.301.858 B2 4.2016 Liang et al. 9.642.660 B2 5/2017 Taksahino et al. 9.301.800 B2 4.2016 Madan et al. 9.641.052 B2 5/2017 Taksahino et al. 9.3018.000 B2 4.2016 Madan et al. 9.649.111 B2 5/2017 Shelton, IV et al. 9.3018.000 B2 4.2016 Bales, Jr. et al. 9.655.670 B2 5/2017 Shelton, IV et al. 9.314.201 B2 4.2016 Bales, Jr. et al. 9.655.670 B2 5/2017 Larson et al. 9.314.201 B2 4.2016 Bales, Jr. et al. 9.655.670 B2 5/2017 Larson et al. 9.314.201 B2 4.2016 Bela-Haim et al. 9.650.137 B2 5/2017 Larson et al. 9.314.201 B2 5/2016 Sami et al. 9.650.373 B2 6/2017 Blost et al. 9.326.787 B2 5/2016 Sami et al. 9.6575.374 B2 6/2017 Blost et al. 9.336.388 B2 5/2016 Sami et al. 9.6575.374 B2 6/2017 Keller 9.333.093 B2 5/2016 Blostos et al. 9.700.309 B2 7/2017 Nield 9.333.093 B2 5/2016 Blostos et al. 9.700.309 B2 7/2017 Nield 9.333.093 B2 5/2016 Blostos et al. 9.700.309 B2 7/2017 Nield 9.333.093 B2 5/2016 Blostos et al. 9.700.309 B2 7/2017 Nield 9.333.093 B2 5/2016 Blostos et al. 9.700.309 B2 7/2017 Blostor et al. 9.333.093 B2 5/2016 Blostor et al. 9.700.309 B2 7/2017 Blostor et al. 9.335.674 B2 5/2016 McCullagh et al. 9.707.007 B2 7/2017 Blostor et al. 9.335.674 B2 5/2016 McCullagh et al. 9.707.007 B2 7/2017 Blostor et al. 9.351.726 B2 5/2016 McCullagh et al. 9.707.309 B2 7/2017 Blostor et al. 9.351.726 B2 5/2016 McCullagh et al. 9.707.309 B2 7/2017 Blostor et al. 9.351.726 B2 5/2016 Wet et al. 9.707.309 B2 7/2017 Blostor et al. 9.351.726 B2 5/2016 Wet et al. 9.707.309 B2 7/2017 Blostor et al. 9.735.800 B2 5/2016 Wet et al. 9.707.309 B2 7/2017 Blostor et al. 9.735.800 B2 5/2016 Wet et al. 9.707.309 B2 7/2017 Blostor et al. 9.735.800 B2 7/2017 Blostor et al. 9.735.800 B2 7/2017 Blostor e	9,283,027 B2	3/2016 Monson et al.			
9.295.514 B2 3/2016 Shelton, IV et al. 9.453.6165 B2 5/2017 Dictz et al. 9.301.759 B2 4/2016 Spivey et al. 9.683.770 B2 5/2017 Dictz et al. 9.305.479 B2 4/2016 Spivey et al. 9.682.644 B2 5/2017 Dictz et al. 9.307.388 B2 4/2016 Liang et al. 9.642.664 B2 5/2017 Takashino et al. 9.307.388 B2 4/2016 Hall et al. 9.642.664 B2 5/2017 Takashino et al. 9.308.609 B2 4/2016 Madan et al. 9.649.102 B2 5/2017 Takashino et al. 9.308.609 B2 4/2016 Bales, ir. et al. 9.649.102 B2 5/2017 Shelton, IV et al. 9.308.014 B2 4/2016 Bales, ir. et al. 9.669.102 B2 5/2017 Shelton, IV et al. 9.308.014 B2 4/2016 Bales, ir. et al. 9.669.103 B2 5/2017 Larson et al. 9.308.014 B2 4/2016 Bales, ir. et al. 9.668.806 B2 6/2017 Lugar et al. 9.308.018 B2 4/2016 Bales, ir. et al. 9.668.806 B2 6/2017 Ungar et al. 9.308.018 B2 4/2016 Sanair et al. 9.678.373 B2 6/2017 Sulen et al. 9.308.018 B2 5/2016 Sanair et al. 9.678.373 B2 6/2017 Sulen et al. 9.308.018 B2 5/2016 Sanair et al. 9.678.373 B2 6/2017 Sulen et al. 9.308.018 B2 5/2016 Manson et al. 9.308.018 B2 5/2016 Manson et al. 9.308.018 B2 5/2016 Manson et al. 9.308.018 B2 5/2016 Sanair et al. 9.308.0			9,636,135 B2		
9.305.497 B2 4-2016 Seo et al	9,295,514 B2	3/2016 Shelton, IV et al.			
9.307.388 B2 4/2016 Hall et al. 9.642.669 B2 5/2017 Takashino et al. 9.308,009 B2 4/2016 Madan et al. 9.643.052 B2 5/2017 Tehao et al. 9.308,009 B2 4/2016 Hall et al. 9.649.111 B2 5/2017 Tehao et al. 9.314,261 B2 4/2016 Fischer 9.6491.126 B2 5/2017 Robertson et al. 9.314,209 B2 4/2016 Bales, Ir. et al. 9.655.670 B2 5/2017 Tarson et al. 9.314,301 B2 4/2016 Bar-Haim et al. 9.668.806 B2 5/2017 Omori et al. 9.314,301 B2 4/2016 Bar-Haim et al. 9.668.806 B2 6/2017 Unger et al. 9.326,787 B2 5/2016 Sanai et al. 9.675.375 B2 6/2017 Studen et al. 9.330,76788 B2 5/2016 Sanai et al. 9.687.375 B2 6/2017 Studen et al. 9.333,025 B2 5/2016 Barross et al. 9.687.3078 B2 6/2017 Keller 9.333,024 B2 5/2016 Monson et al. 9.700,309 B2 7/2017 Niedl 9.339,288 B2 5/2016 Robertson 9.700,309 B2 7/2017 Niedl 9.339,328 B2 5/2016 Robertson 9.700,340 B2 7/2017 Niedl 9.339,328 B2 5/2016 McCullagh et al. 9.700,340 B2 7/2017 Messerily et al. 9.345,504 B2 5/2016 McCullagh et al. 9.700,309 B2 7/2017 Messerily et al. 9.345,508 B2 5/2016 McCullagh et al. 9.700,309 B2 7/2017 Davidennikan et al. 9.345,768 B2 5/2016 Wu et al. 9.700,309 B2 7/2017 Davidennikan et al. 9.351,726 B2 5/2016 Valenta et al. 9.717,552 B2 8/2017 Coutton 9.351,726 B2 5/2016 Calmbach et al. 9.717,552 B2 8/2017 Coutton 9.351,726 B2 5/2016 Calmbach et al. 9.717,552 B2 8/2017 Coutton 9.351,726 B2 5/2016 Calmbach et al. 9.717,552 B2 8/2017 Coutton 9.351,726 B2 5/2016 Calmbach et al. 9.737,355 B2 8/2017 Sulden et al. 9.351,726 B2 5/2016 Calmbach et al. 9.737,355 B2 8/2017 Sulden et al. 9.351,726 B2 5/2016 Calmbach et al. 9.737,355 B2 8/2017 Sulden et al. 9.351,726 B2 5/2016 Calmbach et al. 9.737,355 B2 8/2017 Calmbach et al. 9.351,726 B2 5/2016 Calmbach et al. 9.737,355 B2 8/2017 Sulden et al. 9.352,477 B2 5/2016 Calmbach et al. 9.737,355 B2 8/2017 Foliote et al. 9.358,831					
9.308,009 B2 4:2016 Madan et al. 9.308,009 B2 4:2016 Bides, IF, et al. 9.314,261 B2 4:2016 Fischer 9.409,126 B2 5:2017 Robertson et al. 9.314,261 B2 4:2016 Fischer 9.409,126 B2 5:2017 Robertson et al. 9.314,201 B2 4:2016 Bides, IF, et al. 9.655,570 B2 5:2017 Larson et al. 9.314,301 B2 4:2016 Bea-Haim et al. 9.668,806 B2 6:2017 Unger et al. 9.326,787 B2 5:2016 Sanai et al. 9.675,374 B2 5:2016 Sanai et al. 9.675,374 B2 5:2016 Sanai et al. 9.675,375 B2 6:2017 Houser et al. 9.326,787 B2 5:2016 Sanai et al. 9.700,309 B2 7:2017 Jaworek et al. 9.331,302 B2 5:2016 Monson et al. 9.700,309 B2 7:2017 Jaworek et al. 9.331,302 B2 5:2016 Robertson et al. 9.700,339 B2 7:2017 Messerly et al. 9.339,223 B2 5:2016 Robertson et al. 9.700,348 B2 7:2017 Houser et al. 9.339,223 B2 5:2016 McCullagh et al. 9.700,048 B2 7:2017 Jaworek et al. 9.339,223 B2 5:2016 McCullagh et al. 9.700,048 B2 7:2017 Houser et al. 9.331,642 B2 5:2016 McCullagh et al. 9.700,039 B2 7:2017 Davison et al. 9.331,642 B2 5:2016 McCullagh et al. 9.700,039 B2 7:2017 Davison et al. 9.331,642 B2 5:2016 McCullagh et al. 9.700,039 B2 7:2017 Davison et al. 9.331,642 B2 5:2016 McCullagh et al. 9.700,039 B2 7:2017 Davison et al. 9.331,642 B2 5:2016 Macutani et al. 9.715,548 B2 8:2017 Couture 9.331,742 B2 5:2016 Sandari et al. 9.715,548 B2 8:2017 Couture 9.331,743 B2 5:2016 Sandari et al. 9.724,118 B2 8:2017 Couture 9.331,743 B2 5:2016 Sandari et al. 9.731,752 B2 8:2017 Couture 9.331,744 B2 8:2016 Sandari et al. 9.731,752 B2 8:2017 Couture 9.331,744 B2 8:2017 Schulte et al. 9.731,740 B2 8:2016 Sandari et al. 9.731,740 B2 8:2017 Schulte et al. 9.731,740 B2 8:2016 Sandari et al. 9.731,740 B2 8:2017 Schulte et al. 9.731,740 B2 8:2016 Sandari et al. 9.731,740 B2 8:2017 Schulte et	9,307,388 B2	4/2016 Liang et al.			
9,308,014 B2 42016 Fischer 9,314,292 B2 42016 Bales, Jr. et al. 9,314,292 B2 42016 Trees et al. 9,314,292 B2 42016 Trees et al. 9,314,292 B2 42016 Trees et al. 9,314,292 B2 42016 Sales, Jr. et al. 9,326,784 B2 52016 Ben-Haime al. 9,668,306 B2 62017 Unger et al. 9,326,787 B2 52016 Sanai et al. 9,326,787 B2 52016 Sanai et al. 9,326,788 B2 5,2016 Baross et al. 9,326,788 B2 5,2016 Baross et al. 9,333,032 B2 5,2016 Monson et al. 9,333,032 B2 5,2016 Monson et al. 9,333,034 B2 5,2016 Monson et al. 9,333,034 B2 5,2016 Robertson 9,333,034 B2 5,2016 Robertson 9,333,032 B2 5,2016 Robertson 9,333,032 B2 5,2016 Robertson 9,333,032 B2 5,2016 Robertson 9,339,323 B2 5,2016 Karoliagh et al. 9,339,323 B2 5,2016 Karoliagh et al. 9,339,323 B2 5,2016 Karoliagh et al. 9,345,534 B2 5,2016 Karoliagh et al. 9,345,504 B2 5,2016 Karoliagh et al. 9,351,726 B2 5,2016 Caroliagh et al. 9,351,726 B2 5,2016 Caroliagh et al. 9,351,726 B2 5,2016 Caroliagh et al. 9,351,736 B2 5,2016 Caroliagh et al. 9,351,737 B2 5,2016 Caroliagh et al. 9,351,738 B2 5,2016 Caroliagh et al. 9,351,739 B2 6,2016 Caroliagh e					
9.314.292 B2 4/2016 Trees et al. 9.314.292 B2 4/2016 Ben-Haim et al. 9.346.830 B2 6/2017 Unger et al. 9.346.830 B2 6/2017 Unger et al. 9.340.787 B2 5/2016 Polster 9.357.74 B2 5/2016 Bartos et al. 9.357.374 B2 5/2016 Bartos et al. 9.357.374 B2 5/2016 Bartos et al. 9.357.375 B2 5/2016 Bartos et al. 9.357.375 B2 5/2016 Bartos et al. 9.357.375 B2 5/2016 Bartos et al. 9.357.395 B2 6/2017 Keller 9.333.025 B2 5/2016 Bartos et al. 9.700.309 B2 7/2017 Kieller 9.333.028 B2 5/2016 Hancock 9.700.309 B2 7/2017 Wield 9.330,228 B2 5/2016 McCullagh et al. 9.700.309 B2 7/2017 Gilbert 9.330,328 B2 5/2016 Kellagh et al. 9.707.030 B2 7/2017 Gilbert 9.330,328 B2 5/2016 Kellagh et al. 9.707.030 B2 7/2017 Houser et al. 9.345.534 B2 5/2016 Kullagh et al. 9.707.030 B2 7/2017 Ruddenklan et al. 9.345.534 B2 5/2016 Nackami et al. 9.707.030 B2 7/2017 Ruddenklan et al. 9.351.764 B2 5/2016 Valkaria et al. 9.715.307 B2 7/2017 Ruddenklan et al. 9.351.764 B2 5/2016 Leimbach et al. 9.715.307 B2 7/2017 Sittlen et al. 9.351.764 B2 5/2016 Leimbach et al. 9.717.552 B2 8/2017 Comman et al. 9.351.764 B2 5/2016 Valkaria et al. 9.717.552 B2 8/2017 Comman et al. 9.352.173 B2 5/2016 Farmada et al. 9.737.358 B2 8/2017 Comman et al. 9.353.064 B2 6/2016 Shelton, IV et al. 9.370,611 B2 6/2016 Ross et al. 9.370,611 B2 6/2016 Ross et al. 9.375,256 B2 6/2016 Hunt et al. 9.375,256 B2 6/2016 Keret al. 9.375,256 B2 6/2016 Keret al. 9.375,256 B2 6/2016 Keret al. 9.375,268 B2 6/2016 Keret al. 9.375,275 B2 6/2016 Keret al. 9.375,276 B2 8/2017 Keret al. 9.375,276 B2 8/2017 Keret al. 9.375,276 B2 8	9,308,014 B2	4/2016 Fischer			
9,314,301 B2		,			
9,336,787 B2 5/2016 Samai et al. 9,673,375 B2 6/2017 Houser et al. 9,336,788 B2 5/2016 Batross et al. 9,687,290 B2 7,2017 Jaworek et al. 9,333,025 B2 5/2016 Monson et al. 9,700,330 B2 7,2017 Jaworek et al. 9,333,028 B2 5/2016 Robertson 9,700,343 B2 7,2017 Messertly et al. 9,330,328 B2 5/2016 McCullagh et al. 9,700,349 B2 7,2017 Houser et al. 9,330,323 B2 5/2016 McCullagh et al. 9,707,048 B2 7,2017 Houser et al. 9,343,036 B2 5/2016 McCullagh et al. 9,707,090 B2 7,2017 Houser et al. 9,345,534 B2 5/2016 Wie et al. 9,707,090 B2 7,2017 Houser et al. 9,345,590 B2 5/2016 Wie et al. 9,707,090 B2 7,2017 Houser et al. 9,345,590 B2 5/2016 Wie et al. 9,707,090 B2 7,2017 Studen et al. 9,345,590 B2 5/2016 Wie et al. 9,715,48 B2 5/2016 Country et al. 9,715,548 B2 5/2016 House et al. 9,715,548 B2 8,2017 Country et al. 9,351,748 B2 5/2016 Vakharia et al. 9,715,552 B2 8,2017 Country et al. 9,351,748 B2 5/2016 House et al. 9,715,552 B2 8,2017 Country et al. 9,352,733 B2 5/2016 Shelton, IV et al. 9,724,118 B2 8,2017 Southier et al. 9,364,230 B2 6/2016 Shelton, IV et al. 9,737,358 B2 8,2017 Worrell et al. 9,370,400 B2 6/2016 Ross et al. 9,737,358 B2 8,2017 Worrell et al. 9,375,230 B2 6/2016 Ross et al. 9,737,358 B2 8,2017 Vates et al. 9,375,230 B2 6/2016 Hurt et al. 9,743,946 B2 8,2017 Vates et al. 9,375,230 B2 6/2016 Hurt et al. 9,743,946 B2 8,2017 Force et al. 9,375,230 B2 6/2016 Hurt et al. 9,743,946 B2 9,7017 B2 8,7017 Price et al. 9,375,230 B2 6/2016 Kerr et al. 9,757,148 B2 9,7016 Kerr et al. 9,757,148 B2 9,7016 Kerr et al. 9,757,148 B2 9,7016 Kerr et al. 9,757,148 B2 9,7017 Houser et al. 9,7	9,314,301 B2	4/2016 Ben-Haim et al.			
9,336,738 B2 5,2016 Barross et al. 9,687,290 B2 6,2017 Keller 9,333,034 B2 5,2016 Monson et al. 9,700,309 B2 7,2017 Jaworek et al. 9,339,034 B2 5,2016 Hancock 9,700,339 B2 7,2017 Messerly et al. 9,339,323 B2 5,2016 Eder et al. 9,705,456 B2 7,2017 Gilbert 9,339,323 B2 5,2016 Keller et al. 9,705,456 B2 7,2017 Gilbert 9,339,323 B2 5,2016 Keller et al. 9,705,046 B2 7,2017 Gilbert 9,339,326 B2 5,2016 Keller et al. 9,705,046 B2 7,2017 Gilbert 1,339,346,590 B2 5,2016 Keller et al. 9,707,027 B2 7,2017 Ruddenklau et al. 9,345,590 B2 5,2016 Keller et al. 9,707,027 B2 7,2017 Ruddenklau et al. 9,351,726 B2 5,2016 Keller et al. 9,707,030 B2 7,2017 Ruddenklau et al. 9,351,726 B2 5,2016 Keller et al. 9,713,507 B2 7,2017 Ruddenklau et al. 9,351,726 B2 5,2016 Keller et al. 9,713,507 B2 7,2017 Stuten et al. 9,351,726 B2 5,2016 Vakharai et al. 9,713,507 B2 7,2017 Stuten et al. 9,351,726 B2 5,2016 Vakharai et al. 9,713,507 B2 7,2017 Schulte et al. 9,352,173 B2 5,2016 Vakharai et al. 9,724,118 B2 82017 Schulte et al. 9,354,640 B2 6,2016 Eadftow et al. 9,734,152 B2 8,2017 Worrell et al. 9,370,611 B2 6,2016 Parihar 9,335,851 B2 8,2017 Worrell et al. 9,375,236 B2 6,2016 Form et al. 9,733,355 B2 8,2017 Worrell et al. 9,375,236 B2 6,2016 Kerr et al. 9,734,304 B2 8,2017 Beckman et al. 9,375,236 B2 6,2016 Kerr et al. 9,734,304 B2 8,2017 Finite et al. 9,375,246 B2 6,2016 Kerr et al. 9,734,304 B2 8,2017 Finite et al. 9,375,246 B2 6,2016 Kerr et al. 9,735,142 B2 9,2017 Shimizu Price et al. 9,398,037 B2 7,2016 (Son et al. 9,735,142 B2 9,2017 Shimizu Price et al. 9,398,037 B2 7,2016 (Son et al. 9,735,142 B2 9,2017 Worrell et al. 9,398,037 B2 7,2016 (Son et al. 9,735,142 B2 9,2017 Finite et al. 9,398,037 B2 7,2016 (Son et al. 9,735,142 B2 9,2017 Finite et al. 9,408,666 B2 8,2016 Kerre et al. 9,735,142 B2 9,2017 Worrell et al. 9,408,666 B2 8,2016 Kerre et al. 9,808,608 B2 10,2017 Finite et al. 9,408,666 B2 8,2016 Kerre et al. 9,808,608 B2 10,2017 Finite et al. 9,408,668 B2 9,2016 Kerre et al. 9,808,608 B2 10,2017 Finite et al. 9,408,668 B2 9,201					
9,333,034 B2 5/2016 Hancock 9,700,339 B2 7,2017 Nield 9,339,238 B2 5/2016 Hancock 9,700,339 B2 7,0017 Messerly et al. 9,339,236 B2 5/2016 Eder et al. 9,705,456 B2 7,0017 Gilbert 1,001,001 B2 1,001 B2 1					
9,339,289 B2 52016 Robertson 9,700,343 B2 7/2017 Messerty et al. 9,339,323 B2 52016 Eder et al. 9,707,004 B2 7/2017 Houser et al. 9,339,323 B2 52016 McCullagh et al. 9,707,004 B2 7/2017 Houser et al. 9,345,334 B2 52016 McCullagh et al. 9,707,007 B2 7/2017 B2 7/2017 Rotdenklau et al. 9,345,346 B2 7/2018 Wu et al. 9,707,007 B2 7/2017 Davison et al. 9,351,642 B2 52016 Leimbach et al. 9,713,547 B2 5/2016 Leimbach et al. 9,713,547 B2 5/2016 Leimbach et al. 9,717,552 B2 8/2017 Couture 9,351,754 B2 5/2016 Vakharia et al. 9,717,552 B2 8/2017 Couture 9,351,754 B2 5/2016 Vakharia et al. 9,717,552 B2 8/2017 Couture 9,358,065 B2 6/2016 Shelton, IV et al. 9,734,325 B2 8/2017 Worrell et al. 9,364,243 B2 6/2016 Shelton, IV et al. 9,737,335 B2 8/2017 Worrell et al. 9,370,401 B2 6/2016 Ross et al. 9,734,3946 B2 8/2017 Worrell et al. 9,375,230 B2 6/2016 Ross et al. 9,734,3948 B2 8/2017 Holte et al. 9,375,230 B2 6/2016 March et al. 9,734,3948 B2 8/2017 Holte et al. 9,375,230 B2 6/2016 March et al. 9,734,3948 B2 8/2017 Holte et al. 9,375,230 B2 6/2016 March et al. 9,734,3949 B2 8/2017 For et al. 9,375,230 B2 6/2016 March et al. 9,734,3949 B2 8/2017 For et al. 9,375,207 B2 6/2016 Cunningham et al. 9,734,3947 B2 8/2017 For et al. 9,375,207 B2 6/2016 March et al. 9,735,142 B2 9/2017 Shimizu 9/2017 March et al. 9,385,818 B2 7/2016 March et al. 9,735,142 B2 9/2017 Joran et al. 9,385,918 B2 7/2016 March et al. 9,755,148 B2 9/2017 Joran et al. 9,398,911 B2 7/2016 March et al. 9,755,148 B2 9/2017 Joran et al. 9,408,606 B2 8/2016 Ginebaugh et al. 9,795,808 B2 10/2017 Joran et al. 9,408,606 B2 8/2016 Ginebaugh et al. 9,808,308 B2 10/2017 Joran et al. 9,408,606 B2 8/2016 Shelton, IV 9,795,808 B2 10/2017 Joran et al. 9,408,608 B2 8/2016 Ginebaugh et al. 9,808,308 B2 11/2017 Joran et al. 9,808,608 B2 9/2016 Monson et al. 9,808,608 B2 10/2017 Joran et al. 9,808,608 B2 10/2017 J					
9,339,326 B2 52016 McCullagh et al. 9,707,004 B2 7/2017 Houser et al. 9,345,534 B2 52016 Mc ct al. 9,707,027 B2 7/2017 Davison et al. 9,345,534 B2 52016 Wu et al. 9,707,027 B2 7/2017 Davison et al. 9,351,642 B2 52016 Limbach et al. 9,713,507 B2 7/2017 Couture 9,351,754 B2 5/2016 Limbach et al. 9,717,548 B2 8/2017 Couture 9,351,754 B2 5/2016 Vakharia et al. 9,717,552 B2 8/2017 Couture 9,352,173 B2 5/2016 Vakharia et al. 9,717,552 B2 8/2017 Couture 9,352,173 B2 5/2016 Vakharia et al. 9,724,152 B2 8/2017 Couture 9,352,173 B2 5/2016 Vakharia et al. 9,724,152 B2 8/2017 Couture 9,352,173 B2 5/2016 Vakharia et al. 9,724,152 B2 8/2017 Couture 9,352,173 B2 5/2016 Vakharia et al. 9,734,152 B2 8/2017 Varied et al. 9,352,173 B2 5/2016 Parihar 9,375,235 B2 8/2017 Varied et al. 9,376,361 B2 6/2016 Parihar 9,375,355 B2 8/2017 Varied et al. 9,375,232 B2 6/2016 Ross et al. 9,373,358 B2 8/2017 Varied et al. 9,375,232 B2 6/2016 Cunningham et al. 9,743,946 B2 8/2017 Ficie et al. 9,375,232 B2 6/2016 Cunningham et al. 9,743,947 B2 8/2017 Fice et al. 9,375,236 B2 6/2016 Kerr et al. 9,753,186 B2 9/2017 Soudreaux et al. 9,375,267 B2 6/2016 Kerr et al. 9,753,186 B2 9/2017 Wiener et al. 9,386,381 B2 7/2016 Marr et al. 9,755,186 B2 9/2017 Wiener et al. 9,393,037 B2 7/2016 Olson et al. 9,752,186 B2 9/2017 Wiener et al. 9,393,938 B2 7/2016 Olson et al. 9,752,436 B2 9/2017 Varied et al. 9,408,606 B2 8/2016 Sinchobaugh et al. 9,795,436 B2 10/2017 Pirice et al. 9,408,606 B2 8/2016 Sinchobaugh et al. 9,795,436 B2 10/2017 Pirice et al. 9,408,606 B2 8/2016 Sinchobaugh et al. 9,795,436 B2 10/2017 Pirice et al. 9,408,606 B2 8/2016 Sinchobaugh et al. 9,808,638 B2 10/2017 Pirice et al. 9,408,608 B2 8/2016 Sinchobaugh et al. 9,808,638 B2 10/2017 Pirice et al. 9,408,608 B2 8/2016 Sinchobaugh et al. 9,808,638 B2 10/2017 Pirice et al. 9,408,608 B2 9/2016 Wiener et al. 9,808,638 B2 10/2017 Pirice et al. 9,408,608 B2 9/2016 Wiener et al. 9,808,638 B2 11/2017 Fice et al. 9,408,608 B2 9/2016 Wiener et al. 9,808,638 B2 11/2017 Fice et al. 9,408,608 B2 9/2016	9,339,289 B2		9,700,343 B2	7/2017	Messerly et al.
9,345,534 B2 5/2016 Artale et al. 9,707,027 B2 7/2017 Davison et al. 9,345,908 B2 5/2016 Wu et al. 9,707,030 B2 7/2017 Davison et al. 9,345,908 B2 5/2016 Nadkarni et al. 9,713,507 B2 7/2017 Stulen et al. 9,351,746 B2 5/2016 Vakharni et al. 9,713,507 B2 7/2017 Cosman et al. 9,351,748 B2 5/2016 Vakharni et al. 9,717,548 B2 8/2017 Cosman et al. 9,351,748 B2 5/2016 Vakharni et al. 9,714,118 B2 8/2017 Cosman et al. 9,352,173 B2 5/2016 Vakharni et al. 9,724,118 B2 8/2017 Cosman et al. 9,358,056 B2 6/2016 Latikow et al. 9,724,118 B2 8/2017 Horlle et al. 9,358,056 B2 6/2016 Earlie of Aribar 9,737,356 B2 8/2017 Ware et al. 9,370,400 B2 6/2016 Ross et al. 9,733,356 B2 8/2017 Vates et al. 9,370,611 B2 6/2016 Ross et al. 9,743,949 B2 8/2017 Leimbach et al. 9,375,230 B2 6/2016 Ross et al. 9,743,949 B2 8/2017 Faller et al. 9,375,230 B2 6/2016 Hut et al. 9,743,949 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Unningham et al. 9,743,949 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Warr et al. 9,757,142 B2 9,2017 Shimizu 9,385,831 B2 7/2016 Marr et al. 9,757,142 B2 9,2017 Shimizu 9,385,933 B2 7/2016 Olson et al. 9,757,142 B2 9,2017 Shimizu 9,386,933 B2 7/2016 Olson et al. 9,750,440 B2 8/2017 Frice et al. 9,308,911 B2 7/2016 Olson et al. 9,750,440 B2 8/2017 Houser et al. 9,308,911 B2 7/2016 Shelton, IV 9,795,436 B2 10/2017 Houser et al. 9,408,620 B2 8/2016 Ginnebaugh et al. 9,795,405 B2 10/2017 Houser et al. 9,408,620 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Houser et al. 9,414,833 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Houser et al. 9,414,833 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Houser et al. 9,414,833 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Houser et al. 9,414,833 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Houser et al. 9,414,833 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Houser et al. 9,414,833 B2 8/2016 Shelton et al. 9,808,038 B2 11/2017 Shelton, IV et al. 9,421,436 B2 8/2016 Shelton et al. 9,808,038 B2 11/2017 Faller et al. 9,439,468 B2 9/2016 Wiener et al. 9,808,638 B2 11/2017 Faller et al. 9,439,436 B2 9/2016					
9,351,642 B2 5,2016 Nadkarni et al. 9,713,507 B2 7,2017 Couture 9,351,726 B2 5,2016 Leimbach et al. 9,717,552 B2 8,2017 Couture 9,351,734 B2 5,2016 Vakharia et al. 9,717,552 B2 8,2017 Couture 9,352,173 B2 5,2016 Vakharia et al. 9,714,118 B2 8,2017 Couture 9,352,173 B2 5,2016 Vakharia et al. 9,724,118 B2 8,2017 Couture 9,352,173 B2 5,2016 Valmada et al. 9,724,118 B2 8,2017 Horlle et al. 9,358,065 B2 6,2016 Edito, IV et al. 9,737,326 B2 8,2017 Worlell et al. 9,370,400 B2 6,2016 Parihar 9,737,355 B2 8,2017 Worlell et al. 9,370,611 B2 6,2016 Ross et al. 9,737,355 B2 8,2017 Beckman et al. 9,375,230 B2 6,2016 Ross et al. 9,743,929 B2 8,2017 Beckman et al. 9,375,230 B2 6,2016 Cunningham et al. 9,743,947 B2 8,2017 Faller et al. 9,375,236 B2 6,2016 Cunningham et al. 9,743,947 B2 8,2017 Faller et al. 9,375,256 B2 6,2016 Cunningham et al. 9,757,148 B2 9,2017 Shimizu 9,335,331 B2 7,2016 Marr et al. 9,757,148 B2 9,2017 Boudreaux et al. 9,336,933 B2 7,2016 Swensgard et al. 9,757,128 B2 9,2017 Boudreaux et al. 9,336,933 B2 7,2016 Olson et al. 9,752,285 B2 9,2017 Boudreaux et al. 9,408,606 B2 8,2016 Ginnebaugh et al. 9,708,285 B2 10,2017 Price et al. 9,408,606 B2 8,2016 Ginnebaugh et al. 9,795,405 B2 10,2017 Dannaher et al. 9,408,606 B2 8,2016 Stulen et al. 9,808,308 B2 10,2017 Price et al. 9,408,606 B2 8,2016 Stulen et al. 9,808,308 B2 10,2017 Price et al. 9,408,606 B2 8,2016 Stulen et al. 9,808,308 B2 10,2017 Price et al. 9,408,606 B2 8,2016 Stulen et al. 9,808,308 B2 10,2017 Faller et al. 9,408,606 B2 8,2016 Stulen et al. 9,808,308 B2 10,2017 Faller et al. 9,408,608 B2 9,2016 Monson et al. 9,808,308 B2 10,2017 Faller et al. 9,408,608 B2 9,2016 Monson et al. 9,808,308 B2 10,2017 Faller et al. 9,408,608 B2 9,2016 Monson et al. 9,808,308 B2 10,2017 Faller et al. 9,408,408 B2 9,2016 Monson et al. 9,808,308 B2 10,2017 Faller et al. 9,408,408 B2 10,2016 Monson et al. 9,808,308 B2 11,2017 Faller et al. 9,808,408 B2 10,2017 Frice et al. 9,808,408 B2 10,2017 Frice et al. 9,408,408 B2 10,2016 Winer et al. 9,808,608 B2 10,2016 Winer e			9,707,027 B2	7/2017	Ruddenklau et al.
9,351,726 B2 5/2016 Leimbach et al. 9,717,548 B2 8/2017 Couture 9,351,734 B2 5/2016 Vardand et al. 9,717,548 B2 8/2017 Cosman et al. 9,351,734 B2 5/2016 Vardand et al. 9,724,118 B2 8/2017 Schulie et al. 9,358,065 B2 6/2016 Ladtkow et al. 9,724,125 B2 8/2017 Vornell et al. 9,370,400 B2 6/2016 Parihar 9,737,355 B2 8/2017 Vornell et al. 9,370,400 B2 6/2016 Ross et al. 9,737,355 B2 8/2017 Vardes et al. 9,370,400 B2 6/2016 Ross et al. 9,733,355 B2 8/2017 Vardes et al. 9,375,230 B2 6/2016 Ross et al. 9,743,929 B2 8/2017 Leimbach et al. 9,375,230 B2 6/2016 Kerr et al. 9,743,946 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Kerr et al. 9,743,947 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Kerr et al. 9,743,947 B2 9/2017 Schmizzu 9,385,831 B2 7/2016 Kerr et al. 9,757,142 B2 9/2017 Schmizzu 9,385,831 B2 7/2016 Swensgard et al. 9,757,186 B2 9/2017 Vwener et al. 9,393,037 B2 7/2016 Swensgard et al. 9,748,248 B2 9/2017 Vorne et al. 9,393,037 B2 7/2016 Swensgard et al. 9,782,214 B2 9/2017 Vwener et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,782,214 B2 10/2017 Doannaher et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,782,214 B2 10/2017 Doannaher et al. 9,408,606 B2 8/2016 Schlon, IV 9,795,405 B2 10/2017 Vardes et al. 9,408,606 B2 8/2016 Schlon, IV 9,795,405 B2 10/2017 Vardes et al. 9,408,606 B2 8/2016 Monson et al. 9,804,604 B2 8/2016 Monson et al. 9,804,604 B2 8/2016 Monson et al. 9,802,033 B2 10/2017 Vardes et al. 9,414,830 B2 8/2016 Monson et al. 9,803,036 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Ginnebaugh et al. 9,802,038 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Ginnebaugh et al. 9,803,038 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Ginnebaugh et al. 9,803,038 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Ginnebaugh et al. 9,803,038 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Ginnebaugh et al. 9,803,038 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Ginnebaugh et al. 9,803,038 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Ginnebaugh et al. 9,803,038 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Ginnebaugh et al. 9,803					
9,352,173 B2 5/2016 Yamada et al. 9,358,065 B2 6/2016 Ladtkow et al. 9,364,203 B2 6/2016 Selton, IV et al. 9,370,400 B2 6/2016 Parihar 9,373,325 B2 8/2017 Worrell et al. 9,370,400 B2 6/2016 Ross et al. 9,375,230 B2 6/2016 Ross et al. 9,375,233 B2 6/2016 Ross et al. 9,375,233 B2 6/2016 Ross et al. 9,375,233 B2 6/2016 Ross et al. 9,375,235 B2 8/2017 Leimbach et al. 9,375,235 B2 6/2016 Containingham et al. 9,375,236 B2 6/2016 Containingham et al. 9,375,265 B2 6/2016 Containingham et al. 9,375,266 B2 6/2016 Containingham et al. 9,375,142 B2 9/2017 Faller et al. 9,388,831 B2 7/2016 Swensgard et al. 9,375,142 B2 9/2017 Shimizu 9,388,831 B2 7/2016 Olson et al. 9,376,144 B2 9/2017 Wiener et al. 9,389,911 B2 7/2016 Olson et al. 9,378,214 B2 10/2017 Houser et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,402,680 B2 8/2016 Selton, IV 9,795,436 B2 10/2017 Dannaher et al. 9,408,602 B2 8/2016 Stulen et al. 9,408,602 B2 8/2016 Stulen et al. 9,408,602 B2 8/2016 Stulen et al. 9,414,838 B2 8/2016 Stulen et al. 9,414,838 B2 8/2016 Stulen et al. 9,414,838 B2 8/2016 Monson et al. 9,414,838 B2 8/2016 Monson et al. 9,414,838 B2 8/2016 Robertson et al. 9,414,838 B2 8/2016 Robertson et al. 9,414,838 B2 8/2016 Monson et al. 9,414,838 B2 8/2016 Robertson et al. 9,414,838 B2 8/2016 Monson et al. 9,414,838 B2 8/2016 Monson et al. 9,414,838 B2 8/2016 Robertson et al. 9,439,668 B2 9/2016 Monson et al. 9,439,668 B2 9/2016 Monson et al. 9,439,668 B2 9/2016 Monson et al. 9,439,671 B2 9/2016 Wiener et al. 9,439,671 B2 9/2016 Wiener et al. 9,439,674 B2 9/2016 Wiener et al. 9,430,674 B2 9/2016 Wiener et al. 9,430,674 B2 9/2016 Wiener et al. 9,430,674 B2 9			9,717,548 B2	8/2017	Couture
9,358,065 B2 6/2016 Shelton, IV et al. 9,734,326 B2 8/2017 Horfle et al. 9,376,4230 B2 6/2016 Ross et al. 9,737,335 B2 8/2017 Yates et al. 9,375,236 B2 8/2017 Yates et al. 9,375,230 B2 6/2016 Ross et al. 9,737,335 B2 8/2017 Each man et al. 9,375,230 B2 6/2016 Ross et al. 9,743,946 B2 8/2017 Each mach et al. 9,375,230 B2 6/2016 Cunningham et al. 9,743,946 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Cunningham et al. 9,743,947 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Cunningham et al. 9,757,142 B2 9/2017 Shimizu 9,385,831 B2 7/2016 Kerr et al. 9,757,148 B2 9/2017 Shimizu 9,386,983 B2 7/2016 Swensgard et al. 9,757,186 B2 9/2017 Source et al. 9,393,037 B2 7/2016 Olson et al. 9,776,285 B2 9/2017 Coran et al. 9,393,037 B2 7/2016 Auld 9,782,214 B2 10/2017 Houser et al. 9,402,680 B2 8/2016 Shelton, IV 9,795,405 B2 10/2017 Dannaher et al. 9,408,606 B2 8/2016 Shelton, IV 9,795,808 B2 10/2017 Frice et al. 9,414,853 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Shelton, IV 9,795,808 B2 11/2017 Houser et al. 9,421,060 B2 8/2016 Shelton, IV 9,795,808 B2 11/2017 Houser et al. 9,421,060 B2 8/2016 Shelton et al. 9,801,648 B2 10/2017 Houser et al. 9,421,060 B2 8/2016 Shelton et al. 9,802,033 B2 11/2017 Shelton, IV 9,795,808 B2 11/2017 Houser et al. 9,439,669 B2 9/2016 Shelton et al. 9,802,033 B2 11/2017 Houser et al. 9,439,669 B2 9/2016 Shelton et al. 9,802,033 B2 11/2017 Houser et al. 9,439,669 B2 9/2016 Shelton et al. 9,802,033 B2 11/2017 Houser et al. 9,439,669 B2 9/2016 Shelton et al. 9,820,768 B2 11/2017 Frice et al. 9,439,669 B2 9/2016 Shelton et al. 9,820,768 B2 11/2017 Frice et al. 9,456,864 B2 10/2016 Monson et al. 9,820,761 B2 11/2017 Robertson et al. 9,456,864 B2 10/2016 Monson et al. 9,867,670 B2 11/2018					
9,370,400 B2 6/2016 Parihar 9,737,355 B2 8/2017 Yates et al. 9,370,400 B2 6/2016 Ross et al. 9,737,355 B2 8/2017 Beckman et al. 9,375,230 B2 6/2016 Ross et al. 9,743,994 B2 8/2017 Leimbach et al. 9,375,230 B2 6/2016 Hunt et al. 9,743,946 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Cunningham et al. 9,743,947 B2 8/2017 Frice et al. 9,375,267 B2 6/2016 Kerr et al. 9,757,148 B2 9/2017 Shimizu 9,385,831 B2 7/2016 Marr et al. 9,757,186 B2 9/2017 Shimizu 9,385,831 B2 7/2016 Swensgard et al. 9,764,164 B2 9/2017 Wiener et al. 9,398,911 B2 7/2016 Oson et al. 9,770,285 B2 9/2017 Wiener et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,788,851 B2 10/2017 Jannaher et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,795,405 B2 10/2017 Jannaher et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,848 B2 10/2017 Jannaher et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,848 B2 10/2017 Wasserly et al. 9,408,606 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Stulen et al. 9,802,033 B2 11/2017 Faller et al. 9,421,060 B2 8/2016 Stulen et al. 9,808,308 B2 11/2017 Faller et al. 9,439,668 B2 8/2016 Robertson et al. 9,808,308 B2 11/2017 Faller et al. 9,439,668 B2 8/2016 Robertson et al. 9,808,308 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Wiener et al. 9,808,080 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Wiener et al. 9,808,080 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Wiener et al. 9,808,080 B2 11/2017 Faller et al. 9,439,668 B2 9/2016 Wiener et al. 9,808,080 B2 11/2017 Faller et al. 9,439,669 B2 9/2016 Wiener et al. 9,808,080 B2 11/2017 Faller et al. 9,439,669 B2 9/2016 Wiener et al. 9,808,080 B2 11/2017 Faller et al. 9,439,669 B2 9/2016 Wiener et al. 9,808,708 B2 11/2017 Faller et al. 9,445,832 B2 9/2016 Wiener et al. 9,808,708 B2 11/2017 Faller et al. 9,445,832 B2 9/2016 Wiener et al. 9,808,708 B2 11/2017 Faller et al.		6/2016 Ladtkow et al.	9,724,152 B2	8/2017	Horlle et al.
9,370,611 B2 6/2016 Ross et al. 9,737,358 B2 8/2017 Beckman et al. 9,375,230 B2 6/2016 Ross et al. 9,743,929 B2 8/2017 Leimbach et al. 9,375,230 B2 6/2016 Cunningham et al. 9,743,947 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Cunningham et al. 9,743,947 B2 8/2017 Faller et al. 9,375,267 B2 6/2016 Kerr et al. 9,757,142 B2 9,2017 Simizu 9,385,831 B2 7/2016 Marr et al. 9,757,142 B2 9,2017 Simizu 9,385,983 B2 7/2016 Swensgard et al. 9,757,142 B2 9,2017 Simizu 9,393,037 B2 7/2016 Olson et al. 9,770,285 B2 9/2017 Houser et al. 9,393,037 B2 7/2016 Olson et al. 9,770,285 B2 9/2017 Houser et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,782,214 B2 10/2017 Houser et al. 9,402,680 B2 8/2016 Worrell et al. 9,795,405 B2 10/2017 Yates et al. 9,402,680 B2 8/2016 Shelton, IV 9,795,405 B2 10/2017 Yates et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Yates et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Yates et al. 9,408,606 B2 8/2016 Stulen et al. 9,802,643 B2 10/2017 Houser et al. 9,414,830 B2 8/2016 Monson et al. 9,802,643 B2 10/2017 Houser et al. 9,414,830 B2 8/2016 Monson et al. 9,802,643 B2 10/2017 Houser et al. 9,427,249 B2 8/2016 Monson et al. 9,802,643 B2 11/2017 Faller et al. 9,439,669 B2 9/2016 Timm et al. 9,820,771 B2 11/2017 Faller et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Gee et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Faller et al. 19,439,669 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Brockman et al. 9,439,669 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Brockman et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Witer et al. 9,846,848 B2 10/2016 Witer et al. 9,867,651 B2 11/2018 Worrell et al. 9,492,248 B2 11/2016 Worden et al. 9,877,776 B2 11/2018 Worrell et al. 9,492,245 B2 11/2016 Worrell et al. 9,877,776 B2 11/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,		*			
9,375,232 B2 6/2016 Kunt et al. 9,743,946 B2 8/2017 Faller et al. 9,375,256 B2 6/2016 Cunningham et al. 9,743,947 B2 8/2017 Frice et al. 9,375,267 B2 6/2016 Kerr et al. 9,743,947 B2 9/2017 Shimizu 9,385,831 B2 7/2016 Marr et al. 9,757,186 B2 9/2017 Boudreaux et al. 9,386,983 B2 7/2016 Olson et al. 9,764,164 B2 9/2017 Voiener et al. 9,393,037 B2 7/2016 Olson et al. 9,764,164 B2 9/2017 Zoran et al. 9,393,911 B2 7/2016 Auld 9,782,214 B2 10/2017 Houser et al. 9,398,911 B2 7/2016 Ginnebaugh et al. 9,788,851 B2 10/2017 Houser et al. 9,402,680 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Price et al. 9,408,606 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Vates et al. 9,408,606 B2 8/2016 Strob et al. 9,795,808 B2 10/2017 Vates et al. 9,408,606 B2 8/2016 Strob et al. 9,795,808 B2 10/2017 Houser et al. 9,414,880 B2 8/2016 Stulen et al. 9,802,033 B2 10/2017 Houser et al. 9,414,880 B2 8/2016 Stulen et al. 9,808,308 B2 11/2017 Houser et al. 9,421,060 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Shelton, IV et al. 9,427,249 B2 8/2016 Robertson et al. 9,804,439,668 B2 9/2016 Timm et al. 9,820,771 B2 11/2017 Shelton, IV et al. 9,439,669 B2 9/2016 Kagane 9,339,443 B2 12/2017 Brockman et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Fore et al. 9,450,868 B2 10/2016 Moua 9,848,901 B2 12/2017 Frice et al. 9,468,498 B2 10/2016 Wiener et al. 9,848,901 B2 12/2017 Frice et al. 9,468,498 B2 10/2016 Wiener et al. 9,861,428 B2 1/2017 Trees et al. 9,468,498 B2 10/2016 Wiener et al. 9,886,1428 B2 1/2017 Trees et al. 9,468,498 B2 10/2016 Wite et al. 9,861,428 B2 1/2018 Brannan et al. 9,492,246 B2 11/2016 Olden et al. 9,872,776 B2 1/2018 Morisaki 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Broundeaux			9,737,358 B2		
9,375,256 B2 6/2016 Cunningham et al. 9,743,947 B2 8/2017 Price et al. 9,375,267 B2 6/2016 Kerr et al. 9,757,142 B2 9/2017 Shimizu Shimizu 9,385,831 B2 7/2016 Marr et al. 9,757,186 B2 9/2017 Wiener et al. 9,386,983 B2 7/2016 Swensgard et al. 9,764,164 B2 9/2017 Wiener et al. 9,393,037 B2 7/2016 Olson et al. 9,770,285 B2 9/2017 Zoran et al. 9,398,911 B2 7/2016 Aud 9,782,214 B2 10/2017 Houser et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,788,851 B2 10/2017 Price et al. 9,408,660 B2 8/2016 Stulen et al. 9,795,405 B2 10/2017 Vates et al. 9,408,660 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Vates et al. 9,408,660 B2 8/2016 Strobl et al. 9,795,808 B2 10/2017 Vates et al. 9,408,660 B2 8/2016 Strobl et al. 9,801,648 B2 10/2017 Houser et al. 9,414,833 B2 8/2016 Strobl et al. 9,801,648 B2 10/2017 Houser et al. 9,414,830 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,427,249 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Shelton, IV et al. 9,439,668 B2 9/2016 Monson et al. 9,814,514 B2 11/2017 Shelton, IV et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Norton et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Norton et al. 9,445,832 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Robertson et al. 9,848,901 B2 12/2017 Price et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Price et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Price et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,902 B2 12/2017 Price et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,902 B2 12/2017 Price et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,902 B2 12/2017 Price et al. 9,468,498 B2 10/2016 Wiener et al. 9,867,670 B2 1/2018 Brannan et al. 9,445,848 B2 10/2016 Wiener et al. 9,867,670 B2 1/2018 Brannan et al. 9,492,244 B2 11/2016 Boudreaux et al. 9,872,725 B2 1/2018 Worrell et al. 9,492,244 B2 11/2016 Worder et al. 9,872,725 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux					
9,385,831 B2 7/2016 Marr et al. 9,757,186 B2 9/2017 Wiener et al. 9,386,983 B2 7/2016 Olson et al. 9,764,164 B2 9/2017 Wiener et al. 9,393,037 B2 7/2016 Olson et al. 9,770,285 B2 9/2017 Zoran et al. 9,398,911 B2 7/2016 Auld 9,782,214 B2 10/2017 Houser et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,788,851 B2 10/2017 Dannaher et al. 9,402,680 B2 8/2016 Shelton, IV 9,795,405 B2 10/2017 Yates et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,405 B2 10/2017 Yates et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Wiener et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Houser et al. 9,408,606 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Stulen et al. 9,802,033 B2 10/2017 Houser et al. 9,414,880 B2 8/2016 Monson et al. 9,802,033 B2 11/2017 Houser et al. 9,414,880 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,414,808 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,427,249 B2 8/2016 Monson et al. 9,814,514 B2 11/2017 Shelton, IV et al. 9,427,249 B2 8/2016 Wiener et al. 9,820,768 B2 11/2017 Shelton, IV et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Norton et al. 9,439,671 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Faller et al. 9,439,671 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Bockman et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Frice et al. 9,456,863 B2 10/2016 Moua 9,848,907 B2 12/2017 Frice et al. 9,456,863 B2 10/2016 Wiener et al. 9,848,907 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Wiener et al. 9,867,670 B2 11/2018 Wham 9,486,236 B2 11/2016 Frice et al. 9,872,725 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Worrell et al. 9,877,776 B2 11/2018 Worrell et al. 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 11/2018 Worrell et al.		6/2016 Cunningham et al.	9,743,947 B2	8/2017	Price et al.
9,386,983 B2 7/2016 Swensgard et al. 9,764,164 B2 9/2017 Wiener et al. 9,393,037 B2 7/2016 Olson et al. 9,770,285 B2 9/2017 Houser et al. 9,398,911 B2 7/2016 Ginnebaugh et al. 9,782,214 B2 10/2017 Dannaher et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,795,405 B2 10/2017 Dannaher et al. 9,402,682 B2 8/2016 Worrell et al. 9,795,405 B2 10/2017 Price et al. 9,408,606 B2 8/2016 Shelton, IV 9,795,405 B2 10/2017 Wiener et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Wiesserly et al. 9,408,606 B2 8/2016 Stroll et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Monson et al. 9,803,308 B2 11/2017 Faller et al. 9,421,060 B2 8/2016 Monson et al. 9,803,308 B2 11/2017 Faller et al. 9,421,060 B2 8/2016 Robertson et al. 9,820,768 B2 11/2017 Gee et al. 9,439,668 B2 9/2016 Wiener et al. 9,820,768 B2 11/2017 Gee et al. 9,439,668 B2 9/2016 Wiener et al. 9,820,768 B2 11/2017 Lee et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,768 B2 11/2017 Lee et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,806 B2 11/2017 The et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Robertson et al. 9,456,863 B2 10/2016 Wiener et al. 9,848,901 B2 12/2017 Robertson et al. 9,456,864 B2 10/2016 Wiener et al. 9,848,901 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Wiener et al. 9,848,937 B2 12/2017 Trees et al. 9,468,498 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Wham 9,486,236 B2 11/2016 Force et al. 9,861,428 B2 1/2018 Wham 9,486,236 B2 11/2016 Force et al. 9,877,726 B2 1/2018 Worrell et al. 9,492,244 B2 11/2016 Voegele et al. 9,877,776 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux					
9,398,911 B2 7/2016 Auld 9,782,214 B2 10/2017 Houser et al. 9,402,680 B2 8/2016 Ginnebaugh et al. 9,788,851 B2 10/2017 Price et al. 9,402,680 B2 8/2016 Shelton, IV 9,795,405 B2 10/2017 Vates et al. 9,408,606 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Messerly et al. 9,408,660 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,408,660 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,408,460 B2 8/2016 Stulen et al. 9,802,033 B2 10/2017 Houser et al. 9,414,883 B2 8/2016 Stulen et al. 9,802,033 B2 10/2017 Hibner et al. 9,414,880 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,421,060 B2 8/2016 Monson et al. 9,814,514 B2 11/2017 Shelton, IV et al. 9,427,249 B2 8/2016 Wiener et al. 9,820,768 B2 11/2017 Gee et al. 9,439,668 B2 9/2016 Timm et al. 9,820,771 B2 11/2017 Norton et al. 9,439,661 B2 9/2016 Wiener et al. 9,830,806 B2 11/2017 Lee et al. 9,439,671 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Brockman et al. 9,456,863 B2 10/2016 Moua 9,848,901 B2 12/2017 Robertson et al. 9,456,864 B2 10/2016 Witt et al. 9,848,902 B2 12/2017 Price et al. 9,468,498 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Witt et al. 9,867,670 B2 1/2018 Brannan et al. 9,492,146 B2 11/2016 Kostrzewski et al. 9,877,726 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Womer et al. 9,877,726 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Womer et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Womer et al. 9,877,726 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Womer et al. 9,877,726 B2 1/2018 Worrell et al.			9,764,164 B2	9/2017	Wiener et al.
9,402,680 B2 8/2016 Ginnebaugh et al. 9,788,851 B2 10/2017 Dannaher et al. 9,402,682 B2 8/2016 Worrell et al. 9,795,405 B2 10/2017 Price et al. 10/2017 Price et al. 9,408,660 B2 8/2016 Stulen et al. 9,795,405 B2 10/2017 Messerly et al. 9,408,660 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Messerly et al. 9,408,660 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Hibner et al. 9,414,883 B2 8/2016 Stulen et al. 9,802,033 B2 10/2017 Hibner et al. 9,414,883 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,421,060 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,427,249 B2 8/2016 Monson et al. 9,820,768 B2 11/2017 Gee et al. 9,439,668 B2 9/2016 Timm et al. 9,820,771 B2 11/2017 Norton et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,806 B2 11/2017 Lee et al. 9,439,669 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Brockman et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Robertson et al. 9,456,863 B2 10/2016 Moua 9,848,937 B2 12/2017 Trice et al. 9,456,863 B2 10/2016 Witt et al. 9,848,937 B2 12/2017 Trice et al. 9,456,864 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Witt et al. 9,867,651 B2 1/2018 Brannan et al. 9,492,146 B2 11/2016 Price et al. 9,867,651 B2 1/2018 Brannan et al. 9,492,244 B2 11/2016 Price et al. 9,877,776 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Worrell et al. 9,877,776 B2 1/2018 Boudreaux					
9,408,606 B2 8/2016 Shelton, IV 9,795,436 B2 10/2017 Yates et al. 9,408,606 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,408,660 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Stulen et al. 9,802,033 B2 10/2017 Hibner et al. 9,414,880 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,421,060 B2 8/2016 Monson et al. 9,814,514 B2 11/2017 Faller et al. 9,427,249 B2 8/2016 Robertson et al. 9,820,768 B2 11/2017 Gee et al. 9,439,668 B2 9/2016 Timm et al. 9,820,771 B2 11/2017 Norton et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,806 B2 11/2017 Lee et al. 9,439,671 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Brockman et al. 9,451,967 B2 9/2016 Jordan et al. 9,848,901 B2 12/2017 Robertson et al. 9,456,863 B2 10/2016 Moua 9,848,937 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Wham 9,486,236 B2 11/2016 Kostrzewski et al. 9,872,725 B2 1/2018 Morisaki 9,492,242 B2 11/2016 Boudreaux et al. 9,877,770 B2 1/2018 Morrisaki 9,498,245 B2 11/2016 Wham et al. 9,877,720 B2 1/2018 Morrisaki 9,498,245 B2 11/2016 Wham et al. 9,877,770 B2 1/2018 Morrisaki 9,498,275 B2 11/2016 Wham et al.			9,788,851 B2	10/2017	Dannaher et al.
9,408,622 B2 8/2016 Stulen et al. 9,795,808 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Stulen et al. 9,801,648 B2 10/2017 Houser et al. 9,414,853 B2 8/2016 Stulen et al. 9,802,033 B2 10/2017 Hibner et al. 9,414,853 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,821,060 B2 8/2016 Monson et al. 9,814,514 B2 11/2017 Shelton, IV et al. 9,427,249 B2 8/2016 Robertson et al. 9,820,768 B2 11/2017 Gee et al. 9,439,668 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Lee et al. 9,439,669 B2 9/2016 Wiener et al. 9,820,806 B2 11/2017 Lee et al. 9,439,671 B2 9/2016 Akagane 9,839,443 B2 12/2017 Brockman et al. 9,451,967 B2 9/2016 Jordan et al. 9,848,901 B2 12/2017 Robertson et al. 9,456,863 B2 10/2016 Moua 9,848,902 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Brannan et al. 9,492,244 B2 11/2016 Boudreaux et al. 9,872,725 B2 1/2018 Morisaki 9,498,245 B2 11/2016 Wham et al. 9,872,726 B2 1/2018 Morisaki 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Worrell et al.	9,402,682 B2	8/2016 Worrell et al.			
9,414,853 B2 8/2016 Stulen et al. 9,414,880 B2 8/2016 Monson et al. 9,421,060 B2 8/2016 Monson et al. 9,427,249 B2 8/2016 Robertson et al. 9,439,668 B2 9/2016 Wiener et al. 9,439,667 B2 9/2016 Wiener et al. 9,445,832 B2 9/2016 Wiener et al. 9,451,967 B2 9/2016 Monson et al. 9,456,868 B2 10/2016 Monson et al. 9,456,868 B2 10/2016 Wiener et al. 9,456,868 B2 10/2016 Wiener et al. 9,456,868 B2 10/2016 Wiener et al. 9,456,868 B2 10/2016 Monson et al. 9,456,868 B2 10/2016 Wiener et al. 9,456,868 B2 10/2016 Monson et al. 9,861,428 B2 1/2017 Price et al. 9,468,498 B2 10/2016 Witt et al. 9,861,428 B2 1/2017 Trees et al. 9,468,498 B2 10/2016 Witt et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,468,236 B2 11/2016 Frice et al. 9,492,244 B2 11/2016 Kostrzewski et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,877,726 B2 1/2018 Morisaki 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux			9,795,808 B2	10/2017	Messerly et al.
9,414,880 B2 8/2016 Monson et al. 9,808,308 B2 11/2017 Faller et al. 9,414,880 B2 8/2016 Monson et al. 9,814,514 B2 11/2017 Shelton, IV et al. 9,427,249 B2 8/2016 Robertson et al. 9,820,768 B2 11/2017 Gee et al. 9,439,668 B2 9/2016 Timm et al. 9,820,771 B2 11/2017 Lee et al. 9,439,667 B2 9/2016 Wiener et al. 9,820,806 B2 11/2017 Lee et al. 9,439,671 B2 9/2016 Akagane 9,839,443 B2 12/2017 Brockman et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Robertson et al. 9,451,967 B2 9/2016 Moua 9,848,937 B2 12/2017 Price et al. 9,456,863 B2 10/2016 Moua 9,848,937 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Wham 9,486,236 B2 11/2016 Kostrzewski et al. 9,87,775 B2 1/2018 Worrell et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux					
9,427,249 B2 8/2016 Robertson et al. 9,820,768 B2 11/2017 Gee et al. 9,439,668 B2 9/2016 Wiener et al. 9,820,771 B2 11/2017 Lee et al. 9,439,671 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Brockman et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Robertson et al. 9,451,967 B2 9/2016 Wiener et al. 9,848,902 B2 12/2017 Robertson et al. 9,451,967 B2 9/2016 Moua 9,848,903 B2 12/2017 Price et al. 9,456,863 B2 10/2016 Moua 9,848,937 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Sigmon, Jr. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,670 B2 1/2018 Wham 9,486,236 B2 11/2016 Price et al. 9,867,670 B2 1/2018 Worrell et al. 9,492,146 B2 11/2016 Rostrzewski et al. 9,872,725 B2 1/2018 Worrell et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux			9,808,308 B2	11/2017	Faller et al.
9,439,669 B2 9/2016 Timm et al. 9,820,771 B2 11/2017 Norton et al. 9,439,669 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Brockman et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Robertson et al. 9,451,967 B2 9/2016 Jordan et al. 9,848,902 B2 12/2017 Price et al. 9,456,863 B2 10/2016 Moua 9,848,902 B2 12/2017 Price et al. 9,456,864 B2 10/2016 Witt et al. 9,861,428 B2 11/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Wham 9,486,236 B2 11/2016 Price et al. 9,867,670 B2 1/2018 Brannan et al. 9,492,146 B2 11/2016 Rostrzewski et al. 9,872,725 B2 1/2018 Worrell et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux	9,421,060 B2				
9,439,669 B2 9/2016 Wiener et al. 9,839,443 B2 11/2017 Brockman et al. 9,439,671 B2 9/2016 Wiener et al. 9,839,443 B2 12/2017 Brockman et al. 9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Robertson et al. 9,451,967 B2 9/2016 Jordan et al. 9,848,902 B2 12/2017 Price et al. 9,456,863 B2 10/2016 Moua 9,848,937 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Wham 9,486,236 B2 11/2016 Price et al. 9,867,670 B2 1/2018 Brannan et al. 9,492,146 B2 11/2016 Kostrzewski et al. 9,872,725 B2 1/2018 Worrell et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,872,726 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux			9,820,771 B2	11/2017	Norton et al.
9,445,832 B2 9/2016 Wiener et al. 9,848,901 B2 12/2017 Robertson et al. 9,451,967 B2 9/2016 Moua 9,848,902 B2 12/2017 Price et al. 9,456,863 B2 10/2016 Moua 9,848,937 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Wham 9,486,236 B2 11/2016 Price et al. 9,867,670 B2 1/2018 Brannan et al. 9,492,146 B2 11/2016 Kostrzewski et al. 9,872,725 B2 1/2018 Worrell et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,872,726 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Worell et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux					
9,451,967 B2 9/2016 Jordan et al. 9,848,902 B2 12/2017 Price et al. 9,456,863 B2 10/2016 Moua 9,848,937 B2 12/2017 Trees et al. 9,456,864 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Wham 9,486,236 B2 11/2016 Frice et al. 9,867,670 B2 1/2018 Brannan et al. 9,492,146 B2 11/2016 Kostrzewski et al. 9,872,725 B2 1/2018 Worrell et al. 9,498,245 B2 11/2016 Boudreaux et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux			9,848,901 B2	12/2017	Robertson et al.
9,456,864 B2 10/2016 Witt et al. 9,861,428 B2 1/2018 Trees et al. 9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Wham 9,486,236 B2 11/2016 Price et al. 9,867,670 B2 1/2018 Brannan et al. 9,492,146 B2 11/2016 Kostrzewski et al. 9,872,725 B2 1/2018 Worrell et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,872,726 B2 1/2018 Morisaki 9,498,245 B2 11/2016 Voegele et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux	9,451,967 B2	9/2016 Jordan et al.			
9,468,498 B2 10/2016 Sigmon, Jr. 9,867,651 B2 1/2018 Wham 9,486,236 B2 11/2016 Price et al. 9,867,670 B2 1/2018 Brannan et al. 9,492,146 B2 11/2016 Kostrzewski et al. 9,872,725 B2 1/2018 Worrell et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,872,726 B2 1/2018 Morisaki 9,498,245 B2 11/2016 Voegele et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux					
9,492,146 B2 11/2016 Kostrzewski et al. 9,872,725 B2 1/2018 Worrell et al. 9,492,224 B2 11/2016 Boudreaux et al. 9,872,726 B2 1/2018 Morisaki 9,498,245 B2 11/2016 Voegele et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux	9,468,498 B2	10/2016 Sigmon, Jr.	9,867,651 B2	1/2018	Wham
9,492,224 B2 11/2016 Boudreaux et al. 9,872,726 B2 1/2018 Morisaki 9,498,245 B2 11/2016 Voegele et al. 9,877,720 B2 1/2018 Worrell et al. 9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux					
9,498,275 B2 11/2016 Wham et al. 9,877,776 B2 1/2018 Boudreaux	9,492,224 B2	11/2016 Boudreaux et al.	9,872,726 B2	1/2018	Morisaki

(56)	Referen	ices Cited	2004/009292			Kadziauskas et al.
IJ	S PATENT	DOCUMENTS	2004/009299 2004/009791			Adams et al. Murakami et al.
, and the second		BOCOMETIE	2004/009791	2 A1	5/2004	Gonnering
9,888,958 E		Evans et al.	2004/009791			Wellman et al.
9,907,563 E		Germain et al.	2004/009799 2004/011695			Rabiner et al. Sakurai et al.
9,913,656 E 9,913,680 E		Stulen Voegele et al.	2004/012242			Dycus et al.
9,915,080 E 9,925,003 E		Parihar et al.	2004/013238			Langford et al.
9,949,785 E		Price et al.	2004/013862			Jahns et al.
9,949,788 E		Boudreaux	2004/014266 2004/014793			Lochhead et al. Kiester
9,962,182 E 9,987,033 E		Dietz et al. Neurohr et al.	2004/014794			Fritzsch
10,004,526 E		Dycus et al.	2004/015823			Abboud et al.
10,010,339 E		Witt et al.	2004/016750			Wham et al.
10,010,341 E	32 7/2018	Houser et al.	2004/017668 2004/017675			Hare et al. Weitzner et al.
10,022,142 E		Aranyi et al.	2004/01/07/3		9/2004	
10,022,567 E 10,022,568 E		Messerly et al. Messerly et al.	2004/019919			Hayashi et al.
10,028,761 E		Leimbach et al.	2004/021513		10/2004	Yoon
10,028,786 E	32 7/2018	Mucilli et al.	2004/024314		12/2004	
10,034,684 E		Weisenburgh, II et al.	2004/024937 2004/026027		12/2004	Tetzlaff et al.
10,034,704 E 10,045,794 E		Asher et al. Witt et al.	2004/026030			Gorensek et al.
10,045,754 E	32 8/2018	Schall et al.	2005/001512			Mioduski et al.
10,045,819 E	8/2018	Jensen et al.	2005/002096		1/2005	
10,070,916 E			2005/002101 2005/002106			Anderson et al. Yamada et al.
10,085,762 E 10,085,792 E		Timm et al. Johnson et al.	2005/002107			Vleugels et al.
10,083,792 E	32 10/2018 32 10/2018	Boudreaux et al.	2005/003327			McClurken et al.
10,092,344 E		Mohr et al.	2005/003333			Muir et al.
10,092,348 E		Boudreaux	2005/007080		3/2005	
10,111,699 E		Boudreaux	2005/008828 2005/009081		4/2005 4/2005	
10,111,703 E 10,117,667 E		Cosman, Jr. et al. Robertson et al.	2005/009668			Ellins et al.
10,117,702 E		Danziger et al.	2005/009982			Dowling et al.
2001/0025173 A	1 9/2001	Ritchie et al.	2005/013139			Heinrich et al.
2001/0025183 A		Shahidi	2005/014376 2005/014910		7/2005	White et al.
2001/0025184 A 2001/0031950 A		Messerly Ryan	2005/016542			Douglas et al.
2001/0031930 A		Francischelli et al.	2005/017152	2 A1	8/2005	Christopherson
2002/0002377 A		Cimino	2005/017718		8/2005	
2002/0002380 A		Bishop	2005/018233 2005/018874		8/2005 9/2005	Lee et al.
2002/0019649 A 2002/0022836 A		Sikora et al. Goble et al.	2005/019261			Houser et al.
2002/0022036 A		Goble et al.	2005/019261	1 A1		Houser
2002/0029055 A		Bonutti	2005/022259			Ho et al.
2002/0049551 A		Friedman et al.	2005/023448 2005/024966		10/2005	Houser et al. Tuszynski et al.
2002/0052617 A 2002/0077550 A		Anis et al. Rabiner et al.	2005/025640			Makin et al.
2002/0077530 F		Witt et al.	2005/026158			Makin et al.
2002/0156466 A		Sakurai et al.	2005/026217			Iino et al.
2002/0156493 A		Houser et al.	2005/026746 2005/027180			Truckai et al. Iljima et al.
2003/0014053 A 2003/0014087 A		Nguyen et al. Fang et al.	2005/027180			Nieman et al.
2003/0014087 F		Hare et al.	2005/028865			Kimura et al.
2003/0050572 A		Brautigam et al.	2006/002575		2/2006	
2003/0055443 A		Spotnitz	2006/003079 2006/005882			Zhou et al. Ogura et al.
2003/0109875 A 2003/0114851 A		Tetzlaff et al. Truckai et al.	2006/006313			Hayman et al.
2003/0114831 A		Levin et al.	2006/006408		3/2006	
2003/0139741 A		Goble et al.	2006/006618			Bromfield et al.
2003/0144680 A		Kellogg et al.	2006/007444 2006/007987			Noriega et al. Faller et al.
2003/0158548 A		Phan et al. Kanehira et al.	2006/007987			Faller et al.
2003/0171747 A 2003/0199794 A		Sakurai et al.	2006/009504			Trieu et al.
2003/0204199 A		Novak et al.	2006/010906			Dobson et al.
2003/0212332 A	11/2003	Fenton et al.	2006/015973			Shoshan Nichizawa et al
2003/0212363 A			2006/019003 2006/020610			Nishizawa et al. Eskridge et al.
2003/0212392 A 2003/0212422 A		Fenton et al. Fenton et al.	2006/020610			Schomer et al.
2003/0212422 F 2003/0225332 A		Okada et al.	2006/021194			Beaupre
2003/0229344 A	12/2003	Dycus et al.	2006/021772		9/2006	Eskridge et al.
2004/0030254 A		Babaev	2006/022416			Trieu et al.
2004/0030330 A		Brassell et al. Sherrit et al.	2006/024755			Yamada Yoshimine et al.
2004/0047485 A 2004/0054364 A		Aranyi et al.	2006/025305 2006/026480			Hansmann et al.
2004/0054364 P		Mollenauer	2006/026499		11/2006	Fanton et al.
2004/0087943 A		Dycus et al.	2006/027091			Skwarek et al.

(56)	Referen	ices Cited		2008/0243162 A1		Shibata et al.	
U.S.	PATENT	DOCUMENTS		2008/0255413 A1 2008/0281200 A1	11/2008	Zemlok et al. Voic et al.	
				2008/0281315 A1	11/2008		
2006/0271030 A1		Francis et al.		2008/0287944 A1		Pearson et al.	
2006/0293656 A1		Shadduck et al.		2008/0287948 A1 2008/0296346 A1	11/2008 12/2008	Newton et al. Shelton, IV et al.	
2007/0016235 A1 2007/0016236 A1		Tanaka et al. Beaupre		2008/0300588 A1		Groth et al.	
2007/0010230 A1 2007/0021738 A1		Hasser et al.		2009/0012516 A1	1/2009		
2007/0027468 A1		Wales et al.		2009/0023985 A1	1/2009		
2007/0035203 A1*	2/2007	Bromfield	B06B 1/0238	2009/0048537 A1		Lydon et al.	
			310/311	2009/0048589 A1 2009/0054886 A1		Takashino et al. Yachi et al.	
2007/0055228 A1		Berg et al.		2009/0054889 A1		Newton et al.	
2007/0056596 A1 2007/0060935 A1		Fanney et al. Schwardt et al.		2009/0054894 A1	2/2009	Yachi	
2007/0060533 A1 2007/0063618 A1		Bromfield		2009/0076506 A1	3/2009		
2007/0067123 A1	3/2007	Jungerman		2009/0082716 A1	3/2009	Akahoshi	
2007/0073185 A1		Nakao		2009/0082766 A1 2009/0088785 A1	3/2009 4/2009	Unger et al. Masuda	
2007/0073341 A1		Smith et al.		2009/0090763 A1 2009/0090763 A1	4/2009		
2007/0074584 A1 2007/0106317 A1		Talarico et al. Shelton et al.		2009/0112204 A1*	4/2009	Aronow	A61B 18/1233
2007/0100317 A1 2007/0118115 A1		Artale et al.					606/35
2007/0130771 A1		Ehlert et al.		2009/0118751 A1	5/2009	Wiener et al.	
2007/0135803 A1		Belson		2009/0143799 A1	6/2009	Smith et al.	
2007/0149881 A1	6/2007			2009/0143800 A1 2009/0157075 A1*		Deville et al. Wham	A61B 18/1206
2007/0156163 A1 2007/0166663 A1	7/2007	Davison et al. Telles et al.		2007/0137073 AT	0/2003	** IIdiii	606/40
2007/0173803 A1		Wham et al.		2009/0163807 A1	6/2009	Sliwa	000/10
2007/0173804 A1*		Wham	A61B 18/1206	2009/0182322 A1		D'Amelio et al.	
			606/34	2009/0182331 A1		D'Amelio et al.	
2007/0173813 A1		Odom		2009/0182332 A1 2009/0216157 A1		Long et al. Yamada	
2007/0173872 A1 2007/0185474 A1		Neuenfeldt Nahen		2009/0223033 A1		Houser	
2007/0193474 A1 2007/0191712 A1		Messerly et al.		2009/0240244 A1	9/2009	Malis et al.	
2007/0191713 A1		Eichmann et al.		2009/0248021 A1	10/2009	McKenna	
2007/0203483 A1		Kim et al.		2009/0254077 A1 2009/0254080 A1	10/2009 10/2009		
2007/0208336 A1 2007/0208340 A1		Kim et al. Ganz et al.		2009/0264909 A1		Beaupre	
2007/0208340 A1 2007/0219481 A1		Babaev		2009/0270771 A1		Takaĥashi	
2007/0232926 A1		Stulen et al.		2009/0270812 A1		Litscher et al.	
2007/0232928 A1		Wiener et al.		2009/0270853 A1 2009/0270891 A1		Yachi et al. Beaupre	
2007/0236213 A1 2007/0239101 A1		Paden et al. Kellogg		2009/0270891 A1 2009/0270899 A1		Carusillo et al.	
2007/0239101 A1 2007/0249941 A1		Salehi et al.		2009/0287205 A1	11/2009	Ingle	
2007/0260242 A1		Dycus et al.		2009/0299141 A1		Downey et al.	
2007/0265560 A1		Soltani et al.		2009/0327715 A1 2010/0004508 A1	1/2010	Smith et al. Naito et al.	
2007/0265613 A1 2007/0265616 A1		Edelstein et al. Couture et al.		2010/0004308 A1 2010/0022825 A1		Yoshie	
2007/0203010 A1 2007/0265620 A1		Kraas et al.		2010/0030233 A1		Whitman et al.	
2007/0275348 A1	11/2007			2010/0036370 A1		Mirel et al.	
2007/0287933 A1	12/2007	Phan et al.		2010/0049180 A1 2010/0057118 A1		Wells et al. Dietz et al.	
2007/0288055 A1	1/2007			2010/00637118 A1 2010/0063525 A1		Beaupre et al.	
2008/0005213 A1 2008/0013809 A1		Holtzman Zhu et al.		2010/0063528 A1		Beaupre	
2008/0015575 A1		Odom et al.		2010/0081863 A1		Hess et al.	
2008/0039746 A1		Hissong et al.		2010/0081864 A1		Hess et al.	
2008/0051812 A1		Schmitz et al. Darian et al.		2010/0081883 A1 2010/0094323 A1		Murray et al. Isaacs et al.	
2008/0058775 A1 2008/0058845 A1		Shimizu et al.		2010/0106173 A1	4/2010	Yoshimine	
2008/0070349 A1 2008/0071269 A1		Hilario et al.		2010/0158307 A1		Kubota et al.	
2008/0077145 A1		Boyden et al.		2010/0168741 A1		Sanaı et al.	
2008/0082039 A1		Babaev		2010/0187283 A1 2010/0204721 A1		Crainich et al. Young et al.	
2008/0082098 A1 2008/0097501 A1	4/2008	Tanaka et al.		2010/0204721 A1 2010/0222714 A1		Muir et al.	
2008/005/301 A1 2008/0114355 A1		Whayne et al.		2010/0222752 A1	9/2010	Collins, Jr. et al.	
2008/0114364 A1		Goldin et al.		2010/0228250 A1		Brogna	
2008/0122496 A1		Wagner		2010/0234906 A1 2010/0274160 A1	9/2010	Yachi et al.	
2008/0125768 A1 2008/0147058 A1		Tahara et al. Horrell et al.		2010/0274100 A1 2010/0274278 A1		Fleenor et al.	
2008/0147038 A1 2008/0147062 A1		Truckai et al.		2010/0298743 A1	11/2010	Nield et al.	
2008/0147092 A1	6/2008	Rogge et al.		2010/0331742 A1	12/2010		
2008/0171938 A1		Masuda et al.		2011/0004233 A1 2011/0028964 A1		Muir et al. Edwards	
2008/0177268 A1	7/2008 8/2008	Daum et al.		2011/0028964 A1 2011/0082486 A1*		Messerly A	A61B 17/320092
2008/0188755 A1 2008/0200940 A1		Harı Eichmann et al.		2011/0002 (00 P1	1/2011	1.1000011y F	606/169
2008/0208108 A1		Kimura		2011/0087220 A1	4/2011	Felder et al.	
2008/0208231 A1		Ota et al.		2011/0125149 A1		El-Galley et al.	
2008/0214967 A1		Aranyi et al.		2011/0125151 A1		Strauss et al.	.1
2008/0234709 A1	9/2008	Houser		2011/0238010 A1	9/2011	Kirschenman et a	и.

(56)	References Cited	2015/0182277 A1		Wiener et al.
U.S	S. PATENT DOCUMENTS	2015/0230853 A1 2015/0230861 A1	8/2015	Johnson et al. Woloszko et al.
		2015/0257780 A1	9/2015	
2011/0276049 A1	11/2011 Gerhardt	2015/0272659 A1 2015/0272660 A1		Boudreaux et al. Boudreaux et al.
2011/0278343 A1	11/2011 Knodel et al.	2015/0313667 A1		Allen, IV
2011/0284014 A1	11/2011 Cadeddu et al.	2015/0320480 A1		Cosman, Jr. et al.
2011/0290856 A1 2011/0295295 A1	12/2011 Shelton, IV et al. 12/2011 Shelton, IV et al.	2015/0320481 A1		Cosman, Jr. et al.
2011/0293293 A1 2011/0306967 A1	12/2011 Sherion, IV et al. 12/2011 Payne et al.	2015/0340586 A1		Wiener et al.
2011/0300907 A1 2011/0313415 A1	12/2011 Fayne et al. 12/2011 Fernandez et al.	2016/0030076 A1	2/2016	Faller et al.
2012/0004655 A1	1/2012 Kim et al.	2016/0045248 A1	2/2016	Unger et al.
2012/0016413 A1	1/2012 Timm et al.	2016/0051316 A1		Boudreaux
2012/0022519 A1	1/2012 Huang et al.	2016/0051317 A1		Boudreaux
2012/0022526 A1	1/2012 Aldridge et al.	2016/0058492 A1		Yates et al.
2012/0022583 A1	1/2012 Sugalski et al.	2016/0074108 A1 2016/0128762 A1		Woodruff et al. Harris et al.
2012/0059289 A1	3/2012 Nield et al.	2016/0128702 AT 2016/0144204 A1		Akagane
2012/0071863 A1	3/2012 Lee et al.	2016/0157927 A1		Corbett et al.
2012/0078139 A1 2012/0078244 A1	3/2012 Aldridge et al. 3/2012 Worrell et al.	2016/0175024 A1		Yates et al.
2012/00/8244 A1 2012/0080344 A1	4/2012 Shelton, IV	2016/0175029 A1		Witt et al.
2012/0101495 A1	4/2012 Young et al.	2016/0175032 A1	6/2016	Yang
2012/0109186 A1	5/2012 Parrott et al.	2016/0199123 A1		Thomas et al.
2012/0116265 A1	5/2012 Houser et al.	2016/0199125 A1	7/2016	
2012/0116381 A1	5/2012 Houser et al.	2016/0206342 A1		Robertson et al.
2012/0143211 A1	6/2012 Kishi	2016/0228171 A1 2016/0262786 A1		Boudreaux Madan et al.
2012/0150049 A1	6/2012 Zielinski et al.	2016/0270840 A1		Yates et al.
2012/0150169 A1	6/2012 Zielinksi et al. 7/2012 Muir et al.	2016/0270840 A1 2016/0270841 A1		Strobl et al.
2012/0172904 A1 2012/0253328 A1	10/2012 Multi et al. 10/2012 Cunningham et al.	2016/0270842 A1		Strobl et al.
2012/0255328 A1 2012/0265241 A1	10/2012 Cummignam et al.	2016/0270843 A1	9/2016	Boudreaux et al.
2012/0296371 A1	11/2012 Kappus et al.	2016/0278848 A1		Boudreaux et al.
2013/0023925 A1	1/2013 Mueller	2016/0287311 A1		Friedrichs
2013/0035685 A1	2/2013 Fischer et al.	2016/0296249 A1		Robertson
2013/0085510 A1	4/2013 Stefanchik et al.	2016/0296250 A1 2016/0296251 A1		Olson et al. Olson et al.
2013/0123776 A1	5/2013 Monson et al.	2016/0296251 A1 2016/0296252 A1		Olson et al.
2013/0158659 A1 2013/0158660 A1	6/2013 Bergs et al. 6/2013 Bergs et al.	2016/0296268 A1		Gee et al.
2013/0165929 A1	6/2013 Heigs et al.	2016/0296270 A1		Strobl et al.
2013/0214025 A1	8/2013 Zemlok et al.	2016/0302844 A1	10/2016	Strobl et al.
2013/0253256 A1	9/2013 Griffith et al.	2016/0317217 A1		Batross et al.
2013/0296843 A1	11/2013 Boudreaux et al.	2016/0338726 A1		Stulen et al.
2013/0338647 A1	12/2013 Bacher et al.	2016/0346001 A1 2016/0367273 A1		Vakharia et al. Robertson et al.
2014/0001231 A1	1/2014 Shelton, IV et al.	2016/0367273 A1 2016/0367281 A1		Gee et al.
2014/0001234 A1 2014/0005640 A1	1/2014 Shelton, IV et al. 1/2014 Shelton, IV et al.	2016/0374708 A1		Wiener et al.
2014/0005678 A1	1/2014 Shelton, IV et al.	2016/0374709 A1		Timm et al.
2014/0005702 A1	1/2014 Timm et al.	2016/0374712 A1		Stulen et al.
2014/0005705 A1	1/2014 Weir et al.	2016/0374752 A1		Hancock et al.
2014/0005718 A1	1/2014 Shelton, IV et al.	2017/0000512 A1		Conlon et al.
2014/0012299 A1	1/2014 Stoddard et al.	2017/0000513 A1 2017/0000516 A1		Stulen et al.
2014/0014544 A1		2017/0000541 A1		Yates et al.
2014/0114327 A1 2014/0121569 A1		2017/0000542 A1		Yates et al.
2014/0135804 A1		2017/0000553 A1	1/2017	Wiener et al.
2014/0194874 A1		2017/0000554 A1		Yates et al.
2014/0194875 A1	7/2014 Reschke et al.	2017/0056056 A1		Wiener et al.
2014/0246475 A1		2017/0056058 A1 2017/0086876 A1		Voegele et al. Wiener et al.
2014/0263541 A1		2017/0086908 A1		Wiener et al.
2014/0276659 A1	~ · · · · · · · · · · · · · · · · · · ·	2017/0086909 A1		Yates et al.
2014/0276797 A1 2014/0276970 A1		2017/0086910 A1		Wiener et al.
2014/0330271 A1	,	2017/0086911 A1	3/2017	Wiener et al.
2015/0032100 A1	1/2015 Coulson et al.	2017/0086912 A1		Wiener et al.
2015/0032150 A1		2017/0086913 A1		Yates et al.
2015/0080876 A1		2017/0086914 A1		Wiener et al.
2015/0080887 A1		2017/0090507 A1 2017/0105757 A1		Wiener et al. Weir et al.
2015/0080912 A1	3/2015 Sapre	2017/0105737 A1 2017/0105782 A1		Scheib et al.
2015/0088124 A1 2015/0088178 A1	3/2015 Wham 3/2015 Stulen et al.	2017/0105786 A1		Scheib et al.
2015/0088178 A1 2015/0112335 A1		2017/0105791 A1		Yates et al.
2015/0157356 A1		2017/0143371 A1		Witt et al.
2015/0164533 A1	6/2015 Felder et al.	2017/0143877 A1		Witt et al.
2015/0164534 A1		2017/0189095 A1		Danziger et al.
2015/0164535 A1		2017/0189096 A1		Danziger et al.
2015/0164536 A1		2017/0189101 A1		Yates et al.
2015/0164537 A1		2017/0196586 A1		Witt et al.
2015/0164538 A1		2017/0196587 A1 2017/0202570 A1		Witt et al. Shelton, IV et al.
2015/0182276 A1	7/2013 Wiener et al.	2017/0202370 Al	1/201/	Shenon, IV et al.

(56) Referen	nces Cited	EP EP	0342448 A1	11/1989 8/1991
U.S. PATENT	DOCUMENTS	EP	0443256 A1 0456470 A1	11/1991
2017/0202571 A1 7/2017	Chaltan IV at al	EP EP	0238667 B1 0340803 B1	2/1993 8/1993
2017/0202571 A1 7/2017 2017/0202572 A1 7/2017		EP	0598976 A2	6/1994
2017/0202591 A1 7/2017 2017/0202592 A1 7/2017	,	EP EP	0630612 A1 0424685 B1	12/1994 5/1995
2017/0202593 A1 7/2017 2017/0202593 A1 7/2017		EP	0677275 A2	10/1995
2017/0202594 A1 7/2017 2017/0202595 A1 7/2017		EP EP	0482195 B1 0695535 A1	1/1996 2/1996
2017/0202596 A1 7/2017	Shelton, IV et al.	EP	0705571 A1	4/1996
2017/0202597 A1 7/2017 2017/0202598 A1 7/2017		EP EP	0741996 B1 0612570 B1	11/1996 6/1997
2017/0202599 A1 7/2017	Shelton, IV et al.	EP	0557806 B1	5/1998
2017/0202605 A1 7/2017 2017/0202607 A1 7/2017		EP EP	0640317 B1 1108394 A2	9/1999 6/2001
2017/0202608 A1 7/2017	Shelton, IV et al.	EP EP	1138264 A1 0908148 B1	10/2001 1/2002
2017/0202609 A1 7/2017 2017/0207467 A1 7/2017		EP	1229515 A2	8/2002
2017/0209167 A1 7/2017	Nield	EP EP	0722696 B1 1285634 A1	12/2002 2/2003
2017/0238991 A1 8/2017 2017/0245875 A1 8/2017		EP	0908155 B1	6/2003
2017/0312014 A1 11/2017	Strobl et al.	EP EP	0705570 B1 0765637 B1	4/2004 7/2004
2017/0312015 A1 11/2017 2017/0312016 A1 11/2017		EP	0870473 B1	9/2005
2017/0319228 A1 11/2017	Worrell et al.	EP EP	0624346 B1 1594209 A1	11/2005 11/2005
2017/0319265 A1 11/2017 2017/0348064 A1 12/2017		EP	1199044 B1	12/2005
	Dickerson	EP EP	1609428 A1 1199043 B1	12/2005 3/2006
2018/0028257 A1 2/2018 2018/0036061 A1 2/2018	Yates et al. Yates et al.	EP	1293172 B1	4/2006
2018/0036065 A1 2/2018	Yates et al.	EP EP	0875209 B1 1433425 B1	5/2006 6/2006
	Shelton, IV et al. Wiener et al.	EP	1256323 B1	8/2006
	Price et al.	EP EP	1698289 A2 1704824 A1	9/2006 9/2006
	Yates et al. Wiener et al.	EP	1749479 A1	2/2007
	Clauda et al. Boudreaux et al.	EP EP	1767157 A1 1254637 B1	3/2007 8/2007
2018/0235691 A1 8/2018		EP	1815950 A1	8/2007
2018/0280083 A1 10/2018	Parihar et al.	EP EP	1839599 A1 1844720 A1	10/2007 10/2007
FOREIGN PATE	ENT DOCUMENTS	EP EP	1862133 A1 1875875 A1	12/2007 1/2008
CNI 1222044 A	11/1000	EP	1878399 A1	1/2008
CN 1233944 A CN 1253485 A	11/1999 5/2000	EP EP	1915953 A1 1532933 B1	4/2008 5/2008
CN 2460047 Y CN 1634601 A	11/2001 7/2005	EP	1199045 B1	6/2008
CN 1634601 A CN 1640365 A	7/2003 7/2005	EP EP	1707143 B1 1943957 A2	6/2008 7/2008
CN 1694649 A CN 1775323 A	11/2005 5/2006	EP	1964530 A1	9/2008
CN 1922563 A	2/2007	EP EP	1972264 A1 1974771 A1	9/2008 10/2008
CN 2868227 Y CN 1951333 A	2/2007 4/2007	EP	1435852 B1	12/2008
CN 101035482 A	9/2007	EP EP	1498082 B1 1707131 B1	12/2008 12/2008
CN 101040799 A CN 101396300 A	9/2007 4/2009	EP	1477104 B1	1/2009
CN 101467917 A	7/2009	EP EP	2014218 A2 1849424 B1	1/2009 4/2009
CN 101474081 A CN 101674782 A	7/2009 3/2010	EP EP	2042112 A2	4/2009
CN 101883531 A	11/2010	EP	2042117 A1 2060238 A1	4/2009 5/2009
CN 102160045 A CN 202027624 U	8/2011 11/2011	EP EP	1832259 B1 2074959 A1	6/2009 7/2009
CN 102834069 A	12/2012	EP	1810625 B1	8/2009
CN 101313865 B DE 3904558 A1	1/2013 8/1990	EP EP	2090256 A2 2092905 A1	8/2009 8/2009
DE 9210327 U1	11/1992	EP	2105104 A2	9/2009
DE 4300307 A1 DE 4323585 A1	7/1994 1/1995	EP EP	1747761 B1 2106758 A1	10/2009 10/2009
DE 19608716 C1 DE 29623113 U1	4/1997 10/1997	EP EP	2111813 A1	10/2009
DE 20004812 U1	9/2000	EP	2131760 A1	12/2009
DE 20021619 U1 DE 10042606 A1	3/2001 8/2001	EP EP	1769766 B1 2151204 A1	2/2010 2/2010
DE 10201569 A1	7/2003	EP	2153791 A1	2/2010
EP 0171967 A2 EP 0336742 A2	2/1986 10/1989	EP EP	2200145 A1 1214913 B1	6/2010 7/2010
EP 0136855 B1	11/1989	EP	2238938 A1	10/2010

(56)	References Cited	JP	H105237 A	1/1998
	FOREIGN PATENT DOCUMENTS	ЈР ЈР	H10295700 A H11501543 A	11/1998 2/1999
	TOKESON TRIENT BOCOMENTS	JP	H11128238 A	5/1999
EP	2243439 A1 10/2010	JP	H11192235 A	7/1999
EP	2298154 A2 3/2011	ЈР ЈР	H11253451 A H11318918 A	9/1999 11/1999
EP EP	2305144 A1 4/2011 1510178 B1 6/2011	JP	2000041991 A	2/2000
EP	1946708 B1 6/2011	JP.	2000070279 A	3/2000
EP	2335630 A1 6/2011	ЈР ЈР	2000210299 A 2000271145 A	8/2000 10/2000
EP EP	1502551 B1 7/2011 1728475 B1 8/2011	JP	2000271143 A 2000287987 A	10/2000
EP	2353518 A1 8/2011	JP	2001029353 A	2/2001
EP	2361562 A1 8/2011	ЈР ЈР	2001502216 A 2001309925 A	2/2001 11/2001
EP EP	2365608 A2 9/2011 2420197 A2 2/2012	JP JP	2001309923 A 2002059380 A	2/2001
EP	2422721 A2 2/2012 2422721 A2 2/2012	JP	2002177295 A	6/2002
EP	1927321 B1 4/2012	ЈР ЈР	2002186901 A	7/2002
EP EP	2436327 A1 4/2012 2529681 A1 12/2012	JP JP	2002204808 A 2002238919 A	7/2002 8/2002
EP EP	1767164 B1 1/2013	JP	2002263579 A	9/2002
EP	2316359 B1 3/2013	JР	2002301086 A	10/2002
EP	2090238 B1	ЈР ЈР	2002306504 A 2002330977 A	10/2002 11/2002
EP EP	2578172 A2 4/2013 1586275 B1 5/2013	JP	2002542690 A	12/2002
EP	1616529 B1 9/2013	JP	2003000612 A	1/2003
EP	1997438 B1 11/2013	ЈР ЈР	2003010201 A 2003510158 A	1/2003 3/2003
EP EP	2508143 B1 2/2014 2583633 B1 10/2014	JP	2003310138 A 2003116870 A	4/2003
EP	2076195 B1 12/2015	JP	2003126104 A	5/2003
EP	2113210 B1 3/2016	ЈР ЈР	2003126110 A 2003153919 A	5/2003 5/2003
EP EP	2510891 B1 6/2016 2227155 B1 7/2016	JР	2003133919 A 2003530921 A	10/2003
EP	2859858 B1 12/2016	JP	2003310627 A	11/2003
ES	2115068 T3 6/1998	ЈР ЈР	2003339730 A	12/2003
GB	1482943 A 8/1977 2032221 A 4/1980	JP JP	2004129871 A 2004147701 A	4/2004 5/2004
GB GB	2317566 A 4/1988	JP	2005003496 A	1/2005
GB	2379878 B 11/2004	JР	2005027026 A	1/2005
GB	2472216 A 2/2011	ЈР ЈР	2005040222 A 2005066316 A	2/2005 3/2005
GВ JP	2447767 B 8/2011 S50100891 A 8/1975	JP	2005074088 A	3/2005
JP	S5968513 U 5/1984	JP	2005507679 A	3/2005
JP JP	S59141938 A 8/1984 S62221343 A 9/1987	ЈР ЈР	2005534451 A 2005337119 A	11/2005 12/2005
JP JP	S62221343 A 9/1987 S62227343 A 10/1987	JP	2006006410 A	1/2006
JР	S2292154 A 12/1987	JР	2006068396 A	3/2006
JР	S62292153 A 12/1987	ЈР ЈР	2006075376 A 2006081664 A	3/2006 3/2006
JP JP	S63109386 A 5/1988 S63315049 A 12/1988	JP	2006114072 A	4/2006
JР	H01151452 A 6/1989	JP	2006512149 A	4/2006
JР	H01198540 A 8/1989	JP JP	2006116194 A 2006158525 A	5/2006 6/2006
JP JP	H0271510 U 5/1990 H02286149 A 11/1990	JP	2006217716 A	8/2006
JP	H02292193 A 12/1990	JP	2006218296 A	8/2006
JP	H0337061 A 2/1991	ЈР ЈР	2006288431 A 2007050181 A	10/2006 3/2007
JP JP	H0425707 U 2/1992 H0464351 A 2/1992	JP	2007-524459 A	8/2007
JP	H0430508 U 3/1992	JP	2007229454 A	9/2007
JP	H04150847 A 5/1992	ЈР ЈР	2007527747 A 2007296369 A	10/2007 11/2007
JP JP	H04152942 A 5/1992 H0595955 A 4/1993	JP	200801876 A	1/2007
JP	H05115490 A 5/1993	JP	2008018226 A	1/2008
JP	H0670938 A 3/1994	ЈР ЈР	200833644 A 2008036390 A	2/2008 2/2008
JP JP	H06104503 A 4/1994 H06217988 A 8/1994	JP	2008508065 A	3/2008
JP	H06507081 A 8/1994	JP	2008119250 A	5/2008
JР	H 07500514 A 1/1995	ЈР ЈР	2008515562 A	5/2008
JP JP	H07508910 A 10/1995 H07308323 A 11/1995	JР	2008521503 A 2008188160 A	6/2008 8/2008
JP JP	H0824266 A 1/1996	JР	D1339835 S	8/2008
JР	H08229050 A 9/1996	JP	2008212679 A	9/2008
JР	H08275951 A 10/1996	ЈР ЈР	2008536562 A	9/2008
JP JP	H08299351 A 11/1996 H08336544 A 12/1996	JР	2008284374 A 2009511206 A	11/2008 3/2009
JР	H08336545 A 12/1996	JР	2009082711 A	4/2009
JP	H09503146 A 3/1997	JP	2009517181 A	4/2009
JР	H09135553 A 5/1997	JР	4262923 B2	5/2009
JP	H09140722 A 6/1997	JР	2009523567 A	6/2009

(56)	Reference	es Cited	WO	WO-03068046 A2	8/2003
	EODELON DATEN	E DOCER CENTER	WO	WO-03082133 A1	10/2003
	FOREIGN PATEN	I DOCUMENTS	WO WO	WO-2004011037 A2 WO-2004012615 A1	2/2004 2/2004
JP	2009148557 A	7/2009	WO	WO-2004012013 A1 WO-2004026104 A2	4/2004
JP		10/2009	WO	WO-2004032754 A2	4/2004
JР		11/2009	WO	WO-2004032762 A1	4/2004
JP	2010000336 A	1/2010	WO	WO-2004032763 A2	4/2004
JР	2010009686 A	1/2010	WO WO	WO-2004037095 A2 WO-2004060141 A2	5/2004 7/2004
JP JP	2010514923 A	5/2010	WO	WO-2004000141 A2 WO-2004078051 A2	9/2004
JP	2010121865 A 2010534522 A	6/2010 11/2010	WO	WO-2004098426 A1	11/2004
JР		12/2010	WO	WO-2004112618 A2	12/2004
JР	2011505198 A	2/2011	WO	WO-2005052959 A2	6/2005
JP	2012/075899 A	4/2012	WO WO	WO-2005117735 A1 WO-2005122917 A1	12/2005 12/2005
JP	2012071186 A	4/2012	WO	WO-2006012797 A1	2/2005
JP JP	2012235658 A 5208761 B2	11/2012 6/2013	WO	WO-2006021269 A1	3/2006
JР	5714508 B2	5/2015	WO	WO-2006036706 A1	4/2006
JР	2015515339 A	5/2015	WO	WO-2006042210 A2	4/2006
Љ		12/2015	WO	WO-2006055166 A2	5/2006
KR		12/2007	WO WO	WO-2006058223 A2 WO-2006063199 A2	6/2006 6/2006
RU RU	2154437 C1	8/2000 3/2002	WO	WO-2006083988 A1	8/2006
RU	22035 U1 2201169 C2	3/2002	WO	WO-2006101661 A2	9/2006
RU	2304934 C2	8/2007	WO	WO-2006119139 A2	11/2006
RU		12/2010	WO	WO-2006119376 A2	11/2006
SU	850068 A1	7/1981	WO	WO-2006129465 A1	12/2006
WO		11/1981	WO WO	WO-2007008703 A2 WO-2007008710 A2	1/2007 1/2007
WO WO	WO-9222259 A2 WO-9307817 A1	12/1992 4/1993	WO	WO-2007038538 A1	4/2007
WO	WO-930/81/ A1 WO-9308757 A1	5/1993	WO	WO-2007040818 A1	4/2007
WO	WO-9314708 A1	8/1993	WO	WO-2007047380 A2	4/2007
WO	WO-9316646 A1	9/1993	WO	WO-2007047531 A2	4/2007
WO		10/1993	WO	WO-2007056590 A1	5/2007
WO		11/1993	WO WO	WO-2007087272 A2 WO-2007089724 A2	8/2007 8/2007
WO WO	WO-9400059 A1 WO-9421183 A1	1/1994 9/1994	WO	WO-2007143665 A2	12/2007
WO		11/1994	WO	WO-2008016886 A2	2/2008
WO	WO-9509572 A1	4/1995	WO	WO-2008020964 A2	2/2008
WO	WO-9510978 A1	4/1995	WO	WO-2008042021 A1	4/2008
WO		12/1995	WO WO	WO-2008045348 A2 WO-2008049084 A2	4/2008 4/2008
WO		10/1996	WO	WO-2008051764 A2	5/2008
WO WO		11/1996 12/1996	WO	WO-2008089174 A2	7/2008
WO	WO-9710764 A1	3/1997	WO	WO-2008099529 A1	8/2008
WO	WO-9800069 A1	1/1998	WO	WO-2008101356 A1	8/2008
WO	WO-9816156 A1	4/1998	WO WO	WO-2008118709 A1 WO-2008130793 A1	10/2008 10/2008
WO	WO-9826739 A1	6/1998	WO	WO-2009010565 A1	1/2009
WO WO	WO-9835621 A1 WO-9837815 A1	8/1998 9/1998	WO	WO-2009018067 A1	2/2009
WO	WO-9840020 A1	9/1998	WO	WO-2009018406 A2	2/2009
WO		10/1998	WO	WO-2009022614 A1	2/2009
WO		12/1998	WO	WO-2009027065 A1 WO-2009036818 A1	3/2009 3/2009
WO	WO-9920213 A1 WO-9923960 A1	4/1999	WO WO	WO-2009030818 A1 WO-2009039179 A1	3/2009
WO WO	WO-9940857 A1	5/1999 8/1999	WO	WO-2009046234 A2	4/2009
WO	WO-9940861 A1	8/1999	WO	WO-2009059741 A1	5/2009
WO		10/1999	WO	WO-2009073402 A2	6/2009
WO	WO-0024330 A1	5/2000	WO	WO-2009082477 A2	7/2009
WO	WO-0024331 A1	5/2000	WO WO	WO-2009088550 A2 WO-2009120992 A2	7/2009 10/2009
WO WO	WO-0025691 A1 WO-0064358 A2	5/2000 11/2000	wo	WO-2009141616 A1	11/2009
WO		12/2000	WO	WO-2009149234 A1	12/2009
wo	WO-0124713 A1	4/2001	WO	WO-2010017149 A1	2/2010
WO	WO-0128444 A1	4/2001	WO	WO-2010017266 A1	2/2010
WO	WO-0154590 A1	8/2001	WO WO	WO-2010068783 A1 WO-2010104755 A1	6/2010 9/2010
WO	WO-0167970 A1	9/2001	WO	WO-2010104733 A1 WO-2011008672 A2	1/2011
WO WO		10/2001 12/2001	wo	WO-2011/044338 A2	4/2011
WO	WO-0193810 A2 WO-0224080 A2	3/2002	WO	WO-2011044343 A2	4/2011
wo	WO-0238057 A1	5/2002	WO	WO-2011052939 A2	5/2011
WO	WO-02062241 A1	8/2002	WO	WO-2011060031 A1	5/2011
WO		10/2002	WO	WO-2011084768 A1	7/2011
WO	WO-03001986 A2	1/2003	WO	WO-2011089717 A1	7/2011
WO	WO-03013374 A1	2/2003	WO	WO-2011100321 A2	8/2011
WO WO	WO-03020339 A2 WO-03028541 A2	3/2003 4/2003	WO WO	WO-2011144911 A1 WO-2012044597 A1	11/2011 4/2012
WO WO	WO-03028541 A2 WO-03030708 A2	4/2003	WO	WO-2012044696 A2	4/2012
,,, 0	11 0 03030700 AZ	., 2003	"10	11 0 20120 11000 AZ	1/2012

(56) References Cited

FOREIGN PATENT DOCUMENTS

WO	WO 2012061629 A1	5/2012
WO	WO-2012061638 A1	5/2012
WO	WO-2012061722 A2	5/2012
WO	WO-2012128362 A1	9/2012
WO	WO-2012135705 A1	10/2012
WO	WO-2012135721 A1	10/2012
WO	WO-2012/150567 A1	11/2012
WO	WO-2012166510 A1	12/2012
WO	WO-2013018934 A1	2/2013
WO	WO-2013034629 A1	3/2013
WO	WO-2013062978 A2	5/2013
WO	WO-2013102602 A2	7/2013
WO	WO-2013154157 A1	10/2013
WO	WO-2014092108 A1	6/2014
WO	WO-2015197395 A8	12/2015
WO	WO-2016009921 A1	1/2016

OTHER PUBLICATIONS

http://www.medicalexpo.com/medical-manufacturer/electrosurgical-generator-6951.html.

http://www.valleylab.com/product/es/generators/index.html.

AST Products, Inc., "Principles of Video Contact Angle Analysis," 20 pages, (2006).

Lim et al., "A Review of Mechanism Used in Laparoscopic Surgical Instruments," Mechanism and Machine Theory, vol. 38, pp. 1133-1147, (2003).

Sullivan, "Optimal Choice for Number of Strands in a Litz-Wire Transformer Winding," IEEE Transactions on Power Electronics, vol. 14, No. 2, Mar. 1999, pp. 283-291.

Makarov, S. N., Ochmann, M., Desinger, K., "The longitudinal vibration response of a curved fiber used for laser ultrasound surgical therapy," Journal of the Acoustical Society of America 102, 1191-1199 (1997).

Walsh, S. J., White, R. G., "Vibrational Power Transmission in Curved Beams," Journal of Sound and Vibration, 233(3), 455-488 (2000).

Covidien 501(k) Summary Sonicision, dated Feb. 24, 2011 (7 pages).

 $http:/www.ethicon.com/gb-en/healthcare-professionals/products/energy-devices/capital//ge \dots .$

http://www.megadyne.com/es_generator.php.

Graff, K.F., "Elastic Wave Propagation in a Curved Sonic Transmission Line," IEEE Transactions on Sonics and Ultrasonics, SU-17(1), 1-6 (1970).

Morley, L. S. D., "Elastic Waves in a Naturally Curved Rod," Quarterly Journal of Mechanics and Applied Mathematics, 14: 155-172 (1961).

F. A. Duck, "Optical Properties of Tissue Including Ultraviolet and Infrared Radiation," pp. 43-71 in Physical Properties of Tissue (1990)

http://www.apicalinstr.com/generators.htm.

Technology Overview, printed from www.harmonicscalpel.com, Internet site, website accessed on Jun. 13, 2007, (3 pages).

Sherrit et al., "Novel Horn Designs for Ultrasonic/Sonic Cleaning Welding, Soldering, Cutting and Drilling," Proc. SPIE Smart Structures Conference, vol. 4701, Paper No. 34, San Diego, CA, pp. 353-360, Mar. 2002.

Huston et al., "Magnetic and Magnetostrictive Properties of Cube Textured Nickel for Magnetostrictive Transducer Applications," IEEE Transactions on Magnetics, vol. 9(4), pp. 636-640 (Dec. 1973).

Incropera et al., Fundamentals of Heat and Mass Transfer, Wiley, New York (1990). (Book—not attached).

Gooch et al., "Recommended Infection-Control Practices for Dentistry, 1993," Published: May 28, 1993; [retrieved on Aug. 23, 2008]. Retrieved from the internet: URL: http://wonder.cdc.gov/wonder/prevguid/p0000191/p0000191.asp (15 pages).

Sullivan, "Cost-Constrained Selection of Strand Diameter and Number in a Litz-Wire Transformer Winding," IEEE Transactions on Power Electronics, vol. 16, No. 2, Mar. 2001, pp. 281-288.

Orr et al., "Overview of Bioheat Transfer," pp. 367-384 in Optical-Thermal Response of Laser-Irradiated Tissue, A. J. Welch and M. J. C. van Gernert, eds., Plenum, New York (1995).

Fowler, K.R., "A Programmable, Arbitrary Waveform Electrosurgical Device," IEEE Engineering in Medicine and Biology Society 10th Annual International Conference, pp. 1324, 1325 (1988).

LaCourse, J.R.; Vogt, M.C.; Miller, W.T., III; Selikowitz, S.M., "Spectral Analysis Interpretation of Electrosurgical Generator Nerve and Muscle Stimulation," IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, pp. 505-509, Jul. 1988.

Campbell et al, "Thermal Imaging in Surgery," p. 19-3, in Medical Infrared Imaging, N. A. Diakides and J. D. Bronzino, Eds. (2008). Gerhard, Glen C., "Surgical Electrotechnology: Quo Vadis?," IEEE Transactions on Biomedical Engineering, vol. BME-31, No. 12, pp. 787-792, Dec. 1984.

 $\label{lem:http://www.4-traders.com/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-Ethicon-E$

Weir, C.E., "Rate of shrinkage of tendon collagen—heat, entropy and free energy of activation of the shrinkage of untreated tendon. Effect of acid salt, pickle, and tannage on the activation of tendon collagen." Journal of the American Leather Chemists Association, 44, pp. 108-140 (1949).

Henriques. F.C., "Studies in thermal injury V. The predictability and the significance of thermally induced rate processes leading to irreversible epidermal injury." Archives of Pathology, 434, pp. 489-502 (1947).

Arnoczky et al., "Thermal Modification of Conective Tissues: Basic Science Considerations and Clinical Implications," J. Am Acad Orthop Surg, vol. 8, No. 5, pp. 305-313 (Sep./Oct. 2000).

Chen et al., "Heat-Induced Changes in the Mechanics of a Collagenous Tissue: Isothermal Free Shrinkage," Transactions of the ASME, vol. 119, pp. 372-378 (Nov. 1997).

Chen et al., "Heat-Induced Changes in the Mechanics of a Collagenous Tissue: Isothermal, Isotonic Shrinkage," Transactions of the ASME, vol. 120, pp. 382-388 (Jun. 1998).

Chen et al., "Phenomenological Evolution Equations for Heat-Induced Shrinkage of a Collagenous Tissue," IEEE Transactions on Biomedical Engineering, vol. 45, No. 10, pp. 1234-1240 (Oct. 1998)

Harris et al., "Kinetics of Thermal Damage to a Collagenous Membrane Under Biaxial Isotonic Loading," IEEE Transactions on Biomedical Engineering, vol. 51, No. 2, pp. 371-379 (Feb. 2004). Harris et al., "Altered Mechanical Behavior of Epicardium Due to Isothermal Heating Under Biaxial Isotonic Loads," Journal of Biomechanical Engineering, vol. 125, pp. 381-388 (Jun. 2003).

Lee et al., "A multi-sample denaturation temperature tester for collagenous biomaterials," Med. Eng. Phy., vol. 17, No. 2, pp. 115-121 (Mar. 1995).

Moran et al., "Thermally Induced Shrinkage of Joint Capsule," Clinical Orthopaedics and Related Research, No. 281, pp. 248-255 (Dec. 2000).

Wall et al., "Thermal modification of collagen," J Shoulder Elbow Surg, No. 8, pp. 339-344 (Jul./Aug. 1999).

Wells et al., "Altered Mechanical Behavior of Epicardium Under Isothermal Biaxial Loading," Transactions of the ASME, Journal of Biomedical Engineering, vol. 126, pp. 492-497 (Aug. 2004).

Gibson, "Magnetic Refrigerator Successfully Tested," U.S. Department of Energy Research News, accessed online on Aug. 6, 2010 at http://www.eurekalert.org/features/doe/2001-11/dl-mrs062802.php (Nov. 1, 2001).

Humphrey, J.D., "Continuum Thermomechanics and the Clinical Treatment of Disease and Injury," Appl. Mech. Rev., vol. 56, No. 2 pp. 231-260 (Mar. 2003).

National Semiconductors Temperature Sensor Handbook—http://www.national.com/appinfo/tempsensors/files/temphb.pdf; accessed online: Apr. 1, 2011.

Chen et al., "Heat-induced changes in the mechanics of a collagenous tissue: pseudoelastic behavior at 37° C.," Journal of Biomechanics, 31, pp. 211-216 (1998).

Kurt Gieck & Reiner Gieck, *Engineering Formulas* § Z.7 (7th ed. 1997).

Hayashi et al., "The Effect of Thermal Heating on the Length and Histologic Properties of the Glenohumeral Joint Capsule," Ameri-

(56) References Cited

OTHER PUBLICATIONS

can Journal of Sports Medicine, vol. 25, Issue 1, 11 pages (Jan. 1997), URL: http://www.mdconsult.com/das/article/body/156183648-2/jorg=journal&source=MI&sp=1 . . . , accessed Aug. 25, 2009. Wright, et al., "Time-Temperature Equivalence of Heat-Induced

Changes in Cells and Proteins," Feb. 1998. ASME Journal of Biomechanical Engineering, vol. 120, pp. 22-26.

Covidien Brochure, [Value Analysis Brief], LigaSure Advance™ Pistol Grip, dated Rev. Apr. 2010 (7 pages).

Covidien Brochure, LigaSure Impact TM Instrument LF4318, dated Feb. 2013 (3 pages).

Covidien Brochure, LigaSure Atlas™ Hand Switching Instruments, dated Dec. 2008 (2 pages).

Covidien Brochure, The LigaSureTM 5 mm Blunt Tip Sealer/Divider Family, dated Apr. 2013 (2 pages).

https://www.kjmagnetics.com/fieldcalculator.asp, retrieved Jul. 11, 2016, backdated to Nov. 11, 2011 via https://web.archive.org/web/20111116164447/http://www.kjmagnetics.com/fieldcalculator.asp.

Douglas, S.C. "Introduction to Adaptive Filter". Digital Signal Processing Handbook. Ed. Vijay K. Madisetti and Douglas B. Williams. Boca Raton: CRC Press LLC, 1999.

Leonard I. Malis, M.D., "The Value of Irrigation During Bipolar Coagulation," 1989.

Covidien Brochure, The LigaSure Precise™ Instrument, dated Mar. 2011 (2 pages).


Glaser and Subak-Sharpe, Integrated Circuit Engineering, Addison-Wesley Publishing, Reading, MA (1979). (book—not attached). Jang, J. et al. "Neuro-fuzzy and Soft Computing." Prentice Hall, 1997, pp. 13-89, 199-293, 335-393, 453-496, 535-549.


Erbe Electrosurgery VIO® 200 S, (2012), p. 7, 12 pages, accessed Mar. 31, 2014 at http://www.erbe-med.com/erbe/media/Marketing materialien/85140170 ERBE EN VIO 200 S D027541.

Hörmann et al., "Reversible and irreversible denaturation of collagen fibers." Biochemistry, 10, pp. 932-937 (1971).

Dean, D.A., "Electrical Impedance Spectroscopy Study of Biological Tissues," J. Electrostat, 66(3-4), Mar. 2008, pp. 165-177. Accessed Apr. 10, 2018: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597841/.

* cited by examiner













FIG. 3























FIG. 12




FIG. 13








FIG. 14














FIG. 17








FIG. 20









FIG. 21






























































FREQ. SLOPE (kHz/SEC) -1934 0.1-0.08 0.06 0.04 0.02-0-12 10 14 16 -0.02 n -0.04 -0.06 -0.08 -0.1 TIME (SEC) FIG. 44








FIG. 45









DEVICES AND TECHNIQUES FOR CUTTING AND COAGULATING TISSUE

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation application claiming priority under 35 U.S.C. § 120 to U.S. patent application Ser. No. 14/664,233, entitled DEVICES AND TECHNIQUES FOR CUTTING AND COAGULATING TISSUE, filed 10 Mar. 20, 2015, which issued on Nov. 29, 2016 as U.S. Pat. No. 9,504,855, which is a divisional application claiming priority under 35 U.S.C. § 121 to U.S. patent application Ser. No. 12/896,351, entitled DEVICE AND TECHNIQUE FOR CUTTING AND COAGULATING TISSUE, filed Oct. 1, 15 2010, which issued on Jul. 28, 2015 as U.S. Pat. No. 9,089,360, which is a continuation-in-part application claiming priority under of 35 U.S.C. § 120 to U.S. patent application Ser. No. 12/503,775, entitled ULTRASONIC DEVICE FOR CUTTING AND COAGULATING WITH 20 STEPPED OUTPUT, filed Jul. 15, 2009, which issued on Nov. 15, 2011 as U.S. Pat. No. 8,058,771, which claims the benefit under Title 35, United States Code § 119(e), of (1) U.S. Provisional Patent Application Ser. No. 61/086,619, entitled ULTRASONIC DEVICE FOR CUTTING AND 25 COAGULATING WITH STEPPED OUTPUT, filed Aug. 6, 2008 and (2) U.S. Provisional Patent Application Ser. No. 61/188,790, entitled ULTRASONIC DEVICE FOR CUT-TING AND COAGULATING WITH STEPPED OUTPUT, filed Aug. 13, 2008, the entire disclosures of which are 30 hereby incorporated by reference herein.

U.S. patent application Ser. No. 12/896,351 also claims the benefit under Title 35, United States Code § 119(e), of U.S. Provisional Patent Application Ser. No. 61/250,217, entitled A DUAL BIPOLAR AND ULTRASONIC GENERATOR FOR ELECTRO-SURGICAL INSTRUMENTS, filed Oct. 9, 2009, the entire disclosure of which is hereby incorporated by reference herein.

TECHNICAL FIELD

The present disclosure generally relates to ultrasonic surgical systems and, more particularly, to an ultrasonic system that allows surgeons to perform cutting and coagulation.

BACKGROUND

Ultrasonic surgical instruments are finding increasingly widespread applications in surgical procedures by virtue of 50 the unique performance characteristics of such instruments. Depending upon specific instrument configurations and operational parameters, ultrasonic surgical instruments can provide substantially simultaneous cutting of tissue and hemostasis by coagulation, desirably minimizing patient 55 trauma. The cutting action is typically realized by an-end effector, or blade tip, at the distal end of the instrument, which transmits ultrasonic energy to tissue brought into contact with the end effector. Ultrasonic instruments of this nature can be configured for open surgical use, laparoscopic, 60 or endoscopic surgical procedures including robotic-assisted procedures.

Some surgical instruments utilize ultrasonic energy for both precise cutting and controlled coagulation. Ultrasonic energy cuts and coagulates by using lower temperatures than 65 those used by electrosurgery. Vibrating at high frequencies (e.g., 55,500 times per second), the ultrasonic blade dena2

tures protein in the tissue to form a sticky coagulum. Pressure exerted on tissue with the blade surface collapses blood vessels and allows the coagulum to form a hemostatic seal. The precision of cutting and coagulation is controlled by the surgeon's technique and adjusting the power level, blade edge, tissue traction, and blade pressure.

A primary challenge of ultrasonic technology for medical devices, however, continues to be sealing of blood vessels. Work done by the applicant and others has shown that optimum vessel sealing occurs when the inner muscle layer of a vessel is separated and moved away from the adventitia layer prior to the application of standard ultrasonic energy. Current efforts to achieve this separation have involved increasing the clamp force applied to the vessel.

Furthermore, the user does not always have visual feedback of the tissue being cut. Accordingly, it would be desirable to provide some form of feedback to indicate to the user that the cut is complete when visual feedback is unavailable. Moreover, without some form of feedback indicator to indicate that the cut is complete, the user may continue to activate the harmonic instrument even though the cut is complete, which cause possible damage to the harmonic instrument and surrounding tissue by the heat that is generated when activating a harmonic instrument with little to nothing between the jaws.

The ultrasonic transducer may be modeled as an equivalent circuit having first branch comprising a static capacitance and a second "motional" branch comprising a serially connected inductance, resistance and capacitance that defines the electromechanical properties of the resonator. Conventional ultrasonic generators may include a tuning inductor for tuning out the static capacitance at a resonant frequency so that substantially all of generator's current output flows into the motional branch. The motional branch current, along with the drive voltage, define the impedance and phase magnitude. Accordingly, using a tuning inductor, the generator's current output represents the motional branch current, and the generator is thus able to maintain its drive output at the ultrasonic transducer's resonant fre-40 quency. The tuning inductor also transforms the phase impedance plot of the ultrasonic transducer to improve the generator's frequency lock capabilities. However, the tuning inductor must be matched with the specific static capacitance of an ultrasonic transducer. A different ultrasonic 45 transducer having a different static capacitance requires a different tuning inductor.

Electrosurgical devices for applying electrical energy to tissue in order to treat and/or destroy the tissue are also finding increasingly widespread applications in surgical procedures. An electrosurgical device typically includes a handpiece, an instrument having a distally-mounted end effector (e.g., one or more electrodes). The end effector can be positioned against the tissue such that electrical current is introduced into the tissue. Electrosurgical devices can be configured for bipolar or monopolar operation. During bipolar operation, current is introduced into and returned from the tissue by active and return electrodes, respectively, of the end effector. During monopolar operation, current is introduced into the tissue by an active electrode of the end effector and returned through a return electrode (e.g., a grounding pad) separately located on a patient's body. Heat generated by the current flowing through the tissue may form hemostatic seals within the tissue and/or between tissues and thus may be particularly useful for sealing blood vessels, for example. The end effector of an electrosurgical device may also include a cutting member that is movable relative to the tissue and the electrodes to transect the tissue.

Electrical energy applied by an electrosurgical device can be transmitted to the instrument by a generator in communication with the handpiece. The electrical energy may be in the form of radio frequency ("RF") energy. RF energy is a form of electrical energy that may be in the frequency range 5 of 300 kilohertz (kHz) to 1 megahertz (MHz). In application, an electrosurgical device can transmit low frequency RF energy through tissue, which causes ionic agitation, or friction, in effect resistive heating, thereby increasing the temperature of the tissue. Because a sharp boundary is 10 created between the affected tissue and the surrounding tissue, surgeons can operate with a high level of precision and control, without sacrificing un-targeted adjacent tissue. The low operating temperatures of RF energy is useful for removing, shrinking, or sculpting soft tissue while simulta- 15 driving an ultrasonic transducer. neously sealing blood vessels. RF energy works particularly well on connective tissue, which is primarily comprised of collagen and shrinks when contacted by heat.

Due to their unique drive signal, sensing and feedback needs, ultrasonic and electrosurgical instruments have gen- 20 erally required dedicated generators. Additionally, in cases where the instrument is disposable or interchangeable with a handpiece, ultrasonic and electrosurgical generators are limited in their ability to recognize the particular instrument configuration being used and to optimize control and diag- 25 nostic processes accordingly. Moreover, capacitive coupling of signals from the generator into patient-isolated circuits, especially in cases of higher voltage and frequency ranges, may result in exposure of a patient to unacceptable levels of leakage current.

It would be desirable to provide a surgical instrument that overcomes some of the deficiencies of current instruments. The surgical system described herein overcomes those deficiencies.

SUMMARY

One embodiment discloses a method of driving an end effector coupled to an ultrasonic drive system of a surgical instrument. The method comprises generating at least one 40 electrical signal by a generator. The at least one electrical signal is monitored against a first set of logic conditions. A first response of the generator is triggered when the first set of logic conditions is met. A parameter associated with the surgical instrument is determined from the at least one 45 one embodiment. electrical signal.

FIGURES

The novel features of the described embodiments are set 50 forth with particularity in the appended claims. The described embodiments, however, both as to organization and methods of operation, may be best understood by reference to the following description, taken in conjunction with the accompanying drawings in which:

- FIG. 1 is a perspective view illustrating one embodiment of an ultrasonic surgical instrument.
- FIG. 2 is an exploded perspective assembly view of one embodiment of an ultrasonic surgical instrument.
- FIG. 3 is a schematic of one embodiment of a clamp arm 60 illustrating force calculations.
- FIG. 4 is a graphical representation of current, voltage, power, impedance, and frequency waveforms of a conventional oscillator at high power and lightly loaded.
- FIG. 5 is a graphical representation of current, voltage, 65 power, impedance, and frequency waveforms of a conventional oscillator at high power and heavily loaded.

- FIG. 6 is a graphical representation of a current step function waveform and voltage, power, impedance, and frequency waveforms of one embodiment of an oscillator and unloaded.
- FIG. 7 is a graphical representation of a current step function waveform and voltage, power, impedance, and frequency waveforms of one embodiment of an oscillator and lightly loaded.
- FIG. 8 is a graphical representation of a current step function waveform and voltage, power, impedance, and frequency waveforms of one embodiment of an oscillator and heavily loaded.
- FIG. 9 illustrates one embodiment of a drive system of a generator, which creates the ultrasonic electrical signal for
- FIG. 10 illustrates one embodiment of a surgical system comprising an ultrasonic surgical instrument and a generator comprising a tissue impedance module.
- FIG. 11 illustrates one embodiment of a drive system of a generator comprising a tissue impedance module.
- FIG. 12 illustrates one embodiment of a clamp arm assembly that may be employed with a surgical system.
- FIG. 13 is a schematic diagram of a tissue impedance module coupled to a blade and a clamp arm assembly with tissue located therebetween.
 - FIG. 14 illustrates one embodiment of a method for driving an end effector coupled to an ultrasonic drive system of a surgical instrument.
- FIG. 15A illustrates a logic flow diagram of one embodi-30 ment of determining a change in tissue state and activating an output indicator accordingly.
 - FIG. 15B is a logic flow diagram illustrating one embodiment of the operation of the frequency inflection point analysis module.
- FIG. 15C is a logic flow diagram 900 illustrating one embodiment of the operation of the voltage drop analysis
- FIG. 16 illustrates one embodiment of a surgical system comprising a generator and various surgical instruments usable therewith.
- FIG. 17 is a diagram of the surgical system of FIG. 16. FIG. 18 is a model illustrating motional branch current in one embodiment.
- FIG. 19 is a structural view of a generator architecture in
- FIG. 20 is a logic flow diagram of a tissue algorithm that may be implemented in one embodiment of a generator.
- FIG. 21 is a logic flow diagram of a signal evaluation tissue algorithm portion of the tissue algorithm shown in FIG. 20 that may be implemented in one embodiment of a generator.
- FIG. 22 is a logic flow diagram for evaluating condition sets for the signal evaluation tissue algorithm shown in FIG. 21 that may be implemented in one embodiment of a
- FIG. 23 is a graphical representation of frequency slope (first time derivative of frequency) versus time waveform of one embodiment of a generator during a typical tissue cut.
- FIG. 23A is a graphical representation of slope of frequency slope (second time derivative of frequency) versus time waveform shown in dashed line superimposed over the waveform shown in FIG. 23 of one embodiment of a generator during a typical tissue cut.
- FIG. 24 is a graphical representation of frequency versus time waveform of one embodiment of a generator during a typical tissue cut as it relates to the graphical representation shown in FIG. 23.

FIG. 25 is a graphical representation of drive power versus time waveform of one embodiment of a generator during a typical tissue cut as it relates to the graphical representation shown in FIG. 23.

FIG. **26** is a graphical representation of frequency slope ⁵ versus time waveform of one embodiment of a generator during a burn-in test.

FIG. 27 is a graphical representation of frequency versus time waveform of one embodiment of a generator during a burn-in test as it relates to the graphical representation shown in FIG. 26.

FIG. 28 is a graphical representation of power consumption versus time waveform of one embodiment of a generator during a burn-in test as it relates to the graphical representation shown in FIG. 26.

FIG. 29 is a graphical representation of frequency change over time waveform of several generator/instrument combinations during burn-in tests.

FIG. 30 is a graphical representation of normalized combined impedance, current, frequency, power, energy, and temperature waveforms of one embodiment of a generator coupled to an ultrasonic instrument to make 10 successive cuts on excised porcine jejunum tissue as quickly as possible while keeping the generator running throughout.

FIG. 31A is a graphical representation of impedance and current versus time waveforms of one embodiment of a generator during successive tissue cuts over a period of time.

FIG. 31B is a graphical representation of frequency versus time waveform of one embodiment of a generator 30 during successive tissue cuts over a period of time.

FIG. 31C is a graphical representation of power, energy, and temperature versus time waveforms of one embodiment of a generator during successive tissue cuts over a period of time.

FIG. 32 is a combined graphical representation of frequency, weighted frequency slope waveform calculated via exponentially weighted moving average with an alpha value of 0.1, and temperature versus time waveform of one embodiment of a generator.

FIG. 33 is a graphical representation of a frequency versus time waveform shown in FIG. 32.

FIG. 34 is a graphical representation of the weighted frequency slope versus time waveform shown in FIG. 32.

FIG. 35 is a graphical representation of a frequency versus 45 time waveform of one embodiment of a generator over ten cuts on jejunum tissue and a graphical representation of a temperature versus time signal.

FIG. **36** is a graphical representation of the frequency versus time waveform shown in FIG. **35** of one embodiment 50 of a generator over ten cuts on jejunum tissue with activation of intervening tissue.

FIG. 37 is a graphical representation of a frequency slope versus time waveform of one embodiment of a generator over ten cuts on jejunum tissue.

FIG. **38** is a graphical representation of a power versus time waveform representative of power consumed by a one embodiment of a generator over ten cuts on jejunum tissue.

FIG. **39** is a graphical representation of a current versus time waveform of one embodiment of a generator over ten 60 cuts on jejunum tissue.

FIG. **40** is a graphical representation of a "cross-back frequency slope threshold" parameter in connection with a frequency slope vs. time waveform of one embodiment of a generator.

FIG. 41 is a combined graphical representation of a pulsed application of one embodiment of an ultrasonic instrument

6

on an excised carotid artery showing normalized power, current, energy, and frequency waveforms versus time.

FIG. **42**A is a graphical representation of impedance and current versus time waveforms of one embodiment of a generator during successive tissue cuts over a period of time.

FIG. **42**B is a graphical representation of a frequency versus time waveform of one embodiment of a generator during successive tissue cuts over a period of time.

FIG. **42**C is a graphical representation of power, energy, and temperature versus time waveforms of one embodiment of a generator during successive tissue cuts over a period of time.

FIG. 43 is a graphical representation of a calculated
 frequency slope waveform for the pulsed application shown in FIG. 41 and FIGS. 50A-C plotted on a gross scale.

FIG. 44 is a zoomed in view of the graphical representation of the calculated frequency slope waveform for the pulsed application shown in FIG. 43.

FIG. **45** is a graphical representation of other data waveforms of interest such as impedance, power, energy, temperature.

FIG. **46** is a graphical representation of a summary of weighted frequency slope versus power level for various ultrasonic instrument types.

FIG. 47 is a graphical representation of resonant frequency, averaged resonant frequency, and frequency slope versus time waveforms of one embodiment of a generator.

FIG. **48** is a zoomed in view of the resonant frequency and averaged resonant frequency versus time waveforms shown in FIG. **47**.

FIG. 49 is a zoomed in view of the resonant frequency and current versus time waveforms of one embodiment of a generator.

FIG. **50** is a graphical representation of normalized combined power, impedance, current, energy, frequency, and temperature waveforms of one embodiment of a generator coupled to an ultrasonic instrument.

DESCRIPTION

Before explaining various embodiments of ultrasonic surgical instruments in detail, it should be noted that the illustrative embodiments are not limited in application or use to the details of construction and arrangement of parts illustrated in the accompanying drawings and description. The illustrative embodiments may be implemented or incorporated in other embodiments, variations and modifications, and may be practiced or carried out in various ways. Further, unless otherwise indicated, the terms and expressions employed herein have been chosen for the purpose of describing the illustrative embodiments for the convenience of the reader and are not for the purpose of limitation thereof.

Further, it is understood that any one or more of the following-described embodiments, expressions of embodiments, examples, can be combined with any one or more of the other following-described embodiments, expressions of embodiments, and examples.

Various embodiments are directed to improved ultrasonic surgical instruments configured for effecting tissue dissecting, cutting, and/or coagulation during surgical procedures. In one embodiment, an ultrasonic surgical instrument apparatus is configured for use in open surgical procedures, but has applications in other types of surgery, such as laparoscopic, endoscopic, and robotic-assisted procedures. Versatile use is facilitated by selective use of ultrasonic energy.

The various embodiments will be described in combination with an ultrasonic instrument as described herein. Such description is provided by way of example, and not limitation, and is not intended to limit the scope and applications thereof. For example, any one of the described embodiments is useful in combination with a multitude of ultrasonic instruments including those described in, for example, U.S. Pat. Nos. 5,938,633; 5,935,144; 5,944,737; 5,322,055; 5,630,420; and 5,449,370.

As will become apparent from the following description, 10 it is contemplated that embodiments of the surgical instrument described herein may be used in association with an oscillator unit of a surgical system, whereby ultrasonic energy from the oscillator unit provides the desired ultrasonic actuation for the present surgical instrument. It is also 15 contemplated that embodiments of the surgical instrument described herein may be used in association with a signal generator unit of a surgical system, whereby electrical energy in the form of radio frequencies (RF), for example, is used to provide feedback to the user regarding the surgical 20 instrument. The ultrasonic oscillator and/or the signal generator unit may be non-detachably integrated with the surgical instrument or may be provided as separate components, which can be electrically attachable to the surgical instrument.

One embodiment of the present surgical apparatus is particularly configured for disposable use by virtue of its straightforward construction. However, it is also contemplated that other embodiments of the present surgical instrument can be configured for non-disposable or multiple uses. 30 Detachable connection of the present surgical instrument with an associated oscillator and signal generator unit is presently disclosed for single-patient use for illustrative purposes only. However, non-detachable integrated connection of the present surgical instrument with an associated 35 oscillator and/or signal generator unit is also contemplated. Accordingly, various embodiments of the presently described surgical instruments may be configured for single use and/or multiple use with either detachable and/or nondetachable integral oscillator and/or signal generator unit, 40 without limitation, and all combinations of such configurations are contemplated to be within the scope of the present disclosure.

With reference to FIGS. 1-3, one embodiment of a surgical system 19 including an ultrasonic surgical instrument 45 100 is illustrated. The surgical system 19 includes an ultrasonic generator 30 connected to an ultrasonic transducer 50 via a suitable transmission medium such as a cable 22, and an ultrasonic surgical instrument 100. Although in the presently disclosed embodiment, the generator 30 is shown 50 separate from the surgical instrument 100, in one embodiment, the generator 30 may be formed integrally with the surgical instrument 100 to form a unitary surgical system 19. The generator 30 comprises an input device 406 located on a front panel of the generator 30 console. The input device 55 406 may comprise any suitable device that generates signals suitable for programming the operation of the generator 30 as subsequently described with reference to FIG. 9. Still with reference to FIGS. 1-3, the cable 22 may comprise multiple electrical conductors for the application of electri- 60 cal energy to positive (+) and negative (-) electrodes of the ultrasonic transducer 50. It will be noted that, in some applications, the ultrasonic transducer 50 may be referred to as a "handle assembly" because the surgical instrument 100 of the surgical system 19 may be configured such that a 65 surgeon may grasp and manipulate the ultrasonic transducer 50 during various procedures and operations. A suitable

8

generator 30 is the GEN 300 sold by Ethicon Endo-Surgery, Inc. of Cincinnati, Ohio as is disclosed in one or more of the following U.S. Patents, all of which are incorporated by reference herein: U.S. Pat. No. 6,480,796 (Method for Improving the Start Up of an Ultrasonic System Under Zero Load Conditions); U.S. Pat. No. 6,537,291 (Method for Detecting a Loose Blade in a Handle Connected to an Ultrasonic Surgical System); U.S. Pat. No. 6,626,926 (Method for Driving an Ultrasonic System to Improve Acquisition of Blade Resonance Frequency at Startup); U.S. Pat. No. 6,633,234 (Method for Detecting Blade Breakage Using Rate and/or Impedance Information); U.S. Pat. No. 6,662,127 (Method for Detecting Presence of a Blade in an Ultrasonic System); U.S. Pat. No. 6,678,621 (Output Displacement Control Using Phase Margin in an Ultrasonic Surgical Handle); U.S. Pat. No. 6,679,899 (Method for Detecting Transverse Vibrations in an Ultrasonic Handle); U.S. Pat. No. 6,908,472 (Apparatus and Method for Altering Generator Functions in an Ultrasonic Surgical System); U.S. Pat. No. 6,977,495 (Detection Circuitry for Surgical Handpiece System); U.S. Pat. No. 7,077,853 (Method for Calculating Transducer Capacitance to Determine Transducer Temperature); U.S. Pat. No. 7,179,271 (Method for Driving 25 an Ultrasonic System to Improve Acquisition of Blade Resonance Frequency at Startup); and U.S. Pat. No. 7,273, 483 (Apparatus and Method for Alerting Generator Function in an Ultrasonic Surgical System).

In accordance with the described embodiments, the ultrasonic generator 30 produces an electrical signal of a particular voltage, current, and frequency, e.g., 55,500 cycles per second (Hz). The generator is 30 connected by the cable 22 to the handle assembly 68, which contains piezoceramic elements forming the ultrasonic transducer 50. In response to a switch 312a on the handle assembly 68 or a foot switch 434 connected to the generator 30 by another cable the generator signal is applied to the transducer 50, which causes a longitudinal vibration of its elements. A structure connects the transducer 50 to a surgical blade 79, which is thus vibrated at ultrasonic frequencies when the generator signal is applied to the transducer 50. The structure is designed to resonate at the selected frequency, thus amplifying the motion initiated by the transducer 50. In one embodiment, the generator 30 is configured to produce a particular voltage, current, and/or frequency output signal that can be stepped with high resolution, accuracy, and repeatability.

Referring to FIG. 4, in current systems a conventional oscillator is activated at time 0 resulting in current 300 rising to a desired set point of approximately 340 mA. At approximately 2 seconds a light load is applied resulting in corresponding increases to voltage 310, power 320, impedance 330, and changes in resonant frequency 340.

Referring to FIG. 5, in current systems a conventional oscillator is activated at time 0 resulting in the current 300 rising to a desired set point of approximately 340 mA. At approximately 2 seconds an increasing load is applied resulting in corresponding increases to the voltage 310, power 320, impedance 330, and changes in resonant frequency 340. At approximately 7 seconds, the load has increased to the point that the oscillator enters into a flat power mode where further increases in load maintain the power at 35 W as long as the oscillator stays within voltage limits of the power supply. The current 300 and therefore, displacement, varies during flat power mode. At approximately 11.5 seconds, the load is reduced to the point where the current 300 returns to the desired set point of approxi-

mately 340 mA. The voltage 310, power 320, impedance 330, and resonant frequency 340 vary with the load.

With reference now back to FIGS. 1-3, the ultrasonic surgical instrument 100 includes a multi-piece handle assembly 68 adapted to isolate the operator from the vibrations of the acoustic assembly contained within the ultrasonic transducer 50. The handle assembly 68 can be shaped to be held by a user in a conventional manner, but it is contemplated that the present ultrasonic surgical instrument 100 principally be grasped and manipulated by a trigger-like arrangement provided by a handle assembly of the instrument, as will be described. While a multi-piece handle assembly 68 is illustrated, the handle assembly 68 may comprise a single or unitary component. The proximal end of the ultrasonic surgical instrument 100 receives and is 15 fitted to the distal end of the ultrasonic transducer 50 by insertion of the transducer 50 into the handle assembly 68. In one embodiment, the ultrasonic surgical instrument 100 may be attached to and removed from the ultrasonic transducer 50 as a unit. In other embodiments, the ultrasonic 20 surgical instrument 100 and the ultrasonic transducer 50 may be formed as an integral unit. The ultrasonic surgical instrument 100 may include a handle assembly 68, comprising a mating housing portion 69, a housing portion 70, and a transmission assembly 71. When the present instru- 25 ment is configured for endoscopic use, the construction can be dimensioned such that the transmission assembly 71 has an outside diameter of approximately 5.5 mm. The elongated transmission assembly 71 of the ultrasonic surgical instrument 100 extends orthogonally from the instrument 30 handle assembly 68. The transmission assembly 71 can be selectively rotated with respect to the handle assembly 68 by a rotation knob 29 as further described below. The handle assembly 68 may be constructed from a durable plastic, such as polycarbonate or a liquid crystal polymer. It is also 35 contemplated that the handle assembly 68 may alternatively be made from a variety of materials including other plastics, ceramics, or metals.

The transmission assembly 71 may include an outer tubular member or an outer sheath 72, an inner tubular 40 actuating member 76, a waveguide 80, and an end effector 81 comprising, for example, the blade 79, a clamp arm 56, and one or more clamp pads 58. As subsequently described, the outer sheath 72, the actuating member 76, and the waveguide 80 or transmission rod may be joined together for 45 rotation as a unit (together with the ultrasonic transducer 50) relative to the handle assembly 68. The waveguide 80, which is adapted to transmit ultrasonic energy from the ultrasonic transducer 50 to the blade 79 may be flexible, semi-flexible, or rigid. The waveguide 80 also may be configured to 50 amplify the mechanical vibrations transmitted through the waveguide 80 to the blade 79 as is well known in the art. The waveguide 80 may further have features to control the gain of the longitudinal vibration along the waveguide 80 and features to tune the waveguide 80 to the resonant frequency 55 of the system. In particular, the waveguide 80 may have any suitable cross-sectional dimension. For example, the waveguide 80 may have a substantially uniform cross-section or the waveguide 80 may be tapered at various sections or may be tapered along its entire length. In one expression of the 60 midpoint of the optimal tissue treatment area). current embodiment, the waveguide diameter is about 0.113 inches nominal to minimize the amount of deflection at the blade 79 so that gapping in the proximal portion of the end effector 81 is minimized.

The blade 79 may be integral with the waveguide 80 and 65 formed as a single unit. In an alternate expression of the current embodiment, the blade 79 may be connected by a

10

threaded connection, a welded joint, or other coupling mechanisms. The distal end of the blade 79 is disposed near an anti-node in order to tune the acoustic assembly to a preferred resonant frequency f_o when the acoustic assembly is not loaded by tissue. When the ultrasonic transducer 50 is energized, the distal end of the blade 79 is configured to move longitudinally in the range of, for example, approximately 10 to 500 microns peak-to-peak, and preferably in the range of about 20 to about 200 microns at a predetermined vibration frequency f_o of, for example, 55,500 Hz.

With particular reference to FIGS. 1-3, therein is illustrated one embodiment of the clamp member 60 for use with the present ultrasonic surgical instrument 100 and which is configured for cooperative action with the blade 79. The clamp member 60 in combination with the blade 79 is commonly referred to as the end effector 81, and the clamp member 60 is also commonly referred to as the jaw. The clamp member 60 includes a pivotally movable clamp arm 56, which is connected to the distal end of the outer sheath 72 and the actuating member 76, in combination with a tissue engaging pad or clamp pad 58. The clamp arm 56 is pivotally movable by a trigger 34 and the end effector 81 is rotatably movable by the rotation knob 29. In one expression of the embodiment, the clamp pad 58 is formed from TEFLON® a trademark name of E. I. Du Pont de Nemours and Company, a low coefficient of friction polymer material, or any other suitable low-friction material. The clamp pad 58 mounts on the clamp arm 56 for cooperation with the blade 79, with pivotal movement of the clamp arm 56 positioning the clamp pad 58 in substantially parallel relationship to, and in contact with, the blade 79, thereby defining a tissue treatment region. By this construction, tissue is grasped between the clamp pad 58 and the blade 79. As illustrated, the clamp pad 58 may be provided with a non-smooth surface, such as a saw tooth-like configuration to enhance the gripping of tissue in cooperation with the blade 79. The saw tooth-like configuration, or teeth, provide traction against the movement of the blade 79. The teeth also provide counter traction to the blade 79 and clamping movement. As would be appreciated by one skilled in the art, the saw tooth-like configuration is just one example of many tissue engaging surfaces to prevent movement of the tissue relative to the movement of the blade 79. Other illustrative examples include bumps, criss-cross patterns, tread patterns, a bead, or sand blasted surface.

Due to sinusoidal motion, the greatest displacement or amplitude of motion is located at the most distal portion of the blade 79, while the proximal portion of the tissue treatment region is on the order of 50% of the distal tip amplitude. During operation, the tissue in the proximal region of the end effector 81 will desiccate and thin, and the distal portion of the end effector 81 will transect tissue in that distal region, thereby allowing the desiccated and thinned tissue within the proximal region to slide distally into the more active region of the end effector 81 to complete the tissue transection.

FIG. 3 illustrates a force diagram and the relationship between the actuation force F₄ (provided by the actuating member 76) and transection force F_T (measured at the

$$F_T = F_A(X_2/X_1)$$
 (1)

Where F_4 equals the spring preload of a proximal spring 94 (less frictional losses), which, in one embodiment, is about 12.5 pounds, and F_T equals about 4.5 pounds.

F_T is measured in the region of the clamp arm/blade interface where optimal tissue treatment occurs as defined

by tissue marks **61***a* and **61***b*. The tissue marks **61***a*, *b* are etched or raised on the clamp arm **56** to provide a visible mark to the surgeon so the surgeon has a clear indication of the optimal tissue treatment area. The tissue marks **61***a*, *b* are about 7 mm apart in distance, and more preferably about 5 mm apart in distance.

FIG. 9 illustrates one embodiment of a drive system 32 of the generator 30, which creates an ultrasonic electrical signal for driving an ultrasonic transducer. The drive system 32 is flexible and can create an ultrasonic electrical drive signal 416 at a desired frequency and power level setting for driving the ultrasonic transducer 50. In various embodiments, the generator 30 may comprise several separate functional elements, such as modules and/or blocks. Although certain modules and/or blocks may be described 15 by way of example, it can be appreciated that a greater or lesser number of modules and/or blocks may be used and still fall within the scope of the embodiments. Further, although various embodiments may be described in terms of modules and/or blocks to facilitate description, such mod- 20 ules and/or blocks may be implemented by one or more hardware components, e.g., processors, Digital Signal Processors (DSPs), Programmable Logic Devices (PLDs), Application Specific Integrated Circuits (ASICs), circuits, registers and/or software components, e.g., programs, sub- 25 routines, logic and/or combinations of hardware and software components.

In one embodiment, the generator 30 drive system 32 may comprise one or more embedded applications implemented as firmware, software, hardware, or any combination 30 thereof. The generator 30 drive system 32 may comprise various executable modules such as software, programs, data, drivers, application program interfaces (APIs), and so forth. The firmware may be stored in nonvolatile memory (NVM), such as in bit-masked read-only memory (ROM) or 35 flash memory. In various implementations, storing the firmware in ROM may preserve flash memory. The NVM may comprise other types of memory including, for example, programmable ROM (PROM), erasable programmable ROM (EPROM), electrically erasable programmable ROM 40 (EEPROM), or battery backed random-access memory (RAM) such as dynamic RAM (DRAM), Double-Data-Rate DRAM (DDRAM), and/or synchronous DRAM (SDRAM).

In one embodiment, the generator 30 drive system 32 comprises a hardware component implemented as a proces- 45 sor 400 for executing program instructions for monitoring various measurable characteristics of the ultrasonic surgical instrument 100 (FIG. 1) and generating a step function output signal for driving the ultrasonic transducer 50 in cutting and/or coagulation operating modes. It will be appre- 50 ciated by those skilled in the art that the generator 30 and the drive system 32 may comprise additional or fewer components and only a simplified version of the generator 30 and the drive system 32 are described herein for conciseness and clarity. In various embodiments, as previously discussed, the 55 hardware component may be implemented as a DSP, PLD, ASIC, circuits, and/or registers. In one embodiment, the processor 400 may be configured to store and execute computer software program instructions to generate the step function output signals for driving various components of 60 the ultrasonic surgical instrument 100, such as the transducer 50, the end effector 81, and/or the blade 79.

In one embodiment, under control of one or more software program routines, the processor 400 executes the methods in accordance with the described embodiments to 65 generate a step function formed by a stepwise waveform of drive signals comprising current (I), voltage (V), and/or 12

frequency (f) for various time intervals or periods (T). The stepwise waveforms of the drive signals may be generated by forming a piecewise linear combination of constant functions over a plurality of time intervals created by stepping the generator 30 drive signals, e.g., output drive current (I), voltage (V), and/or frequency (f). The time intervals or periods (T) may be predetermined (e.g., fixed and/or programmed by the user) or may be variable. Variable time intervals may be defined by setting the drive signal to a first value and maintaining the drive signal at that value until a change is detected in a monitored characteristic. Examples of monitored characteristics may comprise, for example, transducer impedance, tissue impedance, tissue heating, tissue transection, tissue coagulation, and the like. The ultrasonic drive signals generated by the generator 30 include, without limitation, ultrasonic drive signals capable of exciting the ultrasonic transducer 50 in various vibratory modes such as, for example, the primary longitudinal mode and harmonics thereof as well flexural and torsional vibratory modes.

In one embodiment, the executable modules comprise one or more step function algorithm(s) 402 stored in memory that when executed causes the processor 400 to generate a step function formed by a stepwise waveform of drive signals comprising current (I), voltage (V), and/or frequency (f) for various time intervals or periods (T). The stepwise waveforms of the drive signals may be generated by forming a piecewise linear combination of constant functions over two or more time intervals created by stepping the generator's 30 output drive current (I), voltage (V), and/or frequency (f). The drive signals may be generated either for predetermined fixed time intervals or periods (T) of time or variable time intervals or periods of time in accordance with the one or more stepped output algorithm(s) 402. Under control of the processor 400, the generator 30 steps (e.g., increment or decrement) the current (I), voltage (V), and/or frequency (f) up or down at a particular resolution for a predetermined period (T) or until a predetermined condition is detected, such as a change in a monitored characteristic (e.g., transducer impedance, tissue impedance). The steps can change in programmed increments or decrements. If other steps are desired, the generator 30 can increase or decrease the step adaptively based on measured system characteristics.

In operation, the user can program the operation of the generator 30 using the input device 406 located on the front panel of the generator 30 console. The input device 406 may comprise any suitable device that generates signals 408 that can be applied to the processor 400 to control the operation of the generator 30. In various embodiments, the input device 406 includes buttons, switches, thumbwheels, keyboard, keypad, touch screen monitor, pointing device, remote connection to a general purpose or dedicated computer. In other embodiments, the input device 406 may comprise a suitable user interface. Accordingly, by way of the input device 406, the user can set or program the current (I), voltage (V), frequency (f), and/or period (T) for programming the step function output of the generator 30. The processor 400 then displays the selected power level by sending a signal on line 410 to an output indicator 412.

In various embodiments, the output indicator 412 may provide visual, audible, and/or tactile feedback to the surgeon to indicate the status of a surgical procedure, such as, for example, when tissue cutting and coagulating is complete based on a measured characteristic of the ultrasonic surgical instrument 100, e.g., transducer impedance, tissue impedance, or other measurements as subsequently

described. By way of example, and not limitation, visual feedback comprises any type of visual indication device including incandescent lamps or light emitting diodes (LEDs), graphical user interface, display, analog indicator, digital indicator, bar graph display, digital alphanumeric 5 display. By way of example, and not limitation, audible feedback comprises any type of buzzer, computer generated tone, computerized speech, voice user interface (VUI) to interact with computers through a voice/speech platform. By way of example, and not limitation, tactile feedback comprises any type of vibratory feedback provided through the instrument housing handle assembly 68.

In one embodiment, the processor 400 may be configured or programmed to generate a digital current signal 414 and a digital frequency signal 418. These signals 414, 418 are 15 applied to a direct digital synthesizer (DDS) circuit 420 to adjust the amplitude and the frequency (f) of the current output signal 416 to the transducer 50. The output of the DDS circuit 420 is applied to an amplifier 422 whose output is applied to a transformer 424. The output of the transformer 424 is the signal 416 applied to the ultrasonic transducer 50, which is coupled to the blade 79 by way of the waveguide 80 (FIG. 2).

In one embodiment, the generator 30 comprises one or more measurement modules or components that may be 25 configured to monitor measurable characteristics of the ultrasonic instrument 100 (FIG. 1). In the illustrated embodiment, the processor 400 may be employed to monitor and calculate system characteristics. As shown, the processor 400 measures the impedance Z of the transducer 50 by monitoring the current supplied to the transducer 50 and the voltage applied to the transducer 50. In one embodiment, a current sense circuit 426 is employed to sense the current flowing through the transducer 50 and a voltage sense circuit 428 is employed to sense the output voltage applied to the 35 transducer 50. These signals may be applied to the analogto-digital converter 432 (ADC) via an analog multiplexer 430 circuit or switching circuit arrangement. The analog multiplexer 430 routes the appropriate analog signal to the ADC 432 for conversion. In other embodiments, multiple 40 ADCs 432 may be employed for each measured characteristic instead of the multiplexer 430 circuit. The processor 400 receives the digital output 433 of the ADC 432 and calculates the transducer impedance Z based on the measured values of current and voltage. The processor 400 adjusts the output drive signal 416 such that it can generate a desired power versus load curve. In accordance with programmed step function algorithms 402, the processor 400 can step the drive signal 416, e.g., the current or frequency, in any suitable increment or decrement in 50 response to the transducer impedance Z.

To actually cause the surgical blade 79 to vibrate, e.g., actuate the blade 79, the user activates the foot switch 434 (FIG. 1) or the switch 312a (FIG. 1) on the handle assembly 68. This activation outputs the drive signal 416 to the 55 transducer 50 based on programmed values of current (I), frequency (f), and corresponding time periods (T). After a predetermined fixed time period (T), or variable time period based on a measurable system characteristic such as changes in the impedance Z of the transducer 50, the processor 400 changes the output current step or frequency step in accordance with the programmed values. The output indicator 412 communicates the particular state of the process to the user.

The programmed operation of the generator 30 can be further illustrated with reference to FIGS. 6, 7, and 8, where 65 graphical representations of current 300, voltage 310, power 320, impedance 330, and frequency 340 are shown for the

14

generator 30 in an unloaded state, a lightly loaded state, and a heavily loaded state, respectively. FIG. 6 is a graphical representation of current 300, voltage 310, power 320, impedance 330, and frequency 340 waveforms of one embodiment of the generator 30 in an unloaded state. In the illustrated embodiment, the current 300 output of the generator 30 is stepped. As shown in FIG. 6, the generator 30 is initially activated at about time 0 resulting in the current 300 rising to a first set point I₁ of about 100 mA. The current **300** is maintained at the first set point I_2 for a first period I_1 . At the end of the first period T₁, e.g., about 1 second in the illustrated embodiment, the current 300 set point I₁ is changed, e.g., stepped, by the generator 30 in accordance with the software, e.g., the step function algorithm(s) 402, to a second set point I_2 of about 175 mA for a second period I_2 , e.g., about 2 seconds in the illustrated embodiment. At the end of the second period T2, e.g., at about 3 seconds in the illustrated embodiment, the generator 30 software changes the current 300 to a third set point I₃ of about 350 mA. The voltage 310, current 300, power 320, and frequency respond only slightly because there is no load on the system.

FIG. 7 is a graphical representation of the current 300, voltage 310, power 320, impedance 330, and frequency 340 waveforms of one embodiment of the generator 30 under a lightly loaded state. Referring to FIG. 7, the generator 30 is activated at about time 0 resulting in the current 300 rising to the first current 300 set point I_1 of about 100 mA. At about 1 second the current 300 set point is changed within the generator 30 by the software to I_2 of about 175 mA, and then again at about 3 seconds the generator 30 changes the current 300 set point to I_3 of about 350 mA. The voltage 310, current 300, power 320, and frequency 340 are shown responding to the light load similar to that shown in FIG. 4.

FIG. 8 is a graphical representation of the current 300, voltage 310, power 320, impedance 330, and frequency 340 waveforms of one embodiment of the generator 30 under a heavily loaded state. Referring to FIG. 8, the generator 30 is activated at about time 0 resulting in the current 300 rising to the first set point I_1 of about 100 mA. At about 1 second the current 300 set point is changed within the generator 30 by the software to I_2 of about 175 mA, and then again at about 3 seconds the generator 30 changes the current 300 set point to I_3 of about 350 mA. The voltage 310, current 300, power 320, and frequency 340 are shown responding to the heavy load similar to that shown in FIG. 5.

It will be appreciated by those skilled in the art that the current 300 step function set points (e.g., I_1 , I_2 , I_3) and the time intervals or periods (e.g., T_1 , T_2) of duration for each of the step function set points described in FIGS. 6-8 are not limited to the values described herein and may be adjusted to any suitable value as may be desired for a given set of surgical procedures. Additional or fewer current set points and periods of duration may be selected as may be desired for a given set of design characteristics or performance constraints. As previously discussed, the periods may be predetermined by programming or may be variable based on measurable system characteristics. The embodiments are not limited in this context.

Having described operational details of various embodiments of the surgical system 19, operations for the above surgical system 19 may be further described in terms of a process for cutting and coagulating a blood vessel employing a surgical instrument comprising the input device 406 and the transducer impedance measurement capabilities described with reference to FIG. 9. Although a particular process is described in connection with the operational details, it can be appreciated that the process merely pro-

vides an example of how the general functionality described herein can be implemented by the surgical system 19. Further, the given process does not necessarily have to be executed in the order presented herein unless otherwise indicated. As previously discussed, the input device 406 may 5 be employed to program the stepped output (e.g., current, voltage, frequency) to the ultrasonic transducer 50/blade 79 assembly.

Accordingly, with reference now to FIGS. 1-3 and 6-9, one technique for sealing a vessel includes separating and 10 moving the inner muscle layer of the vessel away from the adventitia layer prior to the application of standard ultrasonic energy to transect and seal the vessel. Although conventional methods have achieved this separation by increasing the force applied to the clamp member 60, 15 disclosed is an alternative apparatus and method for cutting and coagulating tissue without relying on clamp force alone. In order to more effectively separate the tissue layers of a vessel, for example, the generator 30 may be programmed to apply a frequency step function to the ultrasonic transducer 20 50 to mechanically displace the blade 79 in multiple modes in accordance with the step function. In one embodiment, the frequency step function may be programmed by way of the user interface 406, wherein the user can select a steppedfrequency program, the frequency (f) for each step, and the 25 corresponding time period (T) of duration for each step for which the ultrasonic transducer 50 will be excited. The user may program a complete operational cycle by setting multiple frequencies for multiple periods to perform various surgical procedures.

In one embodiment, a first ultrasonic frequency may be set initially to mechanically separate the muscle tissue layer of a vessel prior to applying a second ultrasonic frequency to cut and seal the vessel. By way of example, and not limitation, in accordance with one implementation of the 35 program, initially, the generator 30 is programmed to output a first drive frequency f_1 for a first period T_1 of time (for example less than approximately 1 second), wherein the first frequency f_1 is significantly off resonance, for example, $f_o/2$, 2f_o or other structural resonant frequencies, where f_o is the 40 resonant frequency (e.g., 55.5 kHz). The first frequency f₁ provides a low level of mechanical vibration action to the blade 79 that, in conjunction with the clamp force, mechanically separates the muscle tissue layer (subtherapeutic) of the vessel without causing significant heating that generally 45 occurs at resonance. After the first period T1, the generator 30 is programmed to automatically switch the drive frequency to the resonant frequency f_a for a second period T_2 to transect and seal the vessel. The duration of the second period T₂ may be programmed or may be determined by the 50 length of time it actually takes to cut and seal the vessel as determined by the user or may be based on measured system characteristics such as the transducer impedance Z as described in more detail below.

In one embodiment, the tissue/vessel transection process 55 (e.g., separating the muscle layer of the vessel from the adventitia layer and transecting/sealing the vessel) may be automated by sensing the impedance Z characteristics of the transducer 50 to detect when the transection of the tissue/vessel occurs. The impedance Z can be correlated to the 60 transection of the muscle layer and to the transection/sealing of the vessel to provide a trigger for the processor 400 to generate the frequency and/or current step function output. As previously discussed with reference to FIG. 9, the impedance Z of the transducer 50 may be calculated by the 65 processor 400 based on the current flowing through transducer 50 and the voltage applied to the transducer 50 while

16

the blade 79 is under various loads. Because the impedance Z of the transducer 50 is proportional to the load applied to the blade 79, as the load on the blade 79 increases, the impedance Z of the transducer 50 increases, and as the load on the blade 79 decreases the impedance Z of the transducer 50 decreases. Accordingly, the impedance Z of the transducer 50 can be monitored to detect the transection of the inner muscle tissue layer of the vessel from the adventitia layer and can also be monitored to detect when the vessel has been transected and sealed.

In one embodiment, the ultrasonic surgical instrument 110 may be operated in accordance with a programmed step function algorithm responsive to the transducer impedance Z. In one embodiment, a frequency step function output may be initiated based on a comparison of the transducer impedance Z and one or more predetermined thresholds that have been correlated with tissue loads against the blade 79. When the transducer impedance Z transitions above or below (e.g., crosses) a threshold, the processor 400 applies a digital frequency signal 418 to the DDS circuit 420 to change the frequency of the drive signal 416 by a predetermined step in accordance with the step function algorithm(s) 402 responsive to the transducer impedance Z. In operation, the blade 79 is first located at the tissue treatment site. The processor 400 applies a first digital frequency signal 418 to set a first drive frequency f1 that is off resonance (e.g., f_o/2, 2f_o or other structural resonant frequencies, where for is the resonant frequency). The drive signal 416 is applied to the transducer 50 in response to activation of the switch 312a on the handle assembly 68 or the foot switch 434. During this period the ultrasonic transducer 50 mechanically activates the blade 79 at the first drive frequency f_1 . A force or load may be applied to the clamp member 60 and the blade 79 to facilitate this process. During this period, the processor 400 monitors the transducer impedance Z until the load on the blade 79 changes and the transducer impedance Z crosses a predetermined threshold to indicate that the tissue layer has been transected. The processor 400 then applies a second digital frequency signal 418 to set a second drive frequency f₂, e.g., the resonant frequency f₂ or other suitable frequency for transecting, coagulating, and sealing tissue. Another portion of the tissue (e.g., the vessel) is then grasped between the clamp member 60 and the blade 79. The transducer 50 is now energized by the drive signal 416 at the second drive frequency f₂ by actuating either the foot switch 434 or the switch 312a on the handle assembly 68. It will be appreciated by those skilled in the art that the drive current (I) output also may be stepped as described with reference to FIGS. 6-8 based on the transducer impedance Z.

According to one step function algorithm 402, the processor 400 initially sets a first drive frequency f₁ that is significantly off resonance to separate the inner muscle layer of the vessel from the adventitia layer. During this period of operation the processor 400 monitors the transducer impedance Z to determine when the inner muscle layer is transected or separated from the adventitia layer. Because the transducer impedance Z is correlated to the load applied to the blade 79, for example, cutting more tissue decrease the load on the blade 79 and the transducer impedance Z. The transection of the inner muscle layer is detected when the transducer impedance Z drops below a predetermined threshold. When the change in transducer impedance Z indicates that the vessel has been separated from the inner muscle layer, the processor 400 sets the drive frequency to the resonant frequency fo. The vessel is then grasped between the blade 79 and the clamp member 60 and the transducer 50 is activated by actuating either the foot switch

or the switch on the handle assembly **68** to transect and seal the vessel. In one embodiment, the impedance Z change may range between about 1.5 to about 4 times a base impedance measurements from an initial point of contact with the tissue to a point just before the muscle layer is transected and sealed

FIG. 10 illustrates one embodiment of a surgical system 190 comprising an ultrasonic surgical instrument 120 and a generator 500 comprising a tissue impedance module 502. Although in the presently disclosed embodiment, the generator 500 is shown separate from the surgical instrument 120, in one embodiment, the generator 500 may be formed integrally with the surgical instrument 120 to form a unitary surgical system 190. In one embodiment, the generator 500 may be configured to monitor the electrical impedance of the tissue Z_t and to control the characteristics of time and power level based on the tissue impedance Z_t . In one embodiment, the tissue impedance Z_t may be determined by applying a subtherapeutic radio frequency (RF) signal to the tissue and 20 measuring the current through the tissue by way of a return electrode on the clamp member 60. In the embodiment illustrated in FIG. 10, an end effector 810 portion of the surgical system 190 comprises a clamp arm assembly 451 connected to the distal end of the outer sheath 72. The blade 25 79 forms a first (e.g., energizing) electrode and the clamp arm assembly 451 comprises an electrically conductive portion that forms a second (e.g., return) electrode. The tissue impedance module 502 is coupled to the blade 79 and the clamp arm assembly 451 through a suitable transmission 30 medium such as a cable 504. The cable 504 comprises multiple electrical conductors for applying a voltage to the tissue and providing a return path for current flowing through the tissue back to the impedance module 502. In various embodiments, the tissue impedance module 502 35 may be formed integrally with the generator 500 or may be provided as a separate circuit coupled to the generator 500 (shown in phantom to illustrate this option). The generator 500 is substantially similar to the generator 30 with the added feature of the tissue impedance module 502.

FIG. 11 illustrates one embodiment of a drive system 321 of the generator 500 comprising the tissue impedance module 502. The drive system 321 generates the ultrasonic electrical drive signal 416 to drive the ultrasonic transducer **50**. In one embodiment, the tissue impedance module **502** 45 may be configured to measure the impedance Z_t of tissue grasped between the blade 79 and the clamp arm assembly 451. The tissue impedance module 502 comprises an RF oscillator 506, a voltage sensing circuit 508, and a current sensing circuit **510**. The voltage and current sensing circuits 50 **508**, **510** respond to the RF voltage v_{rf} applied to the blade 79 electrode and the RF current i_{rf} flowing through the blade 79 electrode, the tissue, and the conductive portion of the clamp arm assembly 451. The sensed voltage v_{rf} and current i_{rf} are converted to digital form by the ADC 432 via the 55 analog multiplexer 430. The processor 400 receives the digitized output 433 of the ADC 432 and determines the tissue impedance Z_t by calculating the ratio of the RF voltage v_{rf} to current i_{rf} measured by the voltage sense circuit 508 and the current sense circuit 510. In one embodiment, 60 the transection of the inner muscle layer and the tissue may be detected by sensing the tissue impedance Z_t . Accordingly, detection of the tissue impedance Z, may be integrated with an automated process for separating the inner muscle layer from the outer adventitia layer prior to transecting the tissue 65 without causing a significant amount of heating, which normally occurs at resonance.

18

FIG. 12 illustrates one embodiment of the clamp arm assembly 451 that may be employed with the surgical system 190 (FIG. 10). In the illustrated embodiment, the clamp arm assembly 451 comprises a conductive jacket 472 mounted to a base 449. The conductive jacket 472 is the electrically conductive portion of the clamp arm assembly 451 that forms the second, e.g., return, electrode. In one implementation, the clamp arm 56 (FIG. 3) may form the base 449 on which the conductive jacket 472 is mounted. In various embodiments, the conductive jacket 472 may comprise a center portion 473 and at least one downwardlyextending sidewall 474 which can extend below the bottom surface 475 of the base 449. In the illustrated embodiment, the conductive jacket 472 has two sidewalls 474 extending downwardly on opposite sides of the base 449. In other embodiments, the center portion 473 may comprise at least one aperture 476 which can be configured to receive a projection 477 extending from the base 449. In such embodiments, the projections 477 can be press-fit within the apertures 476 in order to secure the conductive jacket 472 to the base 449. In other embodiments, the projections 477 can be deformed after they are inserted into the apertures 476. In various embodiments, fasteners can be used to secure the conductive jacket 472 to the base 449.

In various embodiments, the clamp arm assembly 451 may comprise a non-electrically conductive or insulative material, such as plastic and/or rubber, for example, positioned intermediate the conductive jacket 472 and the base 449. The electrically insulative material can prevent current from flowing, or shorting, between the conductive jacket 472 and the base 449. In various embodiments, the base 449 may comprise at least one aperture 478, which can be configured to receive a pivot pin (not illustrated). The pivot pin can be configured to pivotably mount the base 449 to the sheath 72 (FIG. 10), for example, such that the clamp arm assembly 451 can be rotated between open and closed positions relative to the sheath 72. In the illustrated embodiment, the base 449 includes two apertures 478 positioned on opposite sides of the base 449. In one embodiment, a pivot pin may be formed of or may comprise a non-electrically conductive or insulative material, such as plastic and/or rubber, for example, which can be configured to prevent current from flowing into the sheath 72 even if the base 449 is in electrical contact with the conductive jacket 472, for example. Additional clamp arm assemblies comprising various embodiments of electrodes may be employed. Examples of such clamp arm assemblies are described in commonlyowned and contemporaneously-filed U.S. patent application Ser. Nos. 12/503,769, 12/503,770, and 12/503,766, each of which is incorporated herein by reference in its entirety.

FIG. 13 is a schematic diagram of the tissue impedance module 502 coupled to the blade 79 and the clamp arm assembly 415 with tissue 514 located therebetween. With reference now to FIGS. 10-13, the generator 500 comprises the tissue impedance module 502 configured for monitoring the impedance of the tissue 514 (Z_t) located between the blade 79 and the clamp arm assembly 451 during the tissue transection process. The tissue impedance module 502 is coupled to the ultrasonic surgical instrument 120 by way of the cable 504. The cable 504 includes a first "energizing" conductor 504a connected to the blade 79 (e.g., positive [+] electrode) and a second "return" conductor 504b connected to the conductive jacket 472 (e.g., negative [-] electrode) of the clamp arm assembly 451. In one embodiment, RF voltage v_{rf} is applied to the blade 79 to cause RF current i_{rf} to flow through the tissue 514. The second conductor $504\dot{b}$ provides the return path for the current i_{rf} back to the tissue

impedance module **502**. The distal end of the return conductor **504**b is connected to the conductive jacket **472** such that the current i_{rf} can flow from the blade **79**, through the tissue **514** positioned intermediate the conductive jacket **472** and the blade **79**, and the conductive jacket **472** to the return conductor **504**b. The impedance module **502** connects in circuit, by way of the first and second conductors **504**a, b. In one embodiment, the RF energy may be applied to the blade **79** through the ultrasonic transducer **50** and the waveguide **80** (FIG. **2**). It is worthwhile noting that the RF energy applied to the tissue **514** for purposes of measuring the tissue impedance Z_t is a low level subtherapeutic signal that does not contribute in a significant manner, or at all, to the treatment of the tissue **514**.

Having described operational details of various embodi- 15 ments of the surgical system 190, operations for the above surgical system 190 may be further described with reference to FIGS. 10-13 in terms of a process for cutting and coagulating a blood vessel employing a surgical instrument comprising the input device 406 and the tissue impedance 20 module 502. Although a particular process is described in connection with the operational details, it can be appreciated that the process merely provides an example of how the general functionality described herein can be implemented by the surgical system 190. Further, the given process does 25 not necessarily have to be executed in the order presented herein unless otherwise indicated. As previously discussed, the input device 406 may be employed to program the step function output (e.g., current, voltage, frequency) to the ultrasonic transducer 50/blade 79 assembly.

In one embodiment, a first conductor or wire may be connected to the outer sheath 72 of the instrument 120 and a second conductor or wire may be connected to the blade 79/transducer 50. By nature of the design, the blade 79 and the transducer 50 are electrically isolated from the outer 35 sheath 72 as well as other elements of the actuation mechanism for the instrument 120 including the base 449 and the inner sheath 76. The outer sheath 79 and other elements of the actuation mechanism including the base 449 and the inner sheath 76 are all electrically continuous with one 40 another—that is, they are all metallic and touch one another. Accordingly, by connecting a first conductor to the outer sheath 72 and connecting a second conductor to the blade 79 or the transducer 50 such that the tissue resides between these two conductive pathways, the system can monitor the 45 electrical impedance of the tissue as long as the tissue contacts both the blade 79 and the base 449. To facilitate this contact, the base 449 itself may include outwardly and possibly downwardly protruding features to assure tissue contact while, effectively integrating conductive jacket 472 50 into base 449.

In one embodiment, the ultrasonic surgical instrument 120 may be operated in accordance with a programmed step function algorithm 402 responsive to the tissue impedance Z_t . In one embodiment, a frequency step function output 55 may be initiated based on a comparison of the tissue impedance Z_t and predetermined thresholds that have been correlated with various tissue states (e.g., desiccation, transection, sealing). When the tissue impedance Z_t transitions above or below (e.g., crosses) a threshold, the processor 400 applies a digital frequency signal 418 to the DDS circuit 420 to change the frequency of an ultrasonic oscillator by a predetermined step in accordance with the step function algorithm 402 responsive to the tissue impedance Z_t .

In operation, the blade **79** is located at the tissue treatment site. The tissue **514** is grasped between the blade **79** and the

20

clamp arm assembly 451 such that the blade 79 and the conductive jacket 472 make electrical contact with the tissue 514. The processor 400 applies a first digital frequency signal 418 to set a first drive frequency f, that is off resonance (e.g., f_e/2, 2f_e or other structural resonant frequencies, where f_o is the resonant frequency). The blade 79 is electrically energized by the low level subtherapeutic RF voltage v_{rf} supplied by the tissue impedance module 502. The drive signal 416 is applied to the transducer 50/blade 79 in response to actuation of the switch 312a on the handle assembly 68 or the foot switch 434 until the tissue impedance Z_t changes by a predetermined amount. A force or load is then applied to the clamp arm assembly 451 and the blade 79. During this period the ultrasonic transducer 50 mechanically activates the blade 79 at the first drive frequency f_1 and as a result, the tissue 514 begins to desiccate from the ultrasonic action applied between the blade 79 and the one or more clamp pads 58 of the clamp arm assembly 451 causing the tissue impedance Z, to increase. Eventually, as the tissue is transected by the ultrasonic action and applied clamp force, the tissue impedance Z, becomes very high or infinite as the tissue fully transects such that no conductive path exists between the blade 79 and the conductive jacket **472**. It will be appreciated by those skilled in the art that the drive current (I) output also may be stepped as described with reference to FIGS. 6-8 based on the tissue impedance

In one embodiment, the tissue impedance Z, may be monitored by the impedance module 502 in accordance with the following process. A measurable RF current i1 is conveyed through the first energizing conductor 504a to the blade 79, through the tissue 514, and back to the impedance module 502 through the conductive jacket 472 and the second conductor 504b. As the tissue 514 is desiccated and cut by the ultrasonic action of the blade 79 acting against the one or more clamp pads 58, the impedance of the tissue 514 increases and thus the current i1 in the return path, i.e., the second conductor 504b, decreases. The impedance module 502 measures the tissue impedance Z, and conveys a representative signal to the ADC 432 whose digital output 433 is provided to the processor 400. The processor 400 calculates the tissue impedance Z_t based on these measured values of v_{rf} and i_{rf} . The processor 400 steps the frequency by any suitable increment or decrement in response to changes in tissue impedance Z_r . The processor 400 controls the drive signals 416 and can make any necessary adjustments in amplitude and frequency in response to the tissue impedance Z_r . In one embodiment, the processor 400 can cut off the drive signal 416 when the tissue impedance Z_t reaches a predetermined threshold value.

Accordingly, by way of example, and not limitation, in one embodiment, the ultrasonic surgical instrument 120 may be operated in accordance with a programmed stepped output algorithm to separate the inner muscle layer of a vessel from the adventitia layer prior to transecting and sealing the vessel. As previously discussed, according to one step function algorithm, the processor 400 initially sets a first drive frequency f1 that is significantly off resonance. The transducer 50 is activated to separate the inner muscle layer of the vessel from the adventitia layer and the tissue impedance module 502 applies a subtherapeutic RF voltage v_{rf} signal to the blade 79. During this period T_1 of operation the processor 400 monitors the tissue impedance Z, to determine when the inner muscle layer is transected or separated from the adventitia layer. The tissue impedance Z. is correlated to the load applied to the blade 79, for example, when the tissue becomes desiccated or when the tissue is

transected the tissue impedance Z, becomes extremely high or infinite. The change in tissue impedance Z, indicates that the vessel has been separated or transected from the inner muscle layer and the generator 500 is deactivated for a second period of time T₂. The processor 400 then sets the 5 drive frequency to the resonant frequency f_o . The vessel is then grasped between the blade 79 and the clamp arm assembly 451 and the transducer 50 is reactivated to transect and seal the vessel. Continuous monitoring of the tissue impedance Z_t provides an indication of when the vessel is transected and sealed. Also, the tissue impedance Z_t may be monitored to provide an indication of the completeness of the tissue cutting and/or coagulating process or to stop the activation of the ultrasonic generator 500 when the tissue impedance Z_t reaches a predetermined threshold value. The 15 threshold for the tissue impedance Z, may be selected, for example, to indicate that the vessel has been transected. In one embodiment, the tissue impedance Z_t may range between about 10 Ohms to about 1000 Ohms from an initial point to a point just before the muscle layer is transected and 20

The applicants have discovered that experiments that run varying current set points (both increasing and decreasing) and dwell times indicate that the described embodiments can be used to separate the inner muscle layer from the outer 25 adventitia layer prior to completing the transection resulting in improved hemostasis and potentially lower total energy (heat) at the transection site. Furthermore, although the surgical instruments 100, 120 have been described in regards to impedance threshold detection schemes to determine 30 when the muscle layer is separated from the adventitia, other embodiments that do not employ any detection scheme are within the scope of the present disclosure. For example, embodiments of the surgical instruments 100, 120 may be employed in simplified surgical systems wherein non-reso- 35 nant power is applied to separate the layers for a predetermined time of approximately 1 second or less, prior to applying a resonant power to cut the tissue. The embodiments are not limited in this context.

Having described operational details of various embodi- 40 ments of the surgical systems 19 (FIG. 1) and 190 (FIG. 10), operations for the above surgical systems 19, 190 may be further described generally in terms of a process for cutting and coagulating tissue employing a surgical instrument comprising the input device 406 and the tissue impedance 45 module 502. Although a particular process is described in connection with the operational details, it can be appreciated that the process merely provides an example of how the general functionality described herein can be implemented by the surgical systems 19, 190. Further, the given process 50 does not necessarily have to be executed in the order presented herein unless otherwise indicated. As previously discussed, the input device 406 may be employed to program the stepped output (e.g., current, frequency) to the ultrasonic transducer 50/blade 79 assembly.

FIG. 14 illustrates one embodiment of a method 600 for driving an end effector coupled to an ultrasonic drive system of a surgical instrument. With reference to FIGS. 1-3, and 6-14, by way of example, and not limitation, the ultrasonic surgical instruments 100, 120 may be operated in accordance with the method 600 to separate the inner muscle layer of a vessel from the adventitia layer prior to transecting and sealing the vessel. Accordingly, in various embodiments, an end effector (e.g., end effector 81, 810) of a surgical instrument (e.g., surgical instrument 100, 120) may be driven in 65 accordance with the method 600. A generator (e.g., generator 30, 500) is coupled to an ultrasonic drive system. The

22

ultrasonic drive system comprises an ultrasonic transducer (e.g., ultrasonic transducer 50) coupled to a waveguide (e.g., waveguide 80) and the end effector 81 is coupled to the waveguide 80. The ultrasonic drive system is configured to resonate at a resonant frequency (e.g., 55.5 kHz). In one embodiment, at 602, the generator 30 generates a first ultrasonic drive signal. At 604, the ultrasonic transducer 50 is actuated with the first ultrasonic drive signal for a first period in response to activating a switch (e.g., switch 34) on a handle assembly (e.g., handle assembly 68) or a foot switch (e.g., foot switch 434) connected to the generator 30. After the first period, at 606, the generator 30 generates a second ultrasonic drive signal. At 608, the ultrasonic transducer 50 is actuated with the second ultrasonic drive signal for a second period in response to activating the switch 34 on the handle assembly 68 or the foot switch 434 connected to the generator 30. The first drive signal is different from the second drive signal over the respective first and second periods. The first and second drive signals define a step function waveform over the first and second periods.

In one embodiment, the generator 30 generates a third ultrasonic drive signal. The ultrasonic transducer 50 is actuated with the third ultrasonic drive signal for a third period. The third drive signal is different from the first second drive signals over the first, second, and third periods. The first, second, and third drive signals define a step function waveform over the first, second, and third periods. In one embodiment, generating the first, second, and third ultrasonic drive signals comprises generating a corresponding first, second, and third drive current and actuating the ultrasonic transducer 50 with the first drive current for the first period, actuating the ultrasonic transducer 50 with the second drive current for the second period, and actuating the ultrasonic transducer 50 with the third drive current for the third period.

In one embodiment, the generator 30 generates the first ultrasonic drive signal at a first frequency, which is different from the resonant frequency. The ultrasonic transducer 50 is then actuated with the first ultrasonic drive signal at the first frequency for the first period. Actuation at the first frequency provides a first level of mechanical vibration to the end effector 81 suitable for separating a first tissue from a second tissue, for example, to separate the inner muscle layer of a vessel from the adventitia layer. The generator 30 generates the second ultrasonic drive signal at the resonant frequency, e.g., 55.5 kHz, and the actuates the ultrasonic transducer 50 with the second ultrasonic drive signal at the resonant frequency for the second period subsequent to the first period. Actuation at the second, resonant frequency, provides a second level of mechanical vibration to the end effector 81 suitable for transecting and sealing the first tissue, such as the vessel, once it separated from the inner muscle layer. In one embodiment, the second ultrasonic drive signal at the resonant frequency is generated automati-55 cally by the generator 30 after the first period. In one embodiment, the first frequency is substantially different from the resonant frequency and the first period is less than about one second. For example, in one embodiment, the first frequency is defined by the following equation: $f_1=2*f_o$, wherein f_1 is the first frequency and f_o is the resonant frequency. In another embodiment, the first frequency is defined by the following equation: $f_1=f_2/2$, wherein f_1 is the first frequency and fo is the resonant frequency. The first, second, and third ultrasonic drive signals are also envisioned to excite be vibratory modes of the ultrasonic transducer 50 in longitudinal, flexural, and torsional modes and harmonics thereof.

In one embodiment, the generator 30 monitors a measurable characteristic of the ultrasonic drive system and generates any one of the first and second drive signals based on the measured characteristic. For example, the generator 30 monitors the impedance Z of the ultrasonic transducer 50. 5 The generator 30 comprises electronic circuitry suitable for measuring the impedance of the transducer **50**. For example, a current sense circuit (e.g., current sense circuit 426) senses the current flowing through the transducer 50 and a voltage sense circuit (e.g., voltage sense circuit 428) senses the 10 output voltage applied to the transducer 50. A multiplexer (e.g., multiplexer 430) routes the appropriate analog signal to an analog-to-digital converter (e.g., ADC 432), whose digital output is provided to a processor (e.g., processor 400). The processor 400 calculates the transducer imped- 15 ance Z based on the measured values of current and voltage.

In one embodiment, the generator 500 comprises an impedance module (e.g., tissue impedance module 502) to measure the impedance of a tissue portion contacting an end effector (e.g., end effector 810). The impedance module 502 20 includes an RF oscillator (e.g., RF oscillator 506) to generate a subtherapeutic RF signal. The subtherapeutic RF signal is applied to a blade (e.g., blade 79) portion of the end effector **810**, which forms an energizing electrode. The tissue portion is grasped between the end effector 810 and a return elec- 25 trode of a clamp arm assembly (e.g., clamp arm assembly 451) and the impedance of the tissue (e.g., tissue 514). The tissue impedance is then measured by a voltage sense circuit (e.g., voltage sense circuit 508) and current sense circuit (e.g., current sense circuit 510) and of the impedance 30 module 502. These signals are applied to the ADC 432 via the multiplexer 430. The digital output of the ADC 432 is provided to the processor 400, which calculates the tissue impedance Zt based on the measured values of current through the tissue and the voltage applied to the blade 79 35 portion of the end effector 810.

FIGS. 15A-C illustrate various embodiments of logic flow diagrams of 700, 800, 900 of operations for determining a change of state of tissue being manipulated by an ultrasonic surgical instrument and providing feedback to the user to 40 indicate that the tissue has undergone such change of state or that there is a high likelihood that the tissue has undergone such change of state. As used herein, the tissue may undergo a change of state when the tissue is separated from other layers of tissue or bone, when the tissue is cut or 45 transected, when the tissue is coagulated, and so forth while being manipulated with an end effector of an ultrasonic surgical instrument, such as, for example, the end effector 81, 810 of the ultrasonic surgical instrument 100, 120 shown in FIGS. 1 and 10. A change in tissue state may be deter- 50 mined based on the likelihood of an occurrence of a tissue separation event.

In various embodiments, the feedback is provided by the output indicator 412 shown in FIGS. 9 and 11. The output indicator 412 is particularly useful in applications where the tissue being manipulated by the end effector 81, 810 is out of the user's field of view and the user cannot see when a change of state occurs in the tissue. The output indicator 412 communicates to the user that a change in tissue state has occurred as determined in accordance with the operations 60 described with respect to the logic flow diagrams 700, 800, 900. As previously discussed, the output indicator 412 may be configured to provide various types of feedback to the user including, without limitation, visual, audible, and/or tactile feedback to indicate to the user (e.g., surgeon, clinician) that the tissue has undergone a change of state or condition of the tissue. By way of example, and not limi-

24

tation, as previously discussed, visual feedback comprises any type of visual indication device including incandescent lamps or LEDs, graphical user interface, display, analog indicator, digital indicator, bar graph display, digital alphanumeric display. By way of example, and not limitation, audible feedback comprises any type of buzzer, computer generated tone, computerized speech, VUI to interact with computers through a voice/speech platform. By way of example, and not limitation, tactile feedback comprises any type of vibratory feedback provided through the instrument housing handle assembly 68. The change of state of the tissue may be determined based on transducer and tissue impedance measurements as previously described, or based on voltage, current, and frequency measurements in accordance with the operations described with respect to the logic flow diagrams $7\bar{0}0$, 800, 900 described below with respect to FIGS. 15A-C.

In one embodiment, the logic flow diagrams 700, 800, 900 may be implemented as executable modules (e.g., algorithms) comprising computer readable instructions to be executed by the processor 400 (FIGS. 9, 11, 14) portion of the generator 30, 500. In various embodiments, the operations described with respect to the logic flow diagrams 700, 800, 900 may be implemented as one or more software components, e.g., programs, subroutines, logic; one or more hardware components, e.g., processors, DSPs, PLDs, ASICs, circuits, registers; and/or combinations of software and hardware. In one embodiment, the executable instructions to perform the operations described by the logic flow diagrams 700, 800, 900 may be stored in memory. When executed, the instructions cause the processor 400 to determine a change in tissue state in accordance with the operations described in the logic flow diagrams 800 and 900 and provide feedback to the user by way of the output indicator 412. In accordance with such executable instructions, the processor 400 monitors and evaluates the voltage, current, and/or frequency signal samples available from the generator 30, 500 and according to the evaluation of such signal samples determines whether a change in tissue state has occurred. As further described below, a change in tissue state may be determined based on the type of ultrasonic instrument and the power level that the instrument is energized at. In response to the feedback, the operational mode of the ultrasonic surgical instrument 100, 120 may be controlled by the user or may be automatically or semi-automatically controlled.

FIG. 15A illustrates a logic flow diagram 700 of one embodiment of determining a change in tissue state and activating the output indicator 412 accordingly. With reference now to the logic flow diagram 700 shown in FIG. 15A and the drive system 32 of the generator 30 shown in FIG. 9, at 702, the processor 400 portion of the drive system 32 samples the voltage (v), current (i), and frequency (f) signals of the generator 30. In the illustrated embodiment, at 704, the frequency and voltage signal samples are analyzed separately to determine the corresponding frequency inflection and/or voltage drop points. In other embodiments, the current signal samples may be separately analyzed in addition to the voltage and frequency signal samples or in place of the voltage signal samples. At 706, the present frequency signal sample is provided to a frequency inflection point analysis module for determining a change in tissue state as illustrated in the logic flow diagram 800 in FIG. 15B. At 708, the present voltage signal sample is provided to a voltage drop point analysis module for determining a change in tissue state as illustrated in the logic flow diagram 900 in FIG. 15C.

The frequency inflection point analysis module and the voltage drop point analysis module determine when a change in tissue state has occurred based on correlated empirical data associated with a particular ultrasonic instrument type and the energy level at which the instrument is 5 driven. At 714, the results 710 from the frequency inflection point analysis module and/or the results 712 from the voltage drop point analysis module are read by the processor 400. The processor 400 determines 716 whether the frequency inflection point result 710 and/or the voltage drop 10 point result 712 indicates a change in tissue state. If the results 710, 714 do not indicate a change in tissue state, the processor 400 continues along the "No" branch to 702 and reads an additional voltage and frequency signal sample from the generator 30. In embodiments that utilize the 15 generator current in the analysis, the processor 400 would now also read an additional current signal sample from the generator 30. If the results 710, 714 indicate a sufficient change in tissue state, the processor 400 continues along the "Yes" branch to 718 and activates the output indicator 412. 20

As previously discussed, the output indicator 412 may provide visual, audible, and/or tactile feedback to alert the user of the ultrasonic surgical instrument 100, 120 that a change in tissue state has occurred. In various embodiments, in response to the feedback from the output indicator 412, 25 the operational mode of the generator 30, 500 and/or the ultrasonic instrument 100, 120 may be controlled manually, automatically, or semi-automatically. The operational modes include, without limitation, disconnecting or shutting down the output power of the generator 30, 500, reducing the 30 output power of the generator 30, 500, cycling the output power of the generator 30, 500, pulsing the output power of the generator 30, 500, and/or outputting a high-power momentary surge from the generator 30, 500. The operational modes of the ultrasonic instrument in response to the 35 change in tissue state can be selected, for example, to minimize heating effects of the end effector 81, 810, e.g., of the clamp pad 58 (FIGS. 1-3), to prevent or minimize possible damage to the surgical instrument 100, 120 and/or surrounding tissue. This is advantageous because heat is 40 generated rapidly when the transducer 50 is activated with nothing between the jaws of the end effector 81, 810 as is the case when a change in tissue state occurs such as when tissue has substantially separated from the end effector.

FIG. 15B is a logic flow diagram 800 illustrating one 45 embodiment of the operation of the frequency inflection point analysis module. At 802, a frequency sample is received by the processor 400 from 706 of the logic flow diagram 700. At 804, the processor 400 calculates an exponentially weighted moving average (EWMA) for the frequency inflection analysis. The EWMA is calculated to filter out noise from the generator from the frequency samples. The EWMA is calculated in accordance with a frequency moving average equation 806 and an alpha value (α) 808:

$$S_{t} = \alpha Y_{t} + (1 - \alpha)S_{t} - 1 \tag{2}$$

Where:

 S_{y} the current moving average of the sampled frequency signal;

 S_{tf-1} =the previous moving average of the sampled frequency 60 signal:

α=the smoothing factor; and

 $Y_{t\!\!/}\!\!=\!\!\text{current}$ data point of the sampled frequency signal.

The α value **808** may vary from about 0 to about 1 in accordance with a desired filtering or smoothing factor, 65 wherein small α values **808** approaching about 0 provide a large amount of filtering or smoothing and large α values

26

808 approaching about 1 provide a small amount of filtering or smoothing. The α value 808 may be selected based on the ultrasonic instrument type and power level. In one embodiment, blocks 804, 806, and 808 may be implemented as a variable digital low pass filter 810 with the α value 808 determining the cutoff point of the filter 810. Once the frequency samples are filtered, the slope of the frequency samples is calculated at 812 as:

Frequency Slope=
$$\Delta f/\Delta t$$
 (3)

The calculated Frequency Slope data points are provided to a "slow response" moving average filter **814** to calculate the EWMA moving average for the Frequency Slope to further reduce system noise. In one embodiment, the "slow response" moving average filter **814** may be implemented by calculating the EWMA for the Frequency Slope at **818** in accordance with the frequency slope moving average equation **820** and alpha value (α) **822**:

$$S'_{tf} = \alpha' Y'_{tf} + (1 - \alpha') S'_{tf-1}$$
 (4)

Where

S'_{t/}—the current moving average of the frequency slope of the sampled frequency signal;

S'_{1/-1}=the previous moving average of the frequency slope of the sampled frequency signal;

 α' =the smoothing factor; and

 Y'_{tf} =current slope data point of the sampled frequency signal.

The α' value **822** varies from about 0 to about 1, as previously discussed with respect to digital filter block **810** in accordance with a desired filtering or smoothing factor, wherein small α' value **822** approaching 0 provide a large amount of filtering or smoothing and large α' value **822** approaching 1 provide a small amount of filtering or smoothing. The α' value **822** may be selected based on the ultrasonic instrument type and power level.

The calculated Frequency Slope data points are provided to a "fast response" filter **816** to calculate the moving average for the Frequency Slope. At **824**, the "fast response" filter **816** calculates the moving average for the Frequency Slope based on a number of data points **826**.

In the illustrated embodiment, the output of the "slow response" moving average filter 814 "Slope EWMA" is applied to a (+) input of an adder 828 and the output of the "fast response" filter **816** "Slope Avg" is applied to (–) input of the adder 828. The adder 828 computes the difference between the outputs of the "slow response" moving average filter 814 and the "fast response" filter 816. The difference between these outputs is compared at 830 to a predetermined limit 832. The limit 832 is determined based on the type of ultrasonic instrument and the power level at which the particular type of ultrasonic instrument is energized at. The limit 832 value may be predetermined and stored in memory in the form of a look-up table or the like. If the difference 55 between the "Slope EWMA" and the "Slope Avg" is not greater than the limit 832, the processor 400 continues along the "No" branch and returns a value 834 to the results 710 block that indicates that no inflection point was found in the sampled frequency signal and, therefore, no change in tissue state was detected. However, if the difference between the "Slope EWMA" and the "Slope Avg" is greater than the limit 832, the processor 400 continues along the "Yes" branch and determines that a frequency inflection point 836 was found and returns point index 838 to the results 710 block indicating that an inflection point was found in the sampled frequency data and, therefore, a change in tissue state was detected. As previously discussed with reference to

FIG. 15A, if a frequency inflection point 836 is found, then, at 718 (FIG. 15A) the processor 400 activates the change in tissue state indicator 718.

FIG. 15C is a logic flow diagram 900 illustrating one embodiment of the operation of the voltage drop analysis 5 module. At 902, a voltage sample is received by the processor 400 from 708 of the logic flow diagram 700. At 904, the processor 400 calculates an exponentially weighted moving average (EWMA) for the frequency inflection analysis. The EWMA is calculated to filter out noise from the generator from the frequency samples. The EWMA is calculated in accordance with a voltage moving average equation 906 and an alpha value (α) 908:

$$S_{tv} = \alpha Y_{tv} + (1 - \alpha) S_{tv-1}$$
 (5)

Where:

 S_n =the current moving average of the sampled voltage signal:

 $S_{r_{r-1}}$ =the previous moving average of the sampled voltage signal;

α=the smoothing factor; and

 Y_{tv} =current data point of the sampled voltage signal.

As previously discussed, the α value 908 may vary from 0 to 1 in accordance with a desired filtering or smoothing factor and may be selected based on the ultrasonic instrument type and power level. In one embodiment, blocks 904, 906, and 908 may be implemented as a variable digital low pass filter 910 with the α value 908 determining the cutoff point of the filter 910. Once the voltage samples are filtered, the slope of the voltage samples is calculated at 912 as:

Voltage Slope=
$$\Delta v/\Delta t$$
 (6

The calculated Voltage Slope data points are provided to a "slow response" moving average filter **914** to calculate the EWMA moving average for the Voltage Slope to further 35 reduce system noise. In one embodiment, the "slow response" moving average filter **914** may be implemented by calculating the EWMA for the Voltage Slope at **918** in accordance with the voltage slope moving average equation **920** and alpha value (α ') **822**:

$$S'_{tv} = \alpha' Y'_{tv} + (1 - \alpha') S'_{tv-1}$$
 (7)

Where:

 S'_{n} =the current moving average of the voltage slope of the sampled voltage signal;

 S'_{tv-1} =the previous moving average of the voltage slope of the sampled voltage signal;

α'=the smoothing factor; and

Y'_{tv}=current slope data point of the sampled voltage signal.

The α' value 922 varies from about 0 to about 1, as 50 previously discussed with respect to digital filter block 910 in accordance with a desired filtering or smoothing factor, wherein small α' value 922 approaching about 0 provide a large amount of filtering or smoothing and large α' value 922 approaching about 1 provide a small amount of filtering or 55 smoothing. The α' value 922 may be selected based on the ultrasonic instrument type and power level.

The calculated Voltage Slope data points are provided to a "fast response" filter **916** to calculate the moving average for the Voltage Slope. At **924**, the "fast response" filter **916** 60 calculates the moving average for the Voltage Slope based on a number of data points **926**.

In the illustrated embodiment, the output of the "slow response" moving average filter 914 "Slope EWMA" is applied to a (+) input of an adder 928 and the output of the 65 "fast response" filter 916 "Slope Avg" is applied to (-) input of the adder 928. The adder 928 computes the difference

28

between the outputs of the "slow response" moving average filter 914 and the "fast response" filter 916. The difference between these outputs is compared at 930 to a predetermined limit 932. The limit 932 is determined based on the type of ultrasonic instrument and the power level at which the particular type of ultrasonic instrument is energized at. The limit 932 value may be predetermined and stored in memory in the form of a look-up table or the like. If the difference between the "Slope EWMA" and the "Slope Avg" is not greater than the limit 932, the processor 400 continues along the "No" branch and resets a counter to zero at 940, then returns a value 934 to the results 710 block that indicates that no voltage drop point was found in the sampled voltage signals and, therefore, no change in tissue state was detected. (5) 15 However, if the difference between the "Slope EWMA" and the "Slope Avg" is greater than the limit 932, the processor 400 continues along the "Yes" branch and increments a counter at 942. At 944, the processor 400 decides whether the counter is greater than 1, or some other predetermined threshold value for example. In other words, the processor 400 takes at least two data points in regards to the voltage drop point. If the counter is not greater than the threshold (e.g., 1 in the illustrated embodiment) the processor 400 continues along the "No" branch and returns a value 934 to the results 710 block that indicates that no voltage drop point was found in the sampled voltage signals and, therefore, no change in tissue state was detected. If the counter is greater than the threshold (e.g., 1 in the illustrated embodiment) the processor 400 continues along the "Yes" branch and determines that a voltage drop point 936 was found and returns a point index 938 to the results 712 block indicating that a voltage drop point was found in the sampled voltage signals and, therefore, a change in tissue state was detected. As previously discussed with reference to FIG. 15A, if a voltage point 836 is found, then, at 718 (FIG. 15A) the processor 400 activates the change in tissue state indicator 718.

FIG. 16 illustrates one embodiment of a surgical system 1000 comprising a generator 1002 and various surgical instruments usable therewith. The generator 1002 is configurable for use with surgical devices. According to various embodiments, the generator 1002 may be configurable for use with different surgical devices of different types including, for example, the ultrasonic device 1004 and electrosurgical or RF surgical devices, such as, the RF device 1006. Although in the embodiment of FIG. 16, the generator 1002 is shown separate from the surgical devices 1004, 1006, in one embodiment, the generator 1002 may be formed integrally with either of the surgical devices 1004, 1006 to form a unitary surgical system. The generator 1002 comprises an input device 1009 located on a front panel of the generator 1002 console. The input device 1009 may comprise any suitable device that generates signals suitable for programming the operation of the generator 1002.

FIG. 17 is a diagram of the surgical system 1000 of FIG. 16. In various embodiments, the generator 1002 may comprise several separate functional elements, such as modules and/or blocks. Different functional elements or modules may be configured for driving the different kinds of surgical devices 1004, 1006. For example, an ultrasonic generator module 1008 may drive ultrasonic devices such as the ultrasonic device 1004. An electrosurgery/RF generator module 1010 may drive the electrosurgical device 1006. For example, the respective modules 1008, 1010 may generate respective drive signals for driving the surgical devices 1004, 1006. In various embodiments, the ultrasonic generator module 1008 and/or the electrosurgery/RF generator module 1010 each may be formed integrally with the

generator 1002. Alternatively, one or more of the modules 1008, 1010 may be provided as a separate circuit module electrically coupled to the generator 1002. (The modules 1008 and 1010 are shown in phantom to illustrate this option.) Also, in some embodiments, the electrosurgery/RF 5 generator module 1010 may be formed integrally with the ultrasonic generator module 1008, or vice versa.

In accordance with the described embodiments, the ultrasonic generator module 1008 may produce a drive signal or signals of particular voltages, currents, and frequencies, e.g., 10 55,500 cycles per second (Hz). The drive signal or signals may be provided to the ultrasonic device 1004, and specifically to the transducer 1014, which may operate, for example, as described above. In one embodiment, the generator 1002 may be configured to produce a drive signal of 15 a particular voltage, current, and/or frequency output signal that can be stepped with high resolution, accuracy, and repeatability.

The generator 1002 may be activated to provide the drive signal to the transducer 1014 in any suitable manner. For 20 example, the generator 1002 may comprise a foot switch 1020 coupled to the generator 1002 via a footswitch cable 1022. A clinician may activate the transducer 1014 by depressing the foot switch 1020. In addition, or instead of the foot switch 1020 some embodiments of the ultrasonic 25 device 1004 may utilize one or more switches positioned on the hand piece that, when activated, may cause the generator 1002 to activate the transducer 1014. In one embodiment, for example, the one or more switches may comprise a pair of toggle buttons 1036a, 1036b (FIG. 16), for example, to 30 determine an operating mode of the device 1004. When the toggle button 1036a is depressed, for example, the ultrasonic generator 1002 may provide a maximum drive signal to the transducer 1014, causing it to produce maximum ultrasonic energy output. Depressing toggle button 1036b may cause 35 the ultrasonic generator 1002 to provide a user-selectable drive signal to the transducer 1014, causing it to produce less than the maximum ultrasonic energy output. The device 1004 additionally or alternatively may comprise a second switch (not shown) to, for example, indicate a position of a 40 jaw closure trigger for operating jaws of the end effector 1026. Also, in some embodiments, the ultrasonic generator 1002 may be activated based on the position of the jaw closure trigger, (e.g., as the clinician depresses the jaw closure trigger to close the jaws, ultrasonic energy may be 45 applied).

Additionally or alternatively, the one or more switches may comprises a toggle button 1036c that, when depressed, causes the generator 1002 to provide a pulsed output. The pulses may be provided at any suitable frequency and 50 grouping, for example. In certain embodiments, the power level of the pulses may be the power levels associated with toggle buttons 1036a, 1036b (maximum, less than maximum), for example.

It will be appreciated that a device 1004 may comprise 55 any combination of the toggle buttons 1036a, 1036b, 1036c. For example, the device 1004 could be configured to have only two toggle buttons: a toggle button 1036a for producing maximum ultrasonic energy output and a toggle button 1036c for producing a pulsed output at either the maximum or less than maximum power level. In this way, the drive signal output configuration of the generator 1002 could be 5 continuous signals and 5 or 4 or 3 or 2 or 1 pulsed signals. In certain embodiments, the specific drive signal configuration may be controlled based upon, for example, 65 EEPROM settings in the generator 1002 and/or user power level selection(s).

30

In certain embodiments, a two-position switch may be provided as an alternative to a toggle button 1036c. For example, a device 1004 may include a toggle button 1036a for producing a continuous output at a maximum power level and a two-position toggle button 1036b. In a first detented position, toggle button 1036b may produce a continuous output at a less than maximum power level, and in a second detented position the toggle button 1036b may produce a pulsed output (e.g., at either a maximum or less than maximum power level, depending upon the EEPROM settings).

In accordance with the described embodiments, the electrosurgery/RF generator module 1010 may generate a drive signal or signals with output power sufficient to perform bipolar electrosurgery using radio frequency (RF) energy. In bipolar electrosurgery applications, the drive signal may be provided, for example, to electrodes of the electrosurgical device 1006, for example. Accordingly, the generator 1002 may be configured for therapeutic purposes by applying electrical energy to the tissue sufficient for treating the tissue (e.g., coagulation, cauterization, tissue welding).

The generator 1002 may comprise an input device 1045 (FIG. 16) located, for example, on a front panel of the generator 1002 console. The input device 1045 may comprise any suitable device that generates signals suitable for programming the operation of the generator 1002. In operation, the user can program or otherwise control operation of the generator 1002 using the input device 1045. The input device 1045 may comprise any suitable device that generates signals that can be used by the generator (e.g., by one or more processors contained in the generator) to control the operation of the generator 1002 (e.g., operation of the ultrasonic generator module 1008 and/or electrosurgery/RF generator module 1010). In various embodiments, the input device 1045 includes one or more of buttons, switches, thumbwheels, keyboard, keypad, touch screen monitor, pointing device, remote connection to a general purpose or dedicated computer. In other embodiments, the input device 1045 may comprise a suitable user interface, such as one or more user interface screens displayed on a touch screen monitor, for example. Accordingly, by way of the input device 1045, the user can set or program various operating parameters of the generator, such as, for example, current (I), voltage (V), frequency (f), and/or period (T) of a drive signal or signals generated by the ultrasonic generator module 1008 and/or electrosurgery/RF generator module 1010.

The generator 1002 may also comprise an output device 1047 (FIG. 16), such as an output indicator, located, for example, on a front panel of the generator 1002 console. The output device 1047 includes one or more devices for providing a sensory feedback to a user. Such devices may comprise, for example, visual feedback devices (e.g., a visual feedback device may comprise incandescent lamps, light emitting diodes (LEDs), graphical user interface, display, analog indicator, digital indicator, bar graph display, digital alphanumeric display, LCD display screen, LED indicators), audio feedback devices (e.g., an audio feedback device may comprise speaker, buzzer, audible, computer generated tone, computerized speech, voice user interface (VUI) to interact with computers through a voice/speech platform), or tactile feedback devices (e.g., a tactile feedback device comprises any type of vibratory feedback, haptic actuator).

Although certain modules and/or blocks of the generator 1002 may be described by way of example, it can be appreciated that a greater or lesser number of modules

and/or blocks may be used and still fall within the scope of the embodiments. Further, although various embodiments may be described in terms of modules and/or blocks to facilitate description, such modules and/or blocks may be implemented by one or more hardware components, e.g., 5 processors, Digital Signal Processors (DSPs), Programmable Logic Devices (PLDs), Application Specific Integrated Circuits (ASICs), circuits, registers and/or software components, e.g., programs, subroutines, logic and/or combinations of hardware and software components.

In one embodiment, the ultrasonic generator drive module 1008 and electrosurgery/RF drive module 1010 may comprise one or more embedded applications implemented as firmware, software, hardware, or any combination thereof. The modules 1008, 1010 may comprise various executable 15 modules such as software, programs, data, drivers, application program interfaces (APIs), and so forth. The firmware may be stored in nonvolatile memory (NVM), such as in bit-masked read-only memory (ROM) or flash memory. In various implementations, storing the firmware in ROM may 20 preserve flash memory. The NVM may comprise other types of memory including, for example, programmable ROM (PROM), erasable programmable ROM (EPROM), electrically erasable programmable ROM (EEPROM), or battery backed random-access memory (RAM) such as dynamic 25 RAM (DRAM), Double-Data-Rate DRAM (DDRAM), and/ or synchronous DRAM (SDRAM).

In one embodiment, the modules 1008, 1010 comprise a hardware component implemented as a processor for executing program instructions for monitoring various measurable 30 characteristics of the devices 1004, 1006 and generating a corresponding output control signals for operating the devices 1004, 1006. In embodiments in which the generator 1002 is used in conjunction with the device 1004, the output control signal may drive the ultrasonic transducer 1014 in 35 cutting and/or coagulation operating modes. Electrical characteristics of the device 1004 and/or tissue may be measured and used to control operational aspects of the generator 1002 and/or provided as feedback to the user. In embodiments in which the generator 1002 is used in conjunction with the 40 device 1006, the output control signal may supply electrical energy (e.g., RF energy) to the end effector 1032 in cutting, coagulation and/or desiccation modes. Electrical characteristics of the device 1006 and/or tissue may be measured and used to control operational aspects of the generator 1002 45 and/or provide feedback to the user. In various embodiments, as previously discussed, the hardware component may be implemented as a DSP, PLD, ASIC, circuits, and/or registers. In one embodiment, the processor may be configured to store and execute computer software program 50 instructions to generate the step function output signals for driving various components of the devices 1004, 1006, such as the ultrasonic transducer 1014 and the end effectors 1026,

FIG. 18 illustrates an equivalent circuit 1050 of an ultrasonic transducer, such as the ultrasonic transducer 1014, according to one embodiment. The circuit 1050 comprises a first "motional" branch having a serially connected inductance L_s , resistance R_s and capacitance C_s that define the electromechanical properties of the resonator, and a second 60 capacitive branch having a static capacitance C_o . Drive current I_g may be received from a generator at a drive voltage V_g , with motional current I_m flowing through the first branch and current I_g - I_m flowing through the capacitive branch. Control of the electromechanical properties of the 65 ultrasonic transducer may be achieved by suitably controlling I_g and V_g . As explained above, conventional generator

32

architectures may include a tuning inductor L_t (shown in phantom in FIG. 18) for tuning out in a parallel resonance circuit the static capacitance Co at a resonant frequency so that substantially all of generator's current output I_g flows through the motional branch. In this way, control of the motional branch current I_m is achieved by controlling the generator current output I_g . The tuning inductor L_t is specific to the static capacitance C_o of an ultrasonic transducer, however, and a different ultrasonic transducer having a different static capacitance requires a different tuning inductor L_t . Moreover, because the tuning inductor L_t is matched to the nominal value of the static capacitance Co at a single resonant frequency, accurate control of the motional branch current I_m is assured only at that frequency, and as frequency shifts down with transducer temperature, accurate control of the motional branch current is compromised.

Embodiments of the generator 1002 do not rely on a tuning inductor L_t to monitor the motional branch current I_m . Instead, the generator 1002 may use the measured value of the static capacitance C_o in between applications of power for a specific ultrasonic surgical device 1004 (along with drive signal voltage and current feedback data) to determine values of the motional branch current I_m on a dynamic and ongoing basis (e.g., in real-time). Such embodiments of the generator 1002 are therefore able to provide virtual tuning to simulate a system that is tuned or resonant with any value of static capacitance C_o at any frequency, and not just at single resonant frequency dictated by a nominal value of the static capacitance C_o .

FIG. 19 is a simplified block diagram of one embodiment of the generator 1002 for proving inductorless tuning as described above, among other benefits. Additional details of the generator 1002 are described in commonly assigned and contemporaneously filed U.S. patent application Ser. No. 12/896,360, now U.S. Patent Application Publication No. 2011/0087256 A1, titled "Surgical Generator For Ultrasonic And Electrosurgical Devices," the disclosure of which is incorporated herein by reference in its entirety. With reference to FIG. 19, the generator 1002 may comprise a patient isolated stage 1052 in communication with a non-isolated stage 1054 via a power transformer 1056. A secondary winding 1058 of the power transformer 1056 is contained in the isolated stage 1052 and may comprise a tapped configuration (e.g., a center-tapped or a non-center-tapped configuration) to define drive signal outputs 1060a, 1060b, 1060c for outputting drive signals to different surgical devices, such as, for example, an ultrasonic surgical device 1004 and an electrosurgical device 1006. In particular, drive signal outputs 1060a, 1060c may output a drive signal (e.g., a 420V RMS drive signal) to an ultrasonic surgical device 1004, and drive signal outputs 1060b, 160c may output a drive signal (e.g., a 100V RMS drive signal) to an electrosurgical device 1006, with output 1060b corresponding to the center tap of the power transformer 1056. The non-isolated stage 1054 may comprise a power amplifier 1062 having an output connected to a primary winding 1064 of the power transformer 1056. In certain embodiments the power amplifier 1062 may be comprise a push-pull amplifier. For example, the non-isolated stage 1054 may further comprise a logic device 1066 for supplying a digital output to a digital-toanalog converter (DAC) 1068, which in turn supplies a corresponding analog signal to an input of the power amplifier 1062. In certain embodiments the logic device 1066 may comprise a programmable gate array (PGA), a field-programmable gate array (FPGA), programmable logic device (PLD), among other logic circuits, for example. The logic device 1066, by virtue of controlling the input of the power

amplifier **1062** via the DAC **1068**, may therefore control any of a number of parameters (e.g., frequency, waveform shape, waveform amplitude) of drive signals appearing at the drive signal outputs **1060a**, **1060b**, **1060c**. In certain embodiments and as discussed below, the logic device **1066**, in conjunction with a processor (e.g., a digital signal processor discussed below), may implement a number of digital signal processing (DSP)-based and/or other control algorithms to control parameters of the drive signals output by the generator **1002**.

Power may be supplied to a power rail of the power amplifier 1062 by a switch-mode regulator 1070. In certain embodiments the switch-mode regulator 1070 may comprise an adjustable buck regulator, for example. The non-isolated stage 1054 may further comprise a first processor 1074, 15 which in one embodiment may comprise a DSP processor such as an Analog Devices ADSP-21469 SHARC DSP, available from Analog Devices, Norwood, Mass., for example, although in various embodiments any suitable processor may be employed. In certain embodiments the 20 processor 1074 may control operation of the switch-mode power converter 1070 responsive to voltage feedback data received from the power amplifier 1062 by the DSP processor 1074 via an analog-to-digital converter (ADC) 1076. In one embodiment, for example, the DSP processor 1074 may 25 receive as input, via the ADC 1076, the waveform envelope of a signal (e.g., an RF signal) being amplified by the power amplifier 1062. The DSP processor 1074 may then control the switch-mode regulator 1070 (e.g., via a pulse-width modulated (PWM) output) such that the rail voltage supplied 30 to the power amplifier 1062 tracks the waveform envelope of the amplified signal. By dynamically modulating the rail voltage of the power amplifier 1062 based on the waveform envelope, the efficiency of the power amplifier 1062 may be significantly improved relative to a fixed rail voltage ampli- 35

In certain embodiments, the logic device 1066, in conjunction with the DSP processor 1074, may implement a direct digital synthesizer (DDS) control scheme to control the waveform shape, frequency and/or amplitude of drive 40 signals output by the generator 1002. In one embodiment, for example, the logic device 1066 may implement a DDS control algorithm by recalling waveform samples stored in a dynamically-updated look-up table (LUT), such as a RAM LUT, which may be embedded in an FPGA. This control 45 algorithm is particularly useful for ultrasonic applications in which an ultrasonic transducer, such as the ultrasonic transducer 1014, may be driven by a clean sinusoidal current at its resonant frequency. Because other frequencies may excite parasitic resonances, minimizing or reducing the total 50 distortion of the motional branch current may correspondingly minimize or reduce undesirable resonance effects. Because the waveform shape of a drive signal output by the generator 1002 is impacted by various sources of distortion present in the output drive circuit (e.g., the power trans- 55 former 1056, the power amplifier 1062), voltage and current feedback data based on the drive signal may be input into an algorithm, such as an error control algorithm implemented by the DSP processor 1074, which compensates for distortion by suitably pre-distorting or modifying the waveform 60 samples stored in the LUT on a dynamic, ongoing basis (e.g., in real-time). In one embodiment, the amount or degree of pre-distortion applied to the LUT samples may be based on the error between a computed motional branch current and a desired current waveform shape, with the error 65 being determined on a sample-by-sample basis. In this way, the pre-distorted LUT samples, when processed through the

drive circuit, may result in a motional branch drive signal having the desired waveform shape (e.g., sinusoidal) for optimally driving the ultrasonic transducer. In such embodiments, the LUT waveform samples will therefore not represent the desired waveform shape of the drive signal, but rather the waveform shape that is required to ultimately produce the desired waveform shape of the motional branch drive signal when distortion effects are taken into account.

34

The non-isolated stage 1054 may further comprise an 10 ADC 1078 and an ADC 1080 coupled to the output of the power transformer 1056 via respective isolation transformers 1082, 1084 for respectively sampling the voltage and current of drive signals output by the generator 1002. In certain embodiments, the ADCs 1078, 1080 may be configured to sample at high speeds (e.g., 80 MSPS) to enable oversampling of the drive signals. In one embodiment, for example, the sampling speed of the ADCs 1078, 1080 may enable approximately 200x (depending on frequency) oversampling of the drive signals. In certain embodiments, the sampling operations of the ADC 1078, 1080 may be performed by a singe ADC receiving input voltage and current signals via a two-way multiplexer. The use of high-speed sampling in embodiments of the generator 1002 may enable, among other things, calculation of the complex current flowing through the motional branch (which may be used in certain embodiments to implement DDS-based waveform shape control described above), accurate digital filtering of the sampled signals, and calculation of real power consumption with a high degree of precision. Voltage and current feedback data output by the ADCs 1078, 1080 may be received and processed (e.g., FIFO buffering, multiplexing) by the logic device 1066 and stored in data memory for subsequent retrieval by, for example, the DSP processor 1074. As noted above, voltage and current feedback data may be used as input to an algorithm for pre-distorting or modifying LUT waveform samples on a dynamic and ongoing basis. In certain embodiments, this may require each stored voltage and current feedback data pair to be indexed based on, or otherwise associated with, a corresponding LUT sample that was output by the logic device 1066 when the voltage and current feedback data pair was acquired. Synchronization of the LUT samples and the voltage and current feedback data in this manner contributes to the correct timing and stability of the pre-distortion algorithm.

In certain embodiments, the voltage and current feedback data may be used to control the frequency and/or amplitude (e.g., current amplitude) of the drive signals. In one embodiment, for example, voltage and current feedback data may be used to determine impedance phase. The frequency of the drive signal may then be controlled to minimize or reduce the difference between the determined impedance phase and an impedance phase setpoint (e.g., 0°), thereby minimizing or reducing the effects of harmonic distortion and correspondingly enhancing impedance phase measurement accuracy. The determination of phase impedance and a frequency control signal may be implemented in the DSP processor 1074, for example, with the frequency control signal being supplied as input to a DDS control algorithm implemented by the logic device 1066.

In another embodiment, for example, the current feedback data may be monitored in order to maintain the current amplitude of the drive signal at a current amplitude setpoint. The current amplitude setpoint may be specified directly or determined indirectly based on specified voltage amplitude and power setpoints. In certain embodiments, control of the current amplitude may be implemented by control algorithm, such as, for example, a PID control algorithm, in the

processor **1074**. Variables controlled by the control algorithm to suitably control the current amplitude of the drive signal may include, for example, the scaling of the LUT waveform samples stored in the logic device **1066** and/or the full-scale output voltage of the DAC **1068** (which supplies the input to the power amplifier **1062**) via a DAC **1086**.

The non-isolated stage 1054 may further comprise a second processor 1090 for providing, among other things user interface (UI) functionality. In one embodiment, the UI processor 1090 may comprise an Atmel AT91SAM9263 processor having an ARM 926EJ-S core, available from Atmel Corporation, San Jose, Calif., for example. Examples of UI functionality supported by the UI processor 1090 may include audible and visual user feedback, communication with peripheral devices (e.g., via a Universal Serial Bus (USB) interface), communication with the footswitch 1020, communication with an input device 1009 (e.g., a touch screen display) and communication with an output device 1047 (e.g., a speaker). The UI processor 1090 may commu- 20 nicate with the processor 1074 and the logic device 1066 (e.g., via serial peripheral interface (SPI) buses). Although the UI processor 1090 may primarily support UI functionality, it may also coordinate with the DSP processor 1074 to implement hazard mitigation in certain embodiments. For 25 example, the UI processor 1090 may be programmed to monitor various aspects of user input and/or other inputs (e.g., touch screen inputs, footswitch 1020 inputs (FIG. 17), temperature sensor inputs) and may disable the drive output of the generator 1002 when an erroneous condition is 30 detected.

In certain embodiments, both the DSP processor 1074 and the UI processor 1090, for example, may determine and monitor the operating state of the generator 1002. For the DSP processor 1074, the operating state of the generator 35 1002 may dictate, for example, which control and/or diagnostic processes are implemented by the DSP processor 1074. For the UI processor 1090, the operating state of the generator 1002 may dictate, for example, which elements of a user interface (e.g., display screens, sounds) are presented 40 to a user. The respective DSP and UI processors 1074, 1090 may independently maintain the current operating state of the generator 1002 and recognize and evaluate possible transitions out of the current operating state. The DSP processor 1074 may function as the master in this relation- 45 ship and determine when transitions between operating states are to occur. The UI processor 1090 may be aware of valid transitions between operating states and may confirm if a particular transition is appropriate. For example, when the DSP processor 1074 instructs the UI processor 1090 to 50 transition to a specific state, the UI processor 1090 may verify that requested transition is valid. In the event that a requested transition between states is determined to be invalid by the UI processor 1090, the UI processor 1090 may cause the generator 1002 to enter a failure mode.

The non-isolated stage 1054 may further comprise a controller 1096 for monitoring input devices 1045 (e.g., a capacitive touch sensor used for turning the generator 1002 on and off, a capacitive touch screen). In certain embodiments, the controller 1096 may comprise at least one processor and/or other controller device in communication with the UI processor 1090. In one embodiment, for example, the controller 1096 may comprise a processor (e.g., a Mega168 8-bit controller available from Atmel) configured to monitor user input provided via one or more capacitive touch sensors. In one embodiment, the controller 1096 may comprise a touch screen controller (e.g., a QT5480 touch screen

36

controller available from Atmel) to control and manage the acquisition of touch data from a capacitive touch screen.

In certain embodiments, when the generator 1002 is in a "power off" state, the controller 1096 may continue to receive operating power (e.g., via a line from a power supply of the generator 1002, such as the power supply 2011 discussed below). In this way, the controller 196 may continue to monitor an input device 1045 (e.g., a capacitive touch sensor located on a front panel of the generator 1002) for turning the generator 1002 on and off. When the generator 1002 is in the power off state, the controller 1096 may wake the power supply (e.g., enable operation of one or more DC/DC voltage converters 2013 of the power supply 2011) if activation of the "on/off" input device 1045 by a user is detected. The controller 1096 may therefore initiate a sequence for transitioning the generator 1002 to a "power on" state. Conversely, the controller 1096 may initiate a sequence for transitioning the generator 1002 to the power off state if activation of the "on/off" input device 1045 is detected when the generator 1002 is in the power on state. In certain embodiments, for example, the controller 1096 may report activation of the "on/off" input device 1045 to the processor 1090, which in turn implements the necessary process sequence for transitioning the generator 1002 to the power off state. In such embodiments, the controller 196 may have no independent ability for causing the removal of power from the generator 1002 after its power on state has been established.

In certain embodiments, the controller 1096 may cause the generator 1002 to provide audible or other sensory feedback for alerting the user that a power on or power off sequence has been initiated. Such an alert may be provided at the beginning of a power on or power off sequence and prior to the commencement of other processes associated with the sequence.

In certain embodiments, the isolated stage 1052 may comprise an instrument interface circuit 1098 to, for example, provide a communication interface between a control circuit of a surgical device (e.g., a control circuit comprising handpiece switches) and components of the non-isolated stage 1054, such as, for example, the programmable logic device 1066, the DSP processor 1074 and/or the UI processor 190. The instrument interface circuit 1098 may exchange information with components of the non-isolated stage 1054 via a communication link that maintains a suitable degree of electrical isolation between the stages 1052, 1054, such as, for example, an infrared (IR)-based communication link. Power may be supplied to the instrument interface circuit 1098 using, for example, a lowdropout voltage regulator powered by an isolation transformer driven from the non-isolated stage 1054.

In one embodiment, the instrument interface circuit 198 may comprise a logic device 2000 (e.g., logic circuit, programmable logic circuit, PGA, FPGA, PLD) in commu-55 nication with a signal conditioning circuit 2002. The signal conditioning circuit 2002 may be configured to receive a periodic signal from the logic circuit 2000 (e.g., a 2 kHz square wave) to generate a bipolar interrogation signal having an identical frequency. The interrogation signal may be generated, for example, using a bipolar current source fed by a differential amplifier. The interrogation signal may be communicated to a surgical device control circuit (e.g., by using a conductive pair in a cable that connects the generator 102 to the surgical device) and monitored to determine a state or configuration of the control circuit. The control circuit may comprise a number of switches, resistors and/or diodes to modify one or more characteristics (e.g., ampli-

tude, rectification) of the interrogation signal such that a state or configuration of the control circuit is uniquely discernable based on the one or more characteristics. In one embodiment, for example, the signal conditioning circuit 2002 may comprises an ADC for generating samples of a 5 voltage signal appearing across inputs of the control circuit resulting from passage of interrogation signal therethrough. The logic device 2000 (or a component of the non-isolated stage 1054) may then determine the state or configuration of the control circuit based on the ADC samples.

In one embodiment, the instrument interface circuit 1098 may comprise a first data circuit interface 2004 to enable information exchange between the logic circuit 2000 (or other element of the instrument interface circuit 1098) and a first data circuit disposed in or otherwise associated with 15 a surgical device. In certain embodiments, for example, a first data circuit 2006 may be disposed in a cable integrally attached to a surgical device handpiece, or in an adaptor for interfacing a specific surgical device type or model with the generator 1002. In certain embodiments, the first data circuit 20 may comprise a non-volatile storage device, such as an electrically erasable programmable read-only memory (EE-PROM) device. In certain embodiments and referring again to FIG. 19, the first data circuit interface 2004 may be implemented separately from the logic device 2000 and 25 comprise suitable circuitry (e.g., discrete logic devices, a processor) to enable communication between the programmable logic device 2000 and the first data circuit. In other embodiments, the first data circuit interface 2004 may be integral with the logic device 2000.

In certain embodiments, the first data circuit 2006 may store information pertaining to the particular surgical device with which it is associated. Such information may include, for example, a model number, a serial number, a number of operations in which the surgical device has been used, 35 and/or any other type of information. This information may be read by the instrument interface circuit 1098 (e.g., by the logic device 2000), transferred to a component of the non-isolated stage 1054 (e.g., to logic device 1066, DSP processor 1074 and/or UI processor 1090) for presentation 40 to a user via an output device 1047 and/or for controlling a function or operation of the generator 1002. Additionally, any type of information may be communicated to first data circuit 2006 for storage therein via the first data circuit interface 2004 (e.g., using the logic device 2000). Such 45 information may comprise, for example, an updated number of operations in which the surgical device has been used and/or dates and/or times of its usage.

As discussed previously, a surgical instrument may be detachable from a handpiece (e.g., instrument 1024 may be 50 detachable from handpiece 1016) to promote instrument interchangeability and/or disposability. In such cases, conventional generators may be limited in their ability to recognize particular instrument configurations being used and to optimize control and diagnostic processes accord- 55 ingly. The addition of readable data circuits to surgical device instruments to address this issue is problematic from a compatibility standpoint, however. For example, designing a surgical device to remain backwardly compatible with generators that lack the requisite data reading functionality 60 may be impractical due to, for example, differing signal schemes, design complexity, and cost. Embodiments of instruments discussed herein address these concerns by using data circuits that may be implemented in existing surgical instruments economically and with minimal design 65 changes to preserve compatibility of the surgical devices with current generator platforms.

38

Additionally, embodiments of the generator 1002 may enable communication with instrument-based data circuits. For example, the generator 1002 may be configured to communicate with a second data circuit contained in an instrument (e.g., instrument 1024 or 1034) of a surgical device. The instrument interface circuit 1098 may comprise a second data circuit interface 2010 to enable this communication. In one embodiment, the second data circuit interface 2010 may comprise a tri-state digital interface, although other interfaces may also be used. In certain embodiments, the second data circuit may generally be any circuit for transmitting and/or receiving data. In one embodiment, for example, the second data circuit may store information pertaining to the particular surgical instrument with which it is associated. Such information may include, for example, a model number, a serial number, a number of operations in which the surgical instrument has been used, and/or any other type of information. Additionally or alternatively, any type of information may be communicated to second data circuit for storage therein via the second data circuit interface 2010 (e.g., using the logic device 2000). Such information may comprise, for example, an updated number of operations in which the instrument has been used and/or dates and/or times of its usage. In certain embodiments, the second data circuit may transmit data acquired by one or more sensors (e.g., an instrument-based temperature sensor). In certain embodiments, the second data circuit may receive data from the generator 1002 and provide an indication to a user (e.g., an LED indication or other visible indication) based on the received data.

In certain embodiments, the second data circuit and the second data circuit interface 2010 may be configured such that communication between the logic device 2000 and the second data circuit can be effected without the need to provide additional conductors for this purpose (e.g., dedicated conductors of a cable connecting a handpiece to the generator 1002). In one embodiment, for example, information may be communicated to and from the second data circuit using a 1-wire bus communication scheme implemented on existing cabling, such as one of the conductors used transmit interrogation signals from the signal conditioning circuit 2002 to a control circuit in a handpiece. In this way, design changes or modifications to the surgical device that might otherwise be necessary are minimized or reduced. Moreover, because different types of communications implemented over a common physical channel can be frequency-band separated, the presence of a second data circuit may be "invisible" to generators that do not have the requisite data reading functionality, thus enabling backward compatibility of the surgical device instrument.

In certain embodiments, the isolated stage 1052 may comprise at least one blocking capacitor 2096-1 connected to the drive signal output 1060b to prevent passage of DC current to a patient. A single blocking capacitor may be required to comply with medical regulations or standards, for example. While failure in single-capacitor designs is relatively uncommon, such failure may nonetheless have negative consequences. In one embodiment, a second blocking capacitor 2096-2 may be provided in series with the blocking capacitor 2096-1, with current leakage from a point between the blocking capacitors 2096-1, 2096-2 being monitored by, for example, an ADC 2098 for sampling a voltage induced by leakage current. The samples may be received by the logic circuit 2000, for example. Based changes in the leakage current (as indicated by the voltage samples in the embodiment of FIG. 19), the generator 1002 may determine when at least one of the blocking capacitors

2096-1, 2096-2 has failed. Accordingly, the embodiment of FIG. 19 provides a benefit over single-capacitor designs having a single point of failure.

In certain embodiments, the non-isolated stage 1054 may comprise a power supply 2011 for outputting DC power at 5 a suitable voltage and current. The power supply may comprise, for example, a 400 W power supply for outputting a 48 VDC system voltage. The power supply 2011 may further comprise one or more DC/DC voltage converters 2013 for receiving the output of the power supply to 10 generate DC outputs at the voltages and currents required by the various components of the generator 1002. As discussed above in connection with the controller 1096, one or more of the DC/DC voltage converters 2013 may receive an input input device 1045 by a user is detected by the controller 1096 to enable operation of, or wake, the DC/DC voltage converters 2013.

Having described operational details of various embodiments of the surgical systems 19 (FIG. 1), 190 (FIG. 10), 20 1000 (FIG. 16) operations for the above surgical systems 19, 190, 1000 may be further described generally in terms of a process for cutting and coagulating tissue employing a surgical instrument comprising an input device 406, 1009 and the generator 1002. Although a particular process is 25 described in connection with the operational details, it can be appreciated that the process merely provides an example of how the general functionality described herein can be implemented by any one of the surgical systems 19, 190, 1000. Further, the given process does not necessarily have to 30 be executed in the order presented herein unless otherwise indicated. As previously discussed, any one the input devices 406, 1009 may be employed to program the output (e.g., impedance, current, voltage, frequency) of the surgical devices 100 (FIG. 1), 120 (FIG. 10), 1002 (FIG. 16), 1006 35

FIGS. 20-22 illustrate various embodiments of logic flow diagrams of 1200, 1300, 1400 related to a tissue algorithm for detecting when rapid heating of the ultrasonic end effector 1026 blade occurs and provide the opportunity for 40 responding via the output indicator 412 (FIGS. 9, 11) and/or the output device 1047 (FIG. 16) (e.g., annunciation, modulation of power output and/or display of content). According to the present disclosure, when multiple reference numbers are used to described an element such as "ultrasonic surgical 45 instrument 100, 120, 1004," it should be understood to reference any one of the elements, such as, for example, "ultrasonic surgical instrument 100," or "ultrasonic surgical instrument 120," or "ultrasonic surgical instrument 1004."

In various embodiments, feedback may be provided by 50 the output indicator 412 shown in FIGS. 9 and 11 or the output device 1047 in FIG. 16. These feedback devices (e.g., output indicator 412, output device 1047) are particularly useful in applications where the tissue being manipulated by the end effector 81 (FIG. 1), 810 (FIG. 10), 1026 (FIG. 16) 55 is out of the user's field of view and the user cannot see when a change of state occurs in the tissue. The feedback device communicates to the user that a change in tissue state has occurred as determined in accordance with the operations described with respect to the logic flow diagrams 700, 800, 60 900, 1200, 1300, 1400 as they relate to corresponding tissue algorithms. The feedback devices may be configured to provide various types of feedback according to the current state or condition of the tissue. A change of state of the tissue may be determined based on transducer and tissue measure- 65 ments based on voltage, current, and frequency measurements in accordance with the operations described with

40

respect to the logic flow diagrams 700, 800, 900 described above in connection with FIGS. 15A-C and the logic flow diagrams 1200, 1300, 1400 described below in connection with FIGS. 20-22.

In one embodiment, the logic flow diagrams 1200, 1300, 1400 may be implemented as executable modules (e.g., algorithms) comprising computer readable instructions to be executed by the processor 400 (FIGS. 9, 11, 14) portion of the generator 30, 500 or the generator 1002 (FIGS. 16, 17, 19). In various embodiments, the operations described with respect to the logic flow diagrams 1200, 1300, 1400 may be implemented as one or more than one software component, e.g., program, subroutine, logic; one or more than one hardware components, e.g., processor, DSP, PLD, PGA, from the controller 1096 when activation of the "on/off" 15 FPGA, ASIC, circuit, logic circuit, register; and/or combinations of software and hardware. In one embodiment, the executable instructions to perform the operations described by the logic flow diagrams 1200, 1300, 1400 may be stored in memory. When executed, the instructions cause the processor 400, the DSP processor 1074 (FIG. 19) or logic device 1066 (FIG. 19) to determine a change in tissue state in accordance with the operations described in the logic flow diagrams 1200, 1300, and 1400 and provide feedback to the user by way of the output indicator 412 (FIGS. 9, 11) or output indicator 1047 (FIGS. 16, 17). In accordance with such executable instructions, the processor 400, DSP processor 1074, and/or logic device 1066 monitors and evaluates the voltage, current, and/or frequency signal samples available from the generator 30, 500, 1002 and according to the evaluation of such signal samples determines whether a change in tissue state has occurred. As further described below, a change in tissue state may be determined based on the type of ultrasonic instrument and the power level that the instrument is energized at. In response to the feedback, the operational mode of any one of the ultrasonic surgical instruments 100, 120, 1004 may be controlled by the user or may be automatically or semi-automatically controlled.

A brief summary of a tissue algorithm represented by way of the logic flow diagrams 1200, 1300, 1400 will now be described in connection with any one of the ultrasonic surgical instruments 100, 120, 1004 driven by a corresponding generator 30 (FIG. 1), 500 (FIG. 10), 1002 (FIG. 17). In one aspect, the tissue algorithm detects when the temperature of the blade portion (and therefore resonance) of the ultrasonic end effector 81 (FIG. 1), 810 (FIG. 10), 1026 (FIG. 17) is changing rapidly (of most interest is an increasing change). For a clamping or shears type instrument, this change may correspond to a common clinical scenario, among others, when minimal-to-no tissue, tissue debris or fluid is adjacent the blade and the blade is activated against the clamp arm, clamp pad or other suitable tissue biasing member. For non-clamping applications where an instrument with or without a clamp arm and associated mechanisms is used to effect tissue, this change corresponds to conditions where rapid heating occurs such as when the blade is activated against bone or other hard materials or when excessive force is used to couple the blade to tissue targets. These are illustrative cases; one can imagine other clinical scenarios where rapid blade heating may occur and such a tissue algorithm as described here is of benefit.

The tissue algorithm represented by the logic flow diagrams 1200, 1300, 1400 may be employed in conjunction with any of the generators 30, 500, 1002 described herein, and other suitable generators such as the GEN 04, GEN 11 generators sold by Ethicon Endo-Surgery, Inc. of Cincinnati, Ohio, and related devices, systems, that may leverage the algorithm or technology disclosed herein. Accordingly, in

the description of the tissue algorithm in conjunction with the flow diagrams 1200, 1300, 1400 reference is made to the generators 30, 500, 1002 described in connection with corresponding FIGS. 1-9, 10-13, and 16-19.

Accordingly, with reference now to FIGS. 1-14, the 5 frequency of the blade/handpiece resonant system of any one of the ultrasonic surgical instruments 100, 120, 1004 is dependent on temperature. When, for example, an ultrasonic shear type end effector cuts through a clamped piece of tissue, the blade heats and thins the tissue until ultimately it cuts through the tissue. At this point, the blade resides against the tissue pad and, if clamp pressure remains between the two, the blade and pad interface will draw power via the mechanical or vibratory motion of the blade relative to the pad. The power "deposited" at the interface will be largely conducted into the blade tip as the pad material is quite insulative. It is this thermal energy that alters the stiffness of the blade tip and the system resonance will change accordingly due to these localized (to the tip) 20 conditions. The generator 30, 500, 1002 tracks this resonance. The shears example illustrates one scenario for which the algorithm is of use. Additional scenarios are back-cutting with a shears device with the clamp arm closed, blade cutting against tough or hard tissue, or any scenario in which 25 knowing the thermal condition of the blade end-effector is desired. A tissue algorithm that applies logic to this tracking of resonance and, therefore, blade tip thermal condition is now described in connection with logic flow diagrams 1200, 1300, 1400 in FIGS. 20-22.

In addition, the description of the tissue algorithm described in connection with logic flow diagrams 1200, 1300, 1400 will be accompanied with illustrative examples via data obtained using any one of the ultrasonic surgical instruments 100, 120, 1004 comprising a corresponding generator 30, 500, 1002 described herein.

The tissue algorithm described in connection with logic flow diagrams 1200, 1300, 1400 relies on the monitoring of electrical drive signals, especially those correlating to the 40 resonant frequency of the drive signal. The algorithm monitors the resonant frequency and its change with time (i.e., the first derivative of frequency with respect to time). Throughout this disclosure, this change in frequency with time is referred to as frequency slope. Frequency slope is calculated locally (from a time perspective) by calculating the change in frequency of adjacent (or relatively near) data points and dividing by the corresponding change in time. Because of signal transients, averaging or any of a multitude of applicable filtering or smoothing techniques (such that trends are 50 more easily discernable and prevents turning on/off condition sets rapidly) may be employed. The data plots shown in FIGS. 62, 63, 64 illustrate the calculation of frequency slope and the use of averaging techniques (e.g., exponentially weighted moving average or EWMA) to obtain frequency 55 slope values useful for control/monitoring. Other descriptions of frequency slope include, without limitation, "first derivative of frequency" and "frequency change with respect to time."

FIG. 20 is a logic flow diagram 1200 of a tissue algorithm 60 that may be implemented in one embodiment of a generator 30, 500, 1002. At a general level, the tissue algorithm described in connection with logic flow diagram 1200 assesses the electrical signals in real time against a set of logic conditions that correlate to events of interest (e.g., 65 blade of ultrasonic instrument is rapidly heating). Accordingly, the generator 30, 500, 1002 determines when a set of

42

logic conditions occur and triggers a corresponding set of responses. The terms "Condition Set" and "Response set" are defined follows:

(1) Condition Set—a set of logic conditions that electrical signals are monitored against in real time.

(2) Response Set—one or more responses of the generator 30, 500, 1002 system to a Condition Set having been met. At 1202, the generator 30, 500, 1002 is placed in an ultrasonic drive mode in a ready state.

At 1204, the generator 30, 500, 1002 is activated at a predetermined power level N. When the user activates the surgical system 19, 190, 1000, the corresponding generator 30, 500, 1002 responds by seeking the surgical system 19, 190, 1000 resonance and then ramping the output to the end effectors 81, 810, 1026 to the targeted levels for the commanded power level.

At 1206, the tissue algorithm determines whether parameters associated with the tissue algorithm are in use by determining when at least one Condition Sets/Response Sets flag is enabled. When no such flags are enabled, the algorithm proceeds along "NO" path where at 1208 the surgical system 19, 190, 1000 is operated in normal ultrasonic mode and at 1210, the corresponding generator 30, 500, 1002 is deactivated when the tissue procedure is completed.

When at least one flag for setting Condition Sets/Response Sets is enabled, the algorithm proceeds along "YES" path and the generator 30, 500, 1002 utilizes the tissue algorithm 1300 signal evaluation after resetting a Timer X and Timer X latch. In one embodiment, the at least one flag for setting Condition Sets/Response Sets may be stored in an EEPROM image of an instrument 100, 120, 1004 attached to the respective generator 30, 500, 1002. The EEPROM flags for setting the Condition Sets/Response Sets to an enabled state are contained in TABLE 1.

TABLE 1

Fun	Value to Enable	Value for "Normal"	
Name	Description	Function	Drive
Condition Set : Pulsing flag	If Condition Set 1 is met and this function is enabled, the generator pulses power per the pulsing parameters as a part of Response Set 1	1	0
Condition Set 1 LCD display flag	If Condition Set 1 is met and this function is enabled, the generator LCD displays an assigned graphics screen as part of Response Set 1	1	0
Condition Set 1 Audio flag	If Condition Set 1 is met and this function is enabled, the generator plays an assigned audio file as part of Response Set 1	1	0
Condition Set 2 Pulsing flag	If Condition Set 2 is met and this function is enabled, the generator pulses power per the pulsing parameters as a part of Response Set 2	1	0
Condition Set 2 LCD display flag	If Condition Set 2 is met and this function is enabled, the generator LCD displays an assigned graphics screen as part of Response Set 2	1	0
Condition Set 2 Audio flag	1	1	0

In one embodiment, the tissue algorithm 1300 signal evaluation portion of the logic flow diagram 1200 utilizes

two Condition Sets and each of these two Conditions Sets has a Response Set, which are described in more detail in connection with logic flow diagrams 1300, 1400. The tissue algorithm 1300 logic may be illustrated as follows: when Condition Set 1 is met, Response Set 1 is triggered. Having two condition sets enables a hierarchical response (differentiated responses based upon condition level) and also provides the ability to manage a complicated series of events.

At 1210, responses for Condition Sets that are met are 10 triggered. Loop 1212 is repeated until the Condition Sets are met and the generator 30, 500, 1002 is deactivated at 1214.

The pulsing response is more detailed and requires further explanation than the relatively simple audio and LCD display responses. When a pulsing response is triggered, the 15 generator 30, 500, 1002 drives a pulsed output as defined by the by the following four parameters:

- (1) First Pulse Amplitude (EEPROM parameter, one value for each power level)—the drive amplitude for the first pulse;
- (2) First Pulse Time (EEPROM parameter)—the time over which the first pulse amplitude is driven;
- (3) Second Pulse Amplitude (EEPROM parameter, one value for each power level)—the drive amplitude for the second pulse; and
- (4) Second Pulse Time (EEPROM parameter)—the time over which the second pulse amplitude is driven.

When driving a pulsed output, the generator 30, 500, 1002 drives the first pulse, then the second pulse and then repeats. The pulse amplitude may be expressed in units of: percentage of the commanded power level's output current. The commanded power level may be set by the activation switch (MIN or MAX) and the generator setting when MIN is activated

FIG. 21 is a logic flow diagram 1300 of a signal evaluation tissue algorithm portion of the tissue algorithm shown in FIG. 20 that may be implemented in one embodiment of a generator. The tissue algorithm signal evaluation flow shown in FIG. 21 shows the application of a "time to wait" parameter 1304 and the calculation of a frequency slope 40 (also referred to as local frequency slope because it is a running calculation).

At 1302, the algorithm calculates the time since activation was initiated at 1204 (FIG. 20). This time is expressed as T_{Elapse} , which is T_{sytem} – $T_{PowerOn}$. As previously discussed, 45 when the user activates the surgical system 19, 190, 1000, the corresponding generator 30, 500, 1002 responds by seeking the resonance of the ultrasonic system 100, 120, 1004 and then ramping the output to the corresponding end effectors 81, 810, 1026 to the targeted levels for the commanded power level.

During this time, the associated signal transients can make the application of algorithm logic difficult. The algorithm, therefore, utilizes the "time to wait" parameter 1304 that is stored in the EEPROM image located in a hand piece 55 portion of the ultrasonic surgical instrument 100, 120, 1004. The "time to wait" parameter 1304 (EEPROM parameter) is defined as the time at the beginning of an activation during which the generator 30, 500, 1002 does not apply the tissue algorithm to lessen the influence of resonance seek and drive 60 ramp signal transients on algorithm logic. A typical "time to wait" parameter 1304 value is about 0.050 to 0.600 seconds (50 to 600 msec).

At 1306, T_{Elapse} is compared to the "time to wait" parameter 1304 value. When T_{Elapse} is less than or equal to the 65 "time to wait" parameter 1304 value, the algorithm proceeds along "NO" path to calculate at 1302 a new T_{Elapse} . When

44

 $T_{\it Elapse}$ is greater than the "time to wait" parameter 1304 value, the algorithm proceeds along "YES" path to evaluate the signal.

At 1308, the algorithm performs the Signal Evaluation/ Monitoring function. As previously stated, one aspect of the function algorithm is to monitor frequency slope. In a physical sense, frequency slope correlates to heat flux into or out of the resonant system comprising the blade and the handpiece acoustical subassembly, such as the ultrasonic systems 100, 120, 1004 disclosed herein. The changes in frequency and frequency slope during activation on tissue are dominated by the changing conditions occurring at the end-effector (tissue drying out, separating and blade contacting the clamp arm pad). When the blade is being heated (i.e., heat flux into the blade), the frequency slope is negative. When the blade is being cooled (i.e., heat flux out of the blade), the frequency slope is positive. Accordingly, the algorithm calculates the slope between frequency data points, i.e., incoming frequency data points 1310 (F_t) and previous F, data points 1312. The calculated frequency slope also may be referred to as a local frequency slope because it is a running calculation. The local frequency slope may be referred to as F_{Slope_Freq} , F_r , which is the frequency slope (F_{Slope_Freq}) at the resonance frequency (F_t) . The local 25 frequency slope may be routed to a Condition Set 1, Condition Set 2 1400, for example, for evaluation in accordance with the flow diagram 1400 shown in FIG. 22.

FIG. 22 is a logic flow diagram 1400 for evaluating condition sets for the signal evaluation tissue algorithm shown in FIG. 21 that may be implemented in one embodiment of a generator. The logic flow diagram 1400 evaluates Condition Set X, where X is either 1 or 2, for example.

In accordance with the tissue algorithm, at 1402, the local frequency slope calculated at 1308 (FIG. 21) is compared against a frequency slope threshold parameter 1404 value for Condition Set X at Power Level N. The frequency slope threshold parameters 1404 may be stored in an EEPROM located in the attached instrument 100, 120, 1004, where one EEPROM parameter value is stored for each power level. When the local frequency slope calculated at 1308 drops below the frequency slope threshold parameter 1404 value, a first Response Set may be triggered at 1210 (FIG. 20). When the blade is being heated at a relatively rapid rate, the frequency slope will become more negative and the tissue algorithm identifies this condition by way of the frequency slope dropping below the frequency slope threshold parameter 1404 value. Again, the frequency slope indicates the rate of thermal change or heat flux into or out of the blade.

In accordance with the tissue algorithm, also at 1402, the resonant frequency is compared against a frequency threshold parameter 1406 value for Condition set X. The frequency threshold parameter 1406 value may be stored in an EEPROM located in the attached instrument 100, 120, 1004. When the resonant frequency drops below the threshold frequency parameter 1406 value, a second Response Set may be triggered at 1210 (FIG. 20). As a blade is continually heated, the frequency will continue to drop. A frequency threshold parameter 1406 value is intended to improve algorithm robustness by providing additional information about the thermal condition of the blade (in addition to the more dynamic indicator, the frequency slope). Frequency drop from some known condition such as room temperature gives a good indication of the thermal state of the resonant system relative to these known thermal conditions.

At **1402**, when the frequency slope (F_{Slope_Freq}) is less than the frequency slope threshold parameter **1404** value and the resonant frequency (F_r) is less than the frequency thresh-

old parameter **1406** value, the algorithm proceeds along "YES" path to **1408** to increment a Timer X (where X corresponds to the particular Condition Set being evaluated by the tissue algorithm).

In comparing the electrical signals, e.g., the frequency slope (F_{Slope_Freq}) and the resonant frequency (F_t) , against respective thresholds parameters 1404, 1406, borderline conditions where the signal bounces back-and-forth across the threshold can be taken into consideration as follows. In one aspect, the tissue algorithm employs a "required time before trigger" parameter 1412 value (which also may be stored in the instrument EEPROM) for the particular Condition Set X to account for this consideration. The "required time before trigger" parameter 1412 value is defined as the time required before trigger (EEPROM parameter)—re- 15 quired time for frequency slope and/or frequency to be less than their respective thresholds for a Response Set to be triggered. This is intended to prevent rapid "back and forth" triggering of a response. It may be useful, however, to track non-rapid "back and forth" triggering, which may occur.

Thus, at **1414** the algorithm determines whether the Timer X value is greater than the "required time before trigger" parameter **1412** value for Condition Set X. When the Timer X value is greater than the "required time before trigger" parameter **1412** value, the algorithm proceeds along "YES" 25 path to set a latch for Condition Set X at **1416**. Output **1418** indicates that the Condition Set X is met. When the Timer X value is less than or equal to the "required time before trigger" parameter **1412** value, the algorithm proceeds along "NO" path to indicate at output **1420** that the Condition Set X is not met.

At **1402**, when either the frequency slope (F_{Slope_Freq}) greater than or equal to the frequency slope threshold parameter **1404** value or the resonant frequency (F_t) is greater than then or equal to the frequency threshold parameter **1406** value, the algorithm proceeds along "NO" path to reset the Timer X at **1410** (where X corresponds to the particular Condition Set being evaluated by the tissue algorithm).

For additional robustness, two latching parameters are 40 employed by the algorithm. Without the use of latching, the algorithm is configured to end a response set when either (a) the system is deactivated or (b) when the signal or signals are no longer below their respective thresholds. Two latching parameters can be utilized. They are a "minimum latch 45 time" parameter 1422 and a "cross-back frequency slope threshold" parameter 1424. These latch parameters 1422, 1424 are important for robustness around: (a) clamp arm pad surfaces that become more lubricious with elevated temperature and (b) pulsing output where signal transients at the 50 pulse transitions are expected.

The minimum latch time parameter **1422** (EEPROM parameter) can be defined as the minimum amount of time for response(s) to a Condition Set X to be triggered. Considerations for minimum latch time include: (a) the length of 55 time required to play a triggered audible response (e.g., in one embodiment, a "pre-alert" WAV audio file may be about 0.5 seconds long), (b) the typical (about 0.5 to 1.0 sec) or extreme (about 1.5 to 2.0 sec) user response times for an event, or (c) the typical tissue re-grasp time for a multi-cut (known as "marching") application (about 1.1-2.0 seconds with a mean of about 1.6 seconds).

The cross-back frequency slope threshold parameter **1424** (EEPROM parameter) can be defined as the frequency slope threshold above which a triggered response stops (i.e., is no 6 longer triggered). This provides for a higher "cross-back-over" frequency slope threshold that is tasked with distin-

46

guishing between activating against the pad and jaw opened (versus distinguishing between activating on tissue and activating on the pad).

In accordance with the tissue algorithm portion represented by logic flow diagram 1400, after the Timer X is reset at 1410, at 1426, the tissue algorithm determines whether either the latch for Condition Set X or the Cross-back Frequency Slope Latch is set. When both latches are not set, the algorithm proceeds along "NO" to indicate at output 1420 that the Condition Set X is not met. When either one of the latches is set, the algorithm proceeds along "YES" path to 1428.

At 1428, the algorithm determines whether the Latched Time for Condition Set X is greater than the minimum latch time parameter 1422 value for Condition Set X and whether the frequency slope (F_{Slope_Freq}) is greater than the crossback frequency slope threshold parameter 1424 value the algorithm proceeds along "YES" path to reset the Latch for Timer X at 1430 and to indicate at output 1420 that the Condition Set X is not met. When the Latched Time for Condition Set X is less than or equal to the minimum latch time parameter 1422 value for Condition Set X and the frequency slope (F_{Slope_Freq}) less than or equal to the crossback frequency slope threshold parameter 1424 value the algorithm proceeds along "NO" path to indicate at output 1432 that the Condition Set X is met.

As shown in FIGS. 21 and 22, there are two identical Condition Sets 1 and 2 from a flow perspective. These Conditions Sets 1 and 2 have replicate sets of parameters as contained in TABLE 2. Algorithm parameters that are shared by the Condition Sets 1 and 2 are contained in TABLE 3.

TABLE 2 contains a summary of the replicated algorithm EEPROM parameters for each of the Condition Sets and the number parameters per Condition Set.

TABLE 2

10	Algorithm EEPROM Parameter Summary, Replicated Parameters for Each of the Condition Sets		
ю	Replicated Parameters for Each of the Condition Sets	# of Parameters per Condition Set	
15	Required time before triggered Minimum latch time Frequency Slope Thresholds (one for each power level)	1 1 5	
	Frequency Threshold	1	

TABLE 3 contains a summary of the shared algorithm EEPROM parameters for each of the Condition Sets (not replicated) and the number parameters.

TABLE 3

5	Algorithm EEPROM Parameter Summary, Common Parameters to all Condition Sets	
	Parameters Shared by Condition Sets (not replicated)	# of Parameters
0	Time to wait Cross-back Frequency Slope Threshold First Pulse Amplitudes (one for each power	1 1 5
	level) First Pulse Time Second Pulse Amplitudes (one for each power	1 5
5	level) Second Pulse Time	1

For clarity of disclosure, the tissue algorithm described in connection with the logic flow diagrams 1200, 1300, 1400 shown in respective FIGS. 20-22 will now be described in terms of four examples. The basic application of the tissue algorithm includes the monitoring of frequency slope, reso- 5 nant frequency, or both against their respective thresholds. Accordingly, a first example includes the monitoring of frequency slope against its respective threshold and is illustrated in FIGS. 23-28. A second example includes the monitoring of resonant frequency against its respective threshold and is illustrated in FIGS. 29-31. A third example includes the monitoring both the frequency slope and the resonant frequency, against their respective threshold and is illustrated in FIGS. 32-34. Finally, a fourth example also includes the monitoring both of the frequency slope and the $\,^{15}$ resonant frequency, against their respective threshold.

Example 1: Monitoring Frequency Slope Against Respective Threshold

A first example case includes the monitoring of frequency slope against a respective threshold is illustrated with reference to FIGS. 23-28. The first example, and most simple, is the example of triggering a Response Set based only on the frequency slope. TABLE 4 contains representative ²⁵ parameters for this objective for surgical instruments such as any one of the surgical instruments 19, 190, 1000 disclosed herein comprising a corresponding ultrasonic instrument such as ultrasonic instruments 100, 120, 1004 disclosed herein.

TABLE 4

Representative Parameters for Triggering an Audio Indication by Frequency Slope Threshold Only (one Condition Set utilized)

Parameter	Value*
Condition Set 1 Pulsing flag	0
Condition Set 1 LCD display flag	0
Condition Set 1 Audio flag	1
Required time before triggered, Condition Set 1	50 msec
Minimum latch time, Condition Set 1	0 msec*
Frequency Slope Thresholds (one for each	level 5: -0.060 kHz/sec
power level), Condition Set 1	level 4: -0.053 kHz/sec
	level 3: -0.045 kHz/sec
	level 2: -0.038 kHz/sec
	level 1: -0.030 kHz/sec
Frequency Threshold, Condition Set 1	56,000 Hz*
Time to wait	100 msec
Cross-back Frequency Slope Threshold	-0.020 kHz/sec
First Pulse Amplitudes (one for each power level)	N/A
First Pulse Time	N/A
Second Pulse Amplitudes (one for each power	N/A
level) Second Pulse Time	N/A

^{*}These parameter values are set to an appropriate extreme such that they do not effectively take part in the logic flow (e.g., set to always be "true").

FIGS. 23-25 show signal data produced by a generator 55 with the representative/illustrative parameters contained in TABLE 4. The generator may be similar to any one of the generators 30, 500, 1002 disclosed herein, which forms a portion of the respective surgical systems 19, 190, 1000 operating in ultrasonic mode (e.g., ultrasonic system 19, 60 190, 1000) applied on tissue in accordance with the present disclosure.

The use of only the frequency slope to trigger a Response Set may be further demonstrated in the "burn-in" scenario or test. FIGS. **26-28** show signal data produced by a generator 65 with the representative/illustrative parameters contained in TABLE 4 during a "burn-in" scenario or test. A "burn-in"

48

simulates the use case where a user activates a shears type ultrasonic surgical instrument without intervening tissue (e.g., back-cutting with jaws closed). This test also may be useful for quantifying device characteristics, such as, for example, "response time."

The response time of an ultrasonic instrument may be defined as the time required for an ultrasonic system (instrument, handpiece, and generator with tissue algorithm) to respond to the clamp arm pad coming into contact with the blade. The ultrasonic system is usually initially activated "in-air" (i.e., unloaded), the clamp arm is closed against the blade and held for a period of time and then the clamp arm is opened and the ultrasonic system is deactivated. The response time is the time between the point at which the quiescent power (power in-air) begins to change due to the clamp arm pad initiating contact with the blade and the point at which the Response Set is triggered. This is also a test that enables quantification of the rate of cooling—the higher the rate of cooling (assuming similar convective boundary conditions) the more thermal energy or residual heat there is in the blade. The rate of cooling is proportional to the frequency slope (to reinforce: a positive frequency slope value correlates to the instantaneous heat flux out of the blade). As will be detailed later, the rate of cooling also may be monitored and used for control purposes so that, for example, if the rate of cooling as defined by a positive frequency slope is greater than a threshold value, one knows that the blade is "carrying" a large amount of thermal energy and is dissipating it rapidly.

slope versus time of a waveform **1500** of frequency slope versus time of a waveform **1502** of one embodiment of a generator during a typical tissue cut. Frequency slope (kHz/sec) is shown along the vertical axis and time (Sec) is shown along the horizontal axis for a typical tissue cut using any one of the ultrasonic systems comprising corresponding ultrasonic surgical instruments set on power level 5. The frequency slope threshold **1504** used for this application was -0.06 kHz/sec and is shown by the horizontal dashed line. The vertical dash-dot line **1506** shows the time (2.32 seconds) that the tissue began to separate, and the vertical dashed line **1508** shows the time (2.55 seconds) at which the ultrasonic system triggered a Response Set (in this case, per TABLE 4, an audible sound only).

FIG. 23A is a graphical representation of a second time derivative of frequency (slope of frequency slope) versus time waveform 1503 (shown in dashed line) superimposed over the waveform 1502 shown in FIG. 23 of one embodiment of a generator during a typical tissue cut.

FIG. 24 is a graphical representation 1510 of frequency versus time waveform 1512 of one embodiment of a generator during a typical tissue cut as it relates to the graphical representation 1500 shown in FIG. 23. Resonant frequency (kHz) is shown along the vertical axis and time (Sec) is shown along the horizontal axis for the typical tissue cut using any one of the ultrasonic systems set on power level 5. The vertical dash-dot line 1506 shows the time (2.32 seconds) that the tissue began to separate, and the vertical dashed line 1508 shows the time (2.55 seconds) at which the ultrasonic system triggered a Response Set (in this case, an audible sound only).

FIG. 25 is a graphical representation 1514 of power consumption versus time waveform 1514 of one embodiment of a generator during a typical tissue cut as it relates to the graphical representation 1500 shown in FIG. 23. Power (W) is shown along the vertical axis and time (Sec) is shown along the horizontal axis for the typical tissue cut using any one of the ultrasonic systems set on power level 5. The

vertical dash-dot line **1506** shows the time (2.32 seconds) that the tissue began to separate, and the vertical dashed line **1508** shows the time (2.55 seconds) at which the ultrasonic system triggered a Response Set (in this case, an audible sound only).

FIG. 26 is a graphical representation 1516 of frequency slope versus time waveform 1518 of one embodiment of a generator during a burn-in test. The parameters for this test are consistent with those contained in TABLE 4. Frequency slope (kHz/sec) is shown along the vertical axis and time (Sec) is shown along the horizontal axis for a typical tissue cut using any one of the ultrasonic systems set on power level 5. The frequency slope threshold 1504 used for this application was -0.06 kHz/sec as is shown by the horizontal 1 dashed line. The vertical dotted line 1524 shows the point in time (2.49 seconds) that the quiescent power begins to change due to clamping, the vertical dash-dot line 1506 shows the time (2.66 seconds) at which power has completed ramp-up, and the vertical dashed line 1508 shows the 2 time (2.72 seconds) that the ultrasonic system triggered a Response Set (in this case, an audible sound only). As shown in the graphical representation 1516, the frequency slope at 1520 correlates to the rate of cooling or heat flux out of the blade. Also, the response time 1522 of the ultrasonic system is measured as the time lapse between the point in time (2.49 seconds) that the quiescent power begins to change due to clamping and the time (2.72 seconds) that the ultrasonic system triggered a Response Set.

FIG. 27 is a graphical representation 1524 of a frequency versus time waveform 1526 of one embodiment of a generator during a burn-in test as it relates to the graphical representation 1516 shown in FIG. 26. Resonant frequency (kHz) is shown along the vertical axis and time (Sec) is 35 shown along the horizontal axis for the typical tissue cut using any one of the ultrasonic systems set on power level 5

FIG. 28 is a graphical representation 1528 of a power consumption versus time waveform 1530 of one embodiment of a generator during a burn-in test as it relates to the graphical representation 1516 shown in FIG. 26. Power (W) is shown along the vertical axis and time (Sec) is shown along the horizontal axis for the typical tissue cut using any 45 one of the ultrasonic systems set on power level 5.

Example 2: Triggering a Response Set Based Only on the Frequency Threshold

A second example case includes triggering a Response Set based only on the frequency threshold with reference to FIGS. 29-35. TABLE 5 contains representative parameters for this objective in connection with surgical instruments 55 such as any one of the surgical instruments 19, 190, 1000 disclosed herein comprising corresponding ultrasonic instruments such as the ultrasonic instrument 100, 120, 1004 disclosed herein. It will be appreciated that triggering via frequency threshold may be of limited utility as it is less 60 indicative of dynamic end-effector conditions and is presented herein for completeness of disclosure. The inclusion of frequency slope in the tissue algorithm discussed in connection with logic flow diagrams 1200, 1300, 1400 is intended for use in combination logic (combined with use of the frequency slope threshold) which is covered in the next section of this specification.

50

TABLE 5

Representative Parameters for Triggering an Audio Indication by Frequency Threshold Only (one Condition Set utilized)

5	Parameter	Value*
	Condition Set 1 Pulsing flag	0
	Condition Set 1 LCD display flag	0
	Condition Set 1 Audio flag	1
	Required time before triggered, Condition Set 1	50 msec
10		0 msec*
	Frequency Slope Thresholds (one for each power	level 5: 1.00 kHz/sec*
	level), Condition Set 1	level 4: 1.00 kHz/sec*
	<i>"</i>	level 3: 1.00 kHz/sec*
		level 2: 1.00 kHz/sec*
		level 1: 1.00 kHz/sec*
15	Frequency Threshold, Condition Set 1	55,100 Hz
15	Time to wait	100 msec
	Cross-back Frequency Slope Threshold	-1.00 kHz/sec*
	First Pulse Amplitudes (one for each power	N/A
	level)	
	First Pulse Time	N/A
	Second Pulse Amplitudes (one for each	N/A
20	power level)	
	Second Pulse Time	N/A

*These parameter values are set to an appropriate extreme such that they do not effectively take part in logic flow (e.g., set to always be "true")

FIGS. 29-34 show waveforms produced by a generator with the representative/illustrative parameters contained in TABLE 5. The generator may be similar to any one of the generators 30, 500, 1002 disclosed herein, which forms a portion of the respective surgical systems 19, 190, 1000 operating in ultrasonic mode (e.g., ultrasonic system 19, 190, 1000) applied on tissue in accordance with the present disclosure

The selection of 55,100 Hz as the frequency threshold in TABLE 5 was based on test data for two abuse cases: (1) where an ultrasonic instrument is activated against the tissue pad for a prolonged period of time; and (2) where an ultrasonic instrument is used to make 10 successive cuts on excised porcine jejunum tissue as quickly as possible while keeping the generator running throughout. Each of these two abuse cases will be discussed in more detail with reference to respective FIG. 29 and FIGS. 30-31A-C.

FIG. 29 is a graphical representation 1600 of frequency change 1602 over time of waveforms of several generators during a burn-in test. Frequency change (kHz) after X seconds of burn-in is shown along the vertical axis and ultrasonic surgical instrument device number is shown along the horizontal axis. FIG. 29 shows frequency change data after prolonged burn-ins of an ultrasonic surgical instrument where the ultrasonic surgical instrument is activated against 50 the tissue pad for a prolonged period of time (a prolonged burn-in). The selection of 55,100 Hz limits this condition to no more than a 4 second time span or a frequency drop of about a 700 Hz from a nominal room temperature resonant frequency of 55,800 Hz. Frequency change data 16021, 16022, 16023, 16024 was pulled from the generator 30, 500, 1002 data at corresponding 1, 2, 3, and 4 seconds into the burn-in. The nominal start frequency for the five ultrasonic surgical instruments was 55.8 kHz (blades started at room temperature). The second and fifth devices did not run long enough to generate a full set of data for all times.

FIG. 30 is a graphical representation 1604 of normalized combined impedance, current, and frequency versus time waveforms of and power consumption, energy supplied, and temperature for one embodiment of a generator coupled to a corresponding ultrasonic instrument used to make 10 successive cuts on tissue (e.g., on excised porcine jejunum tissue) as quickly as possible while keeping the generator

running throughout. This data and the methods used to obtain it represent abusive use conditions.

The representative data in FIG. 30 is shown more clearly with reference to FIGS. 31A-C. FIG. 31A is a graphical representation 1606 of impedance versus time waveform 5 1608 and current versus time waveform 1610 of one embodiment of a generator during successive tissue cuts over a period of time. Impedance (Ohm) and Current (mA) are shown along the vertical axis and time (Sec) along the horizontal axis.

FIG. 31B is a graphical representation 1612 of resonant frequency waveform 1614 versus time of a signal of one embodiment of a generator during successive tissue cuts over a period of time. Resonant frequency (kHz) is shown along the vertical axis and time (Sec) along the horizontal 15 axis.

FIG. 31C is a graphical representation 1616 of a power waveform 1618, energy waveform 1620, and temperature waveform 1622 versus time of one embodiment of a generator during successive tissue cuts over a period of time. 20 Power (W), Energy (J), and Temp (C) are shown along the horizontal axis and time (Sec) along the horizontal axis.

Accordingly, with reference now to FIGS. 31A-C, as shown in the graphical representation 1612, it can be seen that after the resonant frequency curve 1614 has dropped 25 700 Hz (from 55.8 kHz to 55.1 kHz) at 1615 on the third cut (which is a particularly abusive cut wherein the tissue was tip loaded. After the resonance frequency waveform 1614 has dropped 700 Hz (from 55.8 kHz to 55.1 kHz) on the third cut, the ultrasonic instrument begins to saturate the genera- 30 tor and the current waveform 1610 dips slightly in all successive cuts. Since the drive current waveform 1610 is proportional to blade tip displacement, a dipping current waveform 1610 results in slower speed of tissue effect and therefore a lower energy deposition rate (and lower rate of 35 heating, i.e., frequency slope is less negative). Management of this change due to dipping current waveform 1610 within an application sequence is possible using both frequency change and frequency slope change as will be described in connection with Examples 3 and 4 in subsequent sections of 40 this specification.

FIG. 32 is a combined graphical representation 1630 of a frequency waveform 1632, weighted frequency slope waveform 1634 (calculated via exponentially weighted moving average with an alpha value of 0.1), and temperature wave- 45 form 1636 versus time generated by a generator similar to one embodiment of the generators described herein. The ultrasonic system had a room temperature resonant frequency (longitudinal mode) slightly higher than that for which TABLE 5 was constructed. Therefore, the frequency 50 threshold 1633 was increased accordingly from the 55,100 Hz shown in TABLE 5 to about 55,200 Hz shown in FIG. 33 as indicated by the dashed line. The activation was performed on tissue (e.g., on excised porcine jejunum tissue) with an ultrasonic system having a room temperature reso- 55 nance of about 55.9 kHz set on power level 5. Tissue separation occurs at 6.25 seconds; one side of the tissue separates from the blade at about 8 seconds; and full separation occurs at about 10 seconds. FIG. 33 is a graphical representation of a frequency versus time waveform 1632 of 60 one embodiment of a generator 30, 500, 1002. Frequency (kHz) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis. FIG. 33 shows the example of using a frequency threshold 1633 only using parameters consistent with those shown in TABLE 5, but adjusted to 65 about 55,200 Hz as indicated by the dashed line 1633. The resonant frequency 1632 crosses the frequency threshold

52

1633 (dashed horizontal line—set at 700 Hz below room temperature resonance) at about 11 seconds and a Response Set may be triggered at this time.

FIG. 34 is a graphical representation 1634 of weighted frequency slope versus time waveform 1634 of one embodiment of a generator. Weighted frequency slope (kHz/Sec) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis. The frequency slope waveform 1634 is calculated via exponentially weighted moving average with an alpha value of 0.1. In FIG. 34, the frequency slope waveform 1634 crosses the frequency slope threshold 1635 (dashed horizontal line) and a Response Set may be triggered at about 5.8 seconds.

The remaining Examples 3 and 4 relate to the use of multiple Condition Sets, which require a more complex application of the tissue algorithm and includes the monitoring of frequency slope and/or frequency against their respective thresholds and may include a hierarchical approach to triggering response sets.

Example 3: Triggering a Response Set Based on Both the Frequency Slope Threshold and the Frequency Threshold

A third example case includes triggering a Response Set based on both the frequency slope threshold and the frequency threshold. TABLE 6 contains representative parameters for this objective in connection with surgical instruments such as any one of the surgical instruments 19, 190, 1000 disclosed herein comprising corresponding ultrasonic instruments such as the ultrasonic instruments 100, 120, 1004 disclosed herein.

TABLE 6

Representative Parameters for Triggering Audio Indications by Frequency Slope and Frequency Thresholds (two Condition Sets utilized)

	Parameter	Value*
О	Condition Set 1 Pulsing flag	0
	Condition Set 1 LCD display flag	0
	Condition Set 1 Audio flag	1
	Condition Set 2 Pulsing flag	0
	Condition Set 2 LCD display flag	0
	Condition Set 2 Audio flag	1
5	Required time before triggered, Condition Set 1	50 msec
	Minimum latch time, Condition Set 1	0 msec*
	Frequency Slope Thresholds (one for each power	level 5: -0.060 kHz/sec
	level), Condition Set 1	level 4: -0.053 kHz/sec
		level 3: -0.045 kHz/sec
		level 2: -0.038 kHz/sec
٥.		level 1: -0.030 kHz/sec
J	Frequency Threshold, Condition Set 1	56,000 Hz*
	Required time before triggered, Condition Set 2	50 msec
	Minimum latch time, Condition Set 2	0 msec*
	Frequency Slope Thresholds (one for each power	level 5: 1.00 kHz/sec*
	level), Condition Set 2	level 4: 1.00 kHz/sec*
_		level 3: 1.00 kHz/sec*
5		level 2: 1.00 kHz/sec*
		level 1: 1.00 kHz/sec*
	Frequency Threshold, Condition Set 2	55,100 Hz
	Time to wait	100 msec
	Cross-back Frequency Slope Threshold	-0.020 kHz/sec
	First Pulse Amplitudes (one for each power level)	N/A
0	First Pulse Time	N/A
	Second Pulse Amplitudes (one for each power level)	N/A
	Second Pulse Time	N/A

^{*}These parameter values are set to an appropriate extreme such that they do not effectively take part in logic flow (e.g. set to always be "true")

In this case of Example 3, a tiered or hierarchical response is demonstrated. The combined logic of the frequency slope

threshold and the frequency threshold will be illustrated using the same graphical representations shown in FIGS. 32-34. In FIG. 34, Condition Set 1 is triggered by the frequency slope waveform 1634 crossing the frequency slope threshold 1635 value at about 6 seconds. The 5 Response Set for Condition Set 1 may include a low level audible indicator, for example. As the user continues to activate the instrument with minimal intervening tissue, Condition Set 2 is triggered as the resonant frequency drops below the frequency threshold 1633 at about 11 seconds as shown in FIG. 33. The Response Set for Condition Set 2 may be an elevated audible indicator, for example.

Example 4: Triggering a Response Set Based on Both the Frequency Slope Threshold and the Frequency Threshold

A fourth example extends to the application of both frequency and frequency slope thresholds during abusive conditions of the surgical instrument. For various reasons, 20 the frequency slope signal levels may diminish (i.e., become less negative) with extended application.

In abusive conditions, frequency, frequency slope, and current waveforms may deviate from normal operation may be generated while the ultrasonic instrument is constantly 25 activated at a power level 5, where the jaws of the ultrasonic instrument were opened for 1 second, then closed for 1 second and repeated for 17 cycles.

When an ultrasonic instrument is activated multiple times directly against the pad, the characteristic frequency slope 30 waveform in a first region before the generator saturates becomes less negative than in a second after the generator saturates due, in large part, to the system efficiency and resulting displacement/current drop. In the non-saturation region of the frequency slope waveform, the ultrasonic 35 system has not yet saturated and current is maintained at or near the target current for power level 5. In the saturation region of the frequency slope waveform, the current (and therefore blade tip displacement) continually drops causing the frequency slope to increase (rate of heating drops). Note 40 that at after several abusive cycles, e.g., the fourth abuse cycle, which is the approximate demarcation between the non-saturation and saturation regions, the resonant frequency drops consistent with FIGS. 29-31A-C. Separate Conditions Sets for each of the non-saturation and saturation 45 regions may be applied. A first frequency slope threshold may be employed in the non-saturation region when resonant frequency conditions are above a predetermined frequency threshold and a second, less negative frequency slope threshold may be employed in the saturation region 50 when resonant frequency conditions are below the same predetermined frequency threshold.

A weighted frequency slope (kHz/sec) versus time waveform may be of one embodiment of a generator. When the instrument is used abusive conditions against the pad, the 55 characteristic frequency slope waveform in the non-saturation region becomes less negative than in the saturation region due to material softening and a corresponding reduction in pad coefficient of friction. In the non-saturation region of the frequency slope waveform corresponds to 60 when the tissue pad has not yet begun to heat significantly. In the saturation region of the frequency slope waveform, the pad begins to soften and the interface between the blade and the pad becomes more lubricious causing the frequency slope waveform to increase (rate of heating drops). Separate 65 Conditions Sets for each of the non-saturation and saturation regions may be warranted. A first frequency slope threshold

54

may be employed in the non-saturation region when resonant frequency conditions are above a predetermined frequency slope threshold and a second, less negative frequency slope threshold may be employed in the saturation region when the resonant frequency is below the same predetermined frequency slope threshold.

Another example case is now considered. TABLE 7 contains parameters for an ultrasonic instrument where two Condition Sets are used to account for diminishing frequency slope signal levels due to system saturation and dropping current.

TABLE 7

Representative Parameters for Triggering Audio Indications by Frequency Slope and Frequency Thresholds, accounting for diminishing frequency slope due to system saturation (two Condition Sets utilized)

Parameter	Value*
Condition Set 1 Pulsing flag	0
Condition Set 1 LCD display flag	0
Condition Set 1 Audio flag	1
Condition Set 2 Pulsing flag	0
Condition Set 2 LCD display flag	0
Condition Set 2 Audio flag	1
Required time before triggered, Condition Set 1	50 msec
Minimum latch time, Condition Set 1	0 msec*
Frequency Slope Thresholds (one for each power	level 5: -0.060 kHz/sec
level), Condition Set 1	level 4: -0.053 kHz/sec
	level 3: -0.045 kHz/sec
	level 2: -0.038 kHz/sec
	level 1: -0.030 kHz/sec
Frequency Threshold, Condition Set 1	56,000 Hz*
Required time before triggered, Condition Set 2	50 msec
Minimum latch time, Condition Set 2	0 msec*
Frequency Slope Thresholds (one for each power	level 5: -0.045 kHz/sec
level), Condition Set 2	level 4: -0.038 kHz/sec
	level 3: -0.030 kHz/sec
5	level 2: -0.024 kHz/sec
	level 1: -0.020 kHz/sec
Frequency Threshold, Condition Set 2	55,100 Hz
Time to wait	100 msec
Cross-back Frequency Slope Threshold	-0.020 kHz/sec
First Pulse Amplitudes (one for each power level)	N/A
First Pulse Time	N/A
Second Pulse Amplitudes (one for each power level)	N/A
Second Pulse Time	N/A

*These parameter values are set to an appropriate extreme such that they do not effectively take part in logic flow (e.g., set to always be "true")

The data generated for this example run were generated using an ultrasonic instrument to make ten successive cuts in jejunum tissue as quickly as possible. Using the parameter values from TABLE 7, the Frequency vs. Time plots for the example sample case are shown in FIGS. **35-36**.

FIG. 35 is a graphical representation 1800 of a frequency versus time waveform 1802 of one embodiment of a generator over ten cuts on tissue (e.g., jejunum tissue) and a graphical representation 1804 of a temperature versus time waveform 1805. For the graphical representation 1800, Frequency (Hz) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis. For the graphical representation 1804, Temperature (° F.) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis.

FIG. 36 is a graphical representation 1805 of the frequency versus time waveform 1802 shown in FIG. 35 of one embodiment of a generator over ten cuts on tissue (e.g., jejunum tissue) with activation of intervening tissue at portions indicated by reference number 1806. Frequency (Hz) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis.

The frequency waveform **1802** shown in FIGS. **35** and **36** is for the example case using two Condition Sets to account for diminishing frequency slope due to electrical system saturation (diminishing displacement). Note that this is the same test run as is shown in FIGS. **29-31A-**C. In FIG. **36**, the highlighted portions **1806** indicates activation with intervening tissue (frequency drops, shape of local frequency curve related to dryness of tissue—shallow start slope, steepens as tissue dries), the highlighted portions **1808** indicate activation with minimal or no intervening tissue (local frequency slope very steep, curve shape is more linear, steepens gradually), the section of the curve with no highlighted portions **1810** indicates time within which the device is being repositioned for the next cut, blade cools in air and cools rapidly when placed on tissue (frequency rises).

slope versus time waveform 1814 of one embodiment of a generator over ten cuts on jejunum tissue. Frequency slope (kHZ/Sec) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis. Region B of the frequency slope waveform 1814 shows the area of the ten cut run where Condition Set 2 is triggered prior to Condition Set 1 for the first time during the ten cut run (frequency is below 55.1 kHz and frequency slope is less than -0.045 kHz/sec). The condition illustrated in Region B, where Condition Set 2 is triggered prior to Condition Set 2 is triggered prior to Condition Set 1, is desired because the ultrasonic system is consistently saturating by this point in the run (voltage is saturating and current is diminished resulting in diminished displacement and, therefore, diminished rate of heating requiring a greater frequency slope threshold).

FIG. 38 is a graphical representation 1816 of a power versus time waveform 1818 representative of power consumed by a one embodiment of a generator over ten cuts on 35 tissue (e.g. jejunum tissue). Power (W) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis.

FIG. 39 is a graphical representation 1820 of a current versus time waveform 1822 of one embodiment of a generator over ten cuts on jejunum tissue. Current (mA) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis.

Having described the basic application of the tissue algorithm discussed in connection with the logic flow dia- 45 grams 1200, 1300, 1400 shown in FIGS. 20-22 in terms of monitoring the frequency slope, resonant frequency, or both against their respective thresholds, the discussion now turns to a description of the latching logic and corresponding use as it relates to the tissue algorithm. The motivations for 50 adding the latching logic to the tissue algorithm are: (a) to prevent a Condition Set from resetting (Condition Set changes from true to false) due to a blade/pad interface becoming more lubricious during a blade on pad abuse condition; and (b) to prevent a Condition Set from resetting 55 (Condition Set changes from true to false) due to pulsed activation where periods of rapid heating are interweaved with periods of less rapid heating (sections of heat flux into the blade and sections of heat flux out of the blade are interweaved). The first and second of these motivations are 60 shown in FIGS. 48 and 49 illustrate, respectively. As defined earlier in this disclosure, the two latch parameters addressing these motivations are "cross-back frequency slope threshold" as shown in FIG. 40 and "minimum latch time." For completeness of disclosure, FIG. 43 shows calculated fre- 65 quency slope curves for the pulsed run shown in FIGS. 41 and 42A-C.

56

FIG. 40 is a graphical representation 1900 of a "crossback frequency slope threshold" parameter in connection with frequency slope versus time waveform 1902. As shown in FIG. 40, the "frequency slope threshold" 1904 is shown by the horizontal dashed line at -0.15 kHz/sec. The "crossback frequency slope threshold" 1906 is shown by the horizontal dash-dot line at -0.02 kHz/sec. In this instance, the Condition Set is met and a Response Set is triggered when the local calculated frequency slope crosses the "frequency slope threshold" as shown by arrow 1908 pointing down. The Condition Set is not met (Response Set is no longer triggered) when the local calculated frequency slope crosses over the "cross-back frequency slope threshold" as shown by arrow 1910 pointing up. Note that without using the "cross-back over frequency slope threshold" in this case, the Response Set would not have been triggered when the local frequency slope crossed back over the horizontal dashed line 1904 at about 4.7 seconds shown at cross over

FIG. 41 is a combined graphical representation 1920 of a pulsed application of one embodiment of an ultrasonic instrument on an excised carotid artery showing normalized power, current, energy, and frequency data plotted versus time.

FIG. 42A is a graphical representation 1921 of an impedance versus time waveform 1922 and a current versus time waveform 1924 of one embodiment of a generator during successive tissue cuts over a period of time. The impedance (Ohms) and current (mA) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis.

FIG. 42B is a graphical representation 1923 of a frequency versus time waveform 1925 of one embodiment of a generator during successive tissue cuts over a period of time. Frequency (kHz) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis.

FIG. 42C is a graphical representation 1930 of power waveform 1926, energy waveform 1927, a first temperature waveform 1928 and a second temperature waveform 1929 plotted versus time as of one embodiment of a generator during successive tissue cuts over a period of time. Power (W), Energy (J), and Temperature (° C.) are shown along the vertical axis and Time (Sec) is shown along the horizontal axis

FIGS. 42A-C show a pulsed application of an ultrasonic instrument on an excised carotid artery where the First Pulse Time is 1 second, the First Pulse Amplitude is 100% of power level 3 output current. The Second Pulse Time is 1.5 seconds and the Second Pulse Amplitude is less than 10% of power level 3 output current. Of note, the resonant frequency waveform 1925 exhibits sections of both heating (heat flux into the blade) and cooling (heat flux out of the blade). The "minimum latch time" parameter, defined herein as the minimum amount of time for response(s) to a Condition Set X to be triggered, is intended to maintain triggering of a Response Set during pulsed application (one example of a latch time may be about 1 second). Of additional note, as shown in FIG. 42A, the load or impedance waveform 1922 does not drop below 200 Ohms throughout the run sequence. This may be favorable considering that the impedance waveform 1922 for a marching application consistently drops below about 150 Ohms while operating in air between cuts implying that an impedance limit may be used for resetting Condition Sets. In one aspect this impedance limit may be used for implementation of the "low drive in air" concept as disclosed in U.S. Pat. No. 5,026,387 to Thomas.

FIG. 43 is a graphical representation 1932 of a calculated frequency slope waveform 1934 for the pulsed application shown in FIG. 41 and FIGS. 42A-C plotted on a gross scale. FIG. 44 is a zoomed in view of the graphical representation of the calculated frequency slope waveform 1934 for the 5 pulsed application shown in FIG. 43. Both FIGS. 43 and 44 show the calculated frequency slope waveform 1934 for the pulsed application shown in FIG. 41 and FIGS. 42A-C. Frequency slope (kHz/Sec) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis. Two scales are shown, where FIG. 43 shows a gross scale for frequency slope and FIG. 44 shows a "zoomed in" view. For frequency slope, the same trends seen under continuous drive are shown in pulsed drive including values that correlate well to heat flux into (negative frequency slope) and out of the blade (positive frequency slope). The transient nature of the frequency curve and frequency slope curve due to pulsing, combined with the moving average calculation of frequency slope make use of the frequency slope curve 20 during pulsing difficult. Of note, the tissue separated at 13 seconds. As can be seen in FIG. 43 and especially FIG. 44, the rate of cooling can be used to trigger a response correlating rapid cooling in the dwell portions of pulsed outputs to the completion of a tissue transection using logic 25 (not shown by logic flows in FIGS. 20-22) where frequency slope waveform 1934 exceeds a threshold value, in this case of about 0.04 kHz/sec when sampled at the ends (i.e., the settled regions) of the dwell periods. As can be seen in FIG. 42A, the impedance waveform 1922 can be used to trigger a response correlating high impedance (high resistance to mechanical motion or vibration) to the completion of a tissue transection using logic (again, not shown by logic flows in FIGS. 20-22) where transducer impedance wave- $_{35}$ form 1922 exceeds a threshold value, in this case of about 700 Ohms when sampled at the beginnings (i.e., the settled regions) of the dwell periods.

FIG. **45** is a graphical representation **1936** of other data waveforms **1938** of interest such as impedance, power, 40 energy, temperature. In FIG. **45**, the vertical scale to the right applies to the impedance curve only.

The present disclosure now turns to considerations for power level and clamp pressure profile in an ultrasonic instrument. The rate of heating of a blade to pad interface is 45 proportional to blade displacement, interface coefficient of friction and load (clamp pressure or normal force). Testing was performed to assess the tissue algorithm at a range of displacements (power levels) and device specific combinations of clamp pressure and coefficient of friction (defined 50 largely by pad materials and blade coatings).

FIG. 46 is a graphical representation 1940 of a summary of weighted frequency slope versus power level for various ultrasonic instrument types. Weighted frequency slope (kHz/ Sec) is shown along the vertical axis and power level, device 55 type, and device are shown along the horizontal axis. The instruments used to generate the data summarized in the graphical representation 1940 are generally commercially available with some exceptions. One test procedure included clamping the device, activating the device for three seconds, 60 and calculating the average frequency slope over the full three seconds. Other metrics, however, may be employed. For most devices, the data summarized in FIG. 46 would be approximately indicative of the minimum frequency slope value. FIG. 46 shows the frequency slope summary data for 65 burn-in testing on shears type ultrasonic instruments where the instruments were clamped, then activated for 3 seconds,

58

then unclamped—the average frequency slope over the full three seconds of activation was calculated and plotted as shown

Based on predetermined tests and test data from FIG. 46, the following frequency slope thresholds are suggested for the main power levels of use with some ultrasonic instruments:

- (1) level 5 frequency slope threshold: -0.060 kHz/sec;
- (2) level 3 frequency slope threshold: -0.045 kHz/sec;
- (3) level 5 frequency slope threshold: -0.070 kHz/sec; and

(4) level 3 frequency slope threshold: -0.050 kHz/sec.

System stiffness includes both blade stiffness (cantilevered beam) and pad stiffness/pad thermal stability. The more differentiated the unloaded (no tissue) system stiffness is from the loaded (clamped on tissue) system stiffness, the more robust the tissue algorithm performance. Other constraints, of course, may limit system stiffness on the high end.

Further exploration of displacement effects were analyzed based on a larger set of data. For the ultrasonic system, power levels are essentially differentiated by output current target values and, current, which is proportional to vibratory amplitude or displacement. Analysis of this data also may include digital smoothing of the frequency data to obtain usable frequency slope curves.

FIGS. 47-49 show frequency and current versus time waveforms obtained using one embodiment of a generator and an ultrasonic instrument to excise a porcine carotid artery at power level 5.

FIG. 47 is a graphical representation 1970 of resonant frequency versus time waveform 1972, an averaged resonant frequency versus time waveform 1974, and a frequency slope versus time waveform 1976 of one embodiment of a generator. Frequency (kHz) and Frequency Slope (kHz/Sec) are shown along the vertical axes and Time (Sec) is shown along the horizontal axis. The frequency slope waveform 1976 is based on the averaged frequency data and was obtained by post processing the frequency waveform 1972 data. The raw frequency data is plotted as well as smoothed (via simple moving average) frequency data and frequency slope (calculated from the smoothed data because the raw frequency data contains stair-stepping due to rounding of the streamed data). The average resonant frequency waveform 1974 is obtained via a 70 msec moving average (kHz) of the resonant frequency data.

FIG. 48 is a zoomed in view 1978 of the resonant frequency versus time waveform 1972 and the averaged resonant frequency versus time waveform 1974 of one embodiment of a generator. Frequency (kHz) is shown along the vertical axis and Time (Sec) is shown along the horizontal axis.

FIG. 49 is a zoomed in view 1980 of the resonant frequency waveform 1972 and a current versus time waveform 1982 of one embodiment of a generator. Frequency in (Hz) and Current (A) is shown along the vertical axes.

In FIGS. 48 and 49, the respective zoomed in views 1978, 1980 are shown to see the effect of smoothing frequency data and to see rise information at the start of the application, which may be helpful for assessment of parameters such as Time to Wait.

Other aspects of the tissue algorithm described herein may be applied to situations when little to no intervening tissue remains (between the ultrasonic blade and the clamp arm) and waste energy is being dumped into the end effector. Accordingly, in one embodiment, the tissue algorithm may be modified to provide feedback to the user relative to this

situation. Specifically, the tissue algorithm leverages the fact that the resonance of an ultrasonic blade changes relative to temperature (decreases with increasing temperature and increases with decreasing temperature).

In one aspect the tissue algorithm disclosed herein may be 5 employed to monitor the frequency slope of a waveform where the algorithm monitors the change in resonant frequency slope to indicate the changing condition of the tissue. In the case shown in FIG. 50, for example, the inflection of the frequency response curve correlates to the point at which 10 the tissue begins to separate (i.e., there is a tissue tag and the user continues to activate the instrument), which can be verified by experimentation. The change in frequency slope can be used to provide an indicator (e.g., distinct beeping sound, flashing light, tactile vibration, among others previously discussed) to the user (that waste energy is being dumped into the end effector) or the generator output could be controlled or stopped.

In another aspect, the tissue algorithm disclosed herein may be employed to monitor the frequency threshold of a 20 waveform, where the algorithm monitors the change in frequency as the waveform crosses some threshold or difference from some known state (e.g., room temperature). Similar to monitoring the frequency slope, as the change in frequency drops below some threshold value or difference, 25 an indication can be given to the user that the device end effector is heating at an accelerated rate. Again, FIG. 50 provides a graphical illustrative view of a frequency threshold

In yet another aspect, the tissue algorithm disclosed 30 herein may be employed to monitor the frequency slope change and the frequency threshold in combination. The combination of a significant change in frequency slope and a drop in frequency below some threshold can be used to provide an indication of high temperature.

Turning now to FIG. 50, is a graphical representation 1990 of normalized combined power 1991, impedance 1992, current 1993, energy 1994, frequency 1995, and temperature 1996 waveforms of one embodiment of a generator coupled to an ultrasonic instrument. As shown, the tissue begins to 40 separate at 6.672 seconds. From this point until the tissue fully separates, about 55-60% of the total frequency drop is obtained, the temperature increases by a factor of about 1.92 (from 219° C. to 418° C.) and about 28% of the total energy applied is delivered. The local slopes of the frequency vs. 45 time waveforms are shown by a first set of dashed lines 1997, which represents a rapid change in the resonant frequency slope. Monitoring this slope 1997 affords the opportunity to indicate a dramatic change which typically occurs when there is limited to no intervening tissue and the 50 vast majority of power is being applied to the blade/tissue pad interface. Likewise, the frequency change from its resonance in a known state (e.g., room temperature) can be used to indicate high temperatures—a frequency change threshold is shown with a second dashed line 1998. Also, a 55 change is a rate of cooling. combination of these two, frequency slope change and frequency change threshold, can be monitored for purposes of indication. Note that the frequency changes in this case from an initial value of 55,712 Hz to an end value of 55,168 Hz with the threshold shown at about 55,400 Hz.

While several embodiments have been illustrated and described, it is not the intention of the applicant to restrict or limit the scope of the appended claims to such detail. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the scope 65 of the invention. Moreover, the structure of each element associated with the described embodiments can be alterna-

60

tively described as a means for providing the function performed by the element. Accordingly, it is intended that the described embodiments be limited only by the scope of the appended claims.

Reference throughout the specification to "various embodiments," "some embodiments," "one embodiment," or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases "in various embodiments," "in some embodiments," "in one embodiment," or "in an embodiment" in places throughout the specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Thus, the particular features, structures, or characteristics illustrated or described in connection with one embodiment may be combined, in whole or in part, with the features structures, or characteristics of one or more other embodiments without limitation.

The invention claimed is:

1. A method of driving an end effector coupled to an ultrasonic drive system of a surgical instrument, the method comprising:

generating by a generator at least one electrical signal; monitoring the at least one electrical signal against a first set of logic conditions;

triggering a first response of the generator when the first set of logic conditions is met;

determining from the at least one electrical signal a parameter associated with the surgical instrument,

wherein the determined parameter is indicative of a temperature change of the end effector; and

monitoring impedance of a transducer of the ultrasonic drive system in a dwells region during pulsed activation.

- 2. The method of claim 1, further comprising: resetting the generator when the determined parameter crosses a predetermined threshold.
- 3. The method of claim 1, wherein the determined parameter is a rate of temperature change of the end effector assessed by calculating a frequency slope, the method further comprising:
 - comparing the frequency slope against a predetermined threshold.
- **4**. The method of claim **3**, wherein the rate of temperature change is a rate of cooling.
- 5. The method of claim 3, wherein the rate of temperature change is a rate of heating.
- **6**. The method of claim **1**, wherein the determined parameter is proportional to a frequency slope, and wherein the determined parameter is a rate of temperature change of the end effector.
- 7. The method of claim 6, wherein the rate of temperature change is a rate of cooling.
- 8. The method of claim 6, wherein the rate of temperature change is a rate of heating.
- A method of driving an end effector coupled to an ultrasonic drive system of a surgical instrument, the method 60 comprising:

generating by a generator at least one electrical signal; determining from the at least one electrical signal a parameter associated with the end effector;

comparing the determined parameter against a predetermined parameter.

wherein the determined parameter is indicative of a temperature change of the end effector; and

- monitoring impedance of the end effector of the ultrasonic drive system in a dwells region during pulsed activation
- 10. The method of claim 9, wherein the determined parameter comprises the impedance of the end effector.
- 11. The method of claim 10, comprising resetting the generator when the impedance crosses a predetermined threshold.
- 12. The method of claim 9, wherein the determined parameter is a rate of temperature change of the end effector.
- 13. The method of claim 12, wherein the rate of temperature change is selected from the group consisting of a rate of cooling and a rate of heating.
- **14**. A method of driving an end effector coupled to an ultrasonic drive system of a surgical instrument, the method comprising:

generating by a generator at least one electrical signal; monitoring the at least one electrical signal against a first set of logic conditions; 62

triggering a first response of the generator when the first set of logic conditions is met;

determining a frequency slope of the at least one electrical signal; and

- monitoring impedance of the end effector of the ultrasonic drive system in a dwells region during pulsed activation.
- 15. The method of claim 14, wherein the frequency slope is proportional to a rate of temperature change of the end effector.
 - 16. The method of claim 15, wherein the rate of temperature change is a rate of cooling.
- 17. The method of claim 15, wherein the rate of tempera- $_{15}$ ture change is a rate of heating.
 - 18. The method of claim 14, comprising comparing the frequency slope against a predetermined threshold.

* * * * *



专利名称(译)	用于切割和凝结组织的装置和技术	÷	
公开(公告)号	<u>US10335614</u>	公开(公告)日	2019-07-02
申请号	US15/290570	申请日	2016-10-11
[标]申请(专利权)人(译)	爱惜康内镜外科,LLC		
申请(专利权)人(译)	爱惜康内镜外科,LLC		
当前申请(专利权)人(译)	ETHICON LLC		
[标]发明人	MESSERLY JEFFREY D WIENER EITAN T NOYES BRIAN T ALDRIDGE JEFFREY L GIORDANO JAMES R BEETEL III ROBERT J ABBOTT DANIEL J MILLER MATTHEW C WILEY JEFFREY P PRICE NATHAN J PRICE DANIEL W KOCH JR ROBERT L		
发明人	MESSERLY, JEFFREY D. WIENER, EITAN T. NOYES, BRIAN T. ALDRIDGE, JEFFREY L. GIORDANO, JAMES R. BEETEL, III, ROBERT J. ABBOTT, DANIEL J. MILLER, MATTHEW C. WILEY, JEFFREY P. PRICE, NATHAN J. PRICE, DANIEL W. KOCH, JR., ROBERT L.		
IPC分类号	H01L41/09 B06B1/02 G05B15/02 A61B5/053 A61B5/00	2 A61B18/14 A61B17/32 A61N7/	00 A61N7/02 A61B17/00 A61B18/00
CPC分类号	A61B5/4836 A61B2017/00026 A A61B2018/00005 A61B2018/006	61B2017/00084 A61B2017/00170 33 A61B2018/00303 A61B2018/00 018/00845 A61B2018/00875 A61	7/320092 B06B2201/76 A61B5/053 6 A61B2017/00203 A61B2017/00973 0589 A61B2018/00601 A61B2018 B2018/00994 A61B18/1206 A61B18
优先权	61/250217 2009-10-09 US 61/188790 2008-08-13 US 61/086619 2008-08-06 US		
其他公开文献	US20170095267A1		
外部链接	Espacenet		
按西(20)			

摘要(译)

各种实施例涉及一种驱动耦合到外科器械的超声驱动系统的末端执行器的方法。该方法包括产生至少一个电信号。针对第一组逻辑条件监控至少一个电信号。当满足第一组逻辑条件时,触发第一响应。从至少一个电信号确定参数。

